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FOREWORD
Foreword
Health at a Glance 2017 presents the latest comparable data and trends on key indicators of 
health outcomes and health systems across the 35 OECD member countries. These indicators shed 
light on the performance of health systems, with indicators reflecting health outcomes, non-medical 
determinants of health, the degree of access to care, the quality of care provided, and the financial 
and material resources devoted to health. For a subset of indicators, data are reported for partner 
countries, including Brazil, China, Colombia, Cost Rica, India, Indonesia, Lithuania, the Russian 
Federation and South Africa.
The production of Health at a Glance would not have been possible without the contribution 
of OECD Health Data National Correspondents, Health Accounts Experts, and Health Care Quality 
Indicators Experts from the 35 OECD countries. The OECD gratefully acknowledges their effort in 
supplying most of the data contained in this publication. The OECD also acknowledges the contribution 
of other international organisations, especially the World Health Organization and Eurostat, for sharing 
some of the data presented here, and the European Commission for supporting data development work.
This publication was prepared by a team from the OECD Health Division under the coordination 
of Chris James. Chapter 1 was prepared by Chris James and Alberto Marino; Chapter 2 by Chris 
James and Marion Devaux; Chapter 3 by Eileen Rocard, Chris James, Marie-Clémence Canaud and 
Emily Hewlett; Chapter 4 by Sahara Graf, Marion Devaux and Michele Cecchini; Chapter 5 by Alberto 
Marino, Chris James, Rie Fujisawa, Akiko Maeda, David Morgan and Eileen Rocard; Chapter 6 by Ian 
Brownwood, Frédéric Daniel, Rie Fujisawa, Rabia Khan, Michael Padget and Niek Klazinga; Chapter 7 
by David Morgan, Michael Mueller and Michael Gmeinder; Chapter 8 by Akiko Maeda, Gaëlle Balestat 
and Michael Gmeinder; Chapter 9 by Chris James, Gaëlle Balestat and Alberto Marino; Chapter 10 by 
Rabia Khan, Gaëlle Balestat, Marie-Clémence Canaud, Michael Mueller, Martin Wenzl, Chris James 
and Valérie Paris; Chapter 11 by Tim Muir, Eileen Rocard, Michael Mueller and Elina Suzuki. The OECD 
databases used in this publication are managed by Gaëlle Balestat, Ian Brownwood, Marie-Clémence 
Canaud, Frédéric Daniel, Michael Gmeinder, Gaétan Lafortune and David Morgan.
Detailed country comments improved the quality of this publication, as did comments from 
Francesca Colombo, Gaétan Lafortune, Mark Pearson and Stefano Scarpetta. Format and editing 
support from Marlène Mohier, Kate Lancaster and Andrew Esson are also gratefully acknowledged.
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Executive summary
Health at a Glance 2017 presents up-to-date cross-country comparisons of the health status 
of populations and health system performance in OECD and partner countries. Alongside 
indicator-by-indicator analysis, this edition offers snapshots and dashboard indicators that 
summarise the comparative performance of countries, and a special chapter on the main 
factors driving life expectancy gains.
Most OECD countries have universal health coverage systems which promote equitable 
access for needed health services. Quality of care has also generally improved, but this has 
come at a cost: health spending now accounts for about 9% of GDP on average. Investing in 
cost-effective health promotion interventions is one important way to improve value for 
money and reduce health inequities.
People in OECD countries are living longer, but the burden of mental illness 
and chronic disease is rising
●● life expectancy at birth is 80.6 years, on average, across OECD countries. Japan and Spain 
lead a group of 25 OECD countries with life expectancies over 80 years.
●● Turkey, Korea and Chile have experienced the largest gains in life expectancy since 1970.
●● Health spending contributes to longevity, but only explains part of the cross-country 
differences and gains in life expectancy over time. New regression estimates suggest 
healthier habits and wider social determinants of health are also key.
●● Women can expect to live just over five years longer than men, while people with tertiary 
level education live around six years longer than those with the lowest level of education.
●● Across the OECD, more than one in three deaths are caused by ischaemic heart disease, 
stroke or other circulatory diseases; one in four deaths are due to cancer.
●● Mortality rates for circulatory diseases have fallen rapidly, with 50% fewer deaths due to 
ischaemic heart disease, on average, since 1990. Cancer mortality rates have also fallen, 
though less markedly, by 18% since 1990.
While smoking rates continue to decline, there has been little success in 
tackling obesity and harmful alcohol use, and air pollution is often neglected
●● Smoking rates have decreased in most OECD countries, but 18% of adults still smoke daily. 
Rates are highest in Greece, Hungary and Turkey, and lowest in Mexico.
●● Alcohol consumption in the OECD averaged 9 litres of pure alcohol per person per year, 
equivalent to almost 100 bottles of wine. This figure is driven by the sizeable share of heavy 
drinkers: 30% of men and 12% of women binge-drink at least once per month.
●● In 13 OECD countries alcohol consumption has increased since 2000, most notably in 
Belgium, Iceland, latvia and Poland.
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●● Since the late 1990s, obesity has risen quickly in many OECD countries, and more than 
doubled in Korea and Norway, albeit from low levels.
●● 54% of adults in OECD countries today are overweight, including 19% who are obese. 
Obesity rates are higher than 30% in Hungary, Mexico, New Zealand and the United States.
●● Among 15 year olds, 25% are overweight and only 15% do enough physical activity. Further, 
12% smoke weekly and 22% have been drunk at least twice in their lives.
●● In 21 countries, over 90% of people are exposed to unsafe levels of air pollution.
Most OECD countries have achieved universal or near-universal health 
coverage, but access to care needs to be improved
●● Population coverage for a core set of services is 95% or higher in all but seven OECD 
countries and lowest in Greece, the United States and Poland.
●● Out-of-pocket payments by households make up 20% of all health spending on average 
in the OECD, and over 40% in latvia and Mexico. 
●● Cost concerns lead about 10% of people to skip consultations, while 7% do not purchase 
prescribed medicines. Poorer households are most affected.
●● The number of physicians per 1000 people is much higher in capitals and other cities, 
with variation between areas most marked in the United States and the Netherlands.
●● Waiting times for elective surgery are long in a number of countries, particularly Estonia, 
Poland and Chile.
Patient experiences and outcomes of care are improving, with lower  
mortality rates after a heart attack or stroke and higher survival rates  
for people with cancer
●● Over 80% of patients report positive experiences in terms of their time spent with a doctor, 
easy-to-understand explanations and involvement in treatment decisions.
●● Avoidable hospital admissions for chronic conditions have fallen in most OECD countries, 
indicating an improving quality of primary care.
●● In terms of acute care, fewer people are dying following heart attack or stroke. Improvements 
are particularly striking among heart attack patients in Finland, and stroke patients in 
Australia.
●● Timeliness of hip fracture surgery (a measure of patient safety) has improved in most 
countries, with over 80% occurring within two days of admission.
●● Rates of obstetric trauma have remained relatively unchanged, with tearing of the 
perineum in 5.7% of instrument-assisted vaginal deliveries.
●● Across the OECD, five-year survival rates for breast cancer were 85% and just over 60% 
for colon and rectal cancers, with survival rates improving in most countries over time.
●● Childhood vaccinations are near universal in most OECD countries, though measles 
coverage has fallen slightly in Australia and Italy in recent years.
Having sufficient financial and material resources is critical to the functioning 
of a health system. These resources need to be used wisely to avoid 
ineffective spending
●● Spending on health in the OECD was about USD 4 000 per person on average (adjusted for 
purchasing powers). The United States spends almost USD 10 000 per person.
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●● Health spending was 9% of GDP on average in the OECD, ranging from 4.3% in Turkey to 
17.2% in the United States.
●● In all countries except the United States, government schemes and compulsory health 
insurance are the main health care financing arrangements.
●● Hospitals account for nearly 40% of health spending.
●● Since 2000, the number of doctors and nurses has grown in nearly all OECD countries. 
There are about three nurses per doctor, with the nurse-to-doctor ratio highest in Japan, 
Finland and Denmark.
●● Hospital beds per capita have fallen in all OECD countries except Korea and Turkey, linked 
to lower hospitalisation rates and increased day surgery.
●● Increased use of generics in most OECD countries has generated cost-savings, though 
generics still represent less than 25% of the volume of pharmaceuticals sold in luxembourg, 
Italy, Switzerland and Greece.
●● Population ageing has increased the demand for long-term care, with spending increasing 
more than for any other type of health care.
●● On average, 13% of people aged 50 and older provide weekly care for a dependent relative 
or friend; 60% of informal carers are women.
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Reader’s guide
Health at a Glance 2017 presents comparisons of key indicators for health and health system 
performance across the 35 OECD countries. Candidate and key partner countries are also 
included where possible (Brazil, China, Colombia, Costa Rica, India, Indonesia, lithuania, 
the Russian Federation and South Africa). The data presented in this publication come from 
official national statistics, unless otherwise stated.
Structure of the publication
The general framework underlying this publication assesses the performance of health 
systems within the context of a broader view of public health (Figure 0.1). It is based on a 
framework that has been endorsed and updated for the OECD Health Care Quality Indicators 
project (see source to Figure  0.1). This framework recognises that the ultimate goal of 
health systems is to improve the health status of the population. Many factors influence 
health status, including those that fall outside health care systems, such as the physical 
environment in which people live, and individual lifestyles and behaviours. The demographic, 
economic and social context also affects the demand for and supply of health services, and 
ultimately health status.
Conceptual framework for health system performance assessment
Access
(dashboard 3, chapter 5)
Quality
(dashboard 4, chapter 6)
Health expenditure and financing
(dashboard 5, chapter 7)
Health care resources and activities (dashboard 5)
Health workforce (chapter 8)
Health care activities (chapter 9)
Sub-sector analysis (dashboards 1 & 5)
Pharmaceutical sector (chapter 10)
Ageing and long-term care (chapter 11)
Demographic, economic & social context
Health status
(dashboard 1, chapter 3)
Risk factors for health
(dashboard 2, chapter 4)
Health care system performance
How does the health system perform? What is the level of quality of care and access to services?
What does the performance cost?
Source: Adapted from Carinci, F. et al. (2015), “Towards Actionable International Comparisons of Health System 
Performance: Expert Revision of the OECD Framework and Quality Indicators”, International Journal for Quality in Health 
Care, Vol. 27, No. 2, pp. 137-146.
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At the same time, the performance of health care systems is clearly crucial. Core 
dimensions of performance include the degree of access to care and the quality of care 
provided. Performance measurement needs to take into account the financial resources 
required to achieve these access and quality goals. Health system performance also depends 
critically on the health workers providing services, and the goods and services at their 
disposal.
Health at a Glance 2017 compares OECD countries on each component of this general 
framework. It is structured around eleven chapters. The first two chapters offer an overview 
of health and health system performance. The next nine chapters then provide detailed 
country comparisons across a range of health indicators, including where possible time 
trend analysis.
In Chapter 1, a series of dashboards present the relative strengths and weaknesses of 
OECD countries’ health systems, alongside OECD-wide summary data. These dashboards use 
a subset of the indicators that are presented in more detail in later chapters of the publication. 
Chapter 2 provides a complementary thematic analysis on the determinants of health 
across OECD countries. It assesses the relative contributions of health systems vis-à-vis 
wider social factors to life expectancy.
Following these overview chapters, Chapter 3 on health status highlights variations 
across countries in life expectancy, the main causes of mortality and other measures of 
population health status. This chapter also includes measures of inequality in health status 
by education and income level for key indicators such as life expectancy and perceived 
health status.
Chapter 4 examines major risk factors for health. The focus is on health-related lifestyles 
and behaviours, most of which can be modified by public health and prevention policies. 
These include the major risk factors for non-communicable diseases of smoking, alcohol 
and obesity, for children and adults. At the same time, healthy lifestyles are assessed in 
terms of nutrition and physical activity. Population exposure to air pollution is also analysed.
Chapter  5 on access to care presents a set of indicators related to financial access, 
geographic access and timely access (waiting times). This includes analysis of self-reported 
unmet needs for medical care. Overall measures of population coverage are also presented.
Chapter 6 assesses quality and outcomes of care in terms of clinical effectiveness, patient 
safety and the person responsiveness of care. The chapter seeks to reflect the lifecycle of 
care by presenting indicators related to preventive, primary, chronic and acute care. This 
includes analysis of patient experiences, prescribing practices, management of chronic 
conditions, acute care for heart attack and stroke, patient safety, mental health, cancer care 
and prevention of communicable diseases.
Chapter 7 on health expenditure and financing compares how much countries spend on 
health, both on a per capita basis and in relation to GDP. The chapter analyses how health 
care is paid for, through a mix of government funding, compulsory and voluntary health 
insurance and direct out-of-pocket payments by households. The breakdown of spending 
by health provider and by the type of health care provided is also examined.
Chapter 8 looks at the health workforce, particularly the supply and remuneration of 
doctors and nurses. The chapter also presents data on the number of new graduates from 
medical and nursing education programmes. It features indicators on the international 
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migration of doctors and nurses, comparing countries in terms of their reliance on foreign-
trained workers as well as trends over time.
Chapter 9 on health care activities describes some of the main characteristics of health 
service delivery. It starts with the number of consultations with doctors, often the “entry 
point” of patients to health care systems. Country comparisons on hospital discharges 
and lengths of stay, the utilisation rates of surgical procedures, and the increased use of 
ambulatory surgery for minor surgeries are also included. 
Chapter 10 takes a closer look at the pharmaceutical sector. Analysis of pharmaceutical 
spending gives a sense of the varying scale of the market in different countries. The number 
of pharmacists and pharmacies; consumption on certain high-volume drugs; and the use of 
generics and bio-similars are also compared. Finally, spending on research and development 
in the pharmaceutical sector is assessed.
Chapter 11 focuses on ageing and long-term care. It assesses key factors affecting the 
current and future demand for long-term care. This includes demographic trends, and 
health status indicators for elderly populations, such as life expectancy and self-reported 
measures of health and disability at age 65. Dementia is compared across countries in terms 
of prevalence today and in the future, and in terms of indicators for quality of care. The 
recipients of long-term care and the formal and informal workers providing care for these 
people are also assessed, as are trends in long-term care expenditure in different countries.
Presentation of indicators
With the exception of the first two chapters, indicators covered in the rest of the 
publication are presented over two pages. The first page defines the indicator, provides 
a brief commentary highlighting key findings conveyed by the data, and signals any 
significant national variation from the definition which might affect data comparability. 
On the facing page is a set of figures. These typically show current levels of the indicator 
and, where possible, trends over time. Where an OECD average is included in a figure, it is 
the unweighted average of the OECD countries presented, unless otherwise specified. The 
number of countries included in this OECD average is indicated in the figure, and for charts 
showing more than one year this number refers to the latest year.
Data limitations
limitations in data comparability are indicated both in the text (in the box related to 
“Definition and comparability”) as well as in footnotes to figures.
Data sources
Readers interested in using the data presented in this publication for further analysis 
and research are encouraged to consult the full documentation of definitions, sources 
and methods presented in OECD Health Statistics on OECD.Stat (http://stats.oecd.org/index.
aspx, then choose “Health”). More information on OECD Health Statistics is available at  
http://www.oecd.org/health/health-data.htm.
Population figures
The population figures used to calculate rates per capita throughout this publication 
come from Eurostat for European countries and from OECD data based on UN Demographic 
Yearbook and UN World Population Prospects (various editions) or national estimates for 
non-European OECD countries (data extracted as of early June 2017), and refer to mid-year 
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estimates. Population estimates are subject to revision, so they may differ from the latest 
population figures released by the national statistical offices of OECD member countries.
Note that some countries such as France, the United Kingdom and the United States 
have overseas colonies, protectorates or territories. These populations are generally excluded. 
The calculation of GDP per capita and other economic measures may, however, be based on 
a different population in these countries, depending on the data coverage.
OECD country ISO codes
Australia AUS Korea KOR
Austria AUT Latvia LVA
Belgium BEL Luxembourg LUX
Canada CAN Mexico MEX
Chile CHL Netherlands NLD
Czech Republic CZE New Zealand NZL
Denmark DNK Norway NOR
Estonia EST Poland POL
Finland FIN Portugal PRT
France FRA Slovak Republic SVK
Germany DEU Slovenia SVN
Greece GRC Spain ESP
Hungary HUN Sweden SWE
Iceland ISL Switzerland CHE
Ireland IRL Turkey TUR
Israel ISR United Kingdom GBR
Italy ITA United States USA
Japan JPN
Partner country ISO codes
Brazil BRA Indonesia IDN
China CHN Lithuania LTU
Colombia COL Russian Federation RUS
Costa Rica CRI South Africa ZAF
India IND
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Chapter 1
Indicator overview: OECD snapshots 
and country dashboards
This chapter presents a set of selected indicators on health and health system 
performance, designed to shed light on how well OECD countries perform along 
five dimensions: health status, risk factors for health, access to care, quality and 
outcomes of care, and health care resources. These indicators, taken from the main 
chapters of the publication, are presented in the form of OECD snapshots and 
country dashboards. The former illustrates time trends for the OECD as a whole, 
together with a snapshot of the latest available data (OECD average, top and 
bottom performers). The dashboards summarise how each country performs on all 
indicators compared to the OECD average.
The selection of the indicators presented in this chapter was based on policy 
relevance, data availability and ease of interpretation. The selection and comparison 
of indicators is meant to capture relative strengths and weaknesses of countries 
to help identify possible areas for priority action, though not to identify which 
countries have the best health system overall.
 
 
 
 
The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli 
authorities. The use of such data by the OECD is without prejudice to the status of the Golan Heights, 
East Jerusalem and Israeli settlements in the West Bank under the terms of international law.
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OECD snapshots and country dashboards
Policy makers in OECD countries have a keen interest to understand how well their 
health systems perform. A look at indicators contained in this publication shows that 
significant progress has already been achieved. People in OECD countries are living longer 
than ever before, with life expectancy at birth now exceeding 80 years on average, thanks 
to improvements in living conditions and educational attainments, but also to healthier 
lifestyles and progress in health care.
In most countries, universal health coverage provides financial protection against the 
cost of illness and promotes access to care for the whole population. Quality of care has also 
generally improved, as shown by the reduction in deaths after heart attacks and strokes, 
and the earlier detection and improved treatments for diseases such as diabetes and cancer. 
But these improvements have come at a cost: health spending now accounts for about  
9% of GDP on average in OECD countries, and exceeds 10% in many countries. Higher health 
spending is not necessarily a problem when the benefits exceed the costs, but there is ample 
evidence of inequities and inefficiencies in health. There is also a need to achieve a better 
balance between spending on curative care and disease prevention.
Despite these improvements, important questions remain about how successful 
countries are in achieving good results on different dimensions of health system 
performance. For example, what are the main factors explaining differences in health 
status and life expectancy across OECD countries? Is the increase in the prevalence of 
certain risk factors, such as obesity, offsetting some of the gains from the reduction in 
other risk factors like smoking? To what extent can citizens benefit from adequate and 
timely access to care, and good financial protection against the costs of health care? What 
do we know about the quality and safety of care provided to people for a range of common 
health conditions? What are the financial, human and technical resources allocated to 
health systems in different countries?
Answering these questions is by no means an easy task, but the snapshots and 
dashboards presented in this chapter can help shed light on how well countries do in 
promoting the health of their population and on several dimensions of health system 
performance. They do not have the ambition of identifying which countries have the overall 
best health system; rather, they summarise some of the relative strengths and weaknesses 
of OECD countries on a selected set of indicators of health and health system performance. 
They can be useful to identify areas for priority action, but should be complemented by a 
more in-depth review of the data and factors influencing cross-country variations, presented 
in the main chapters of this publication.
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This chapter presents five sets of indicators, which are discussed in full in the chapters 
in parentheses, highlighting how well countries fare in each of the following dimensions:
●● Health status (Chapters 3 and 11)
●● Risk factors for health (Chapter 4)
●● Access to care (Chapter 5)
●● Quality of care (Chapter 6)
●● Health care resources (Chapters 7, 8 and 9)
For each of these dimensions, a set of 4-5 relevant indicators is presented in the form 
of OECD snapshots and country dashboards. These indicators are selected from the publication 
based on their policy relevance and importance as key factors to monitor in a health system, 
but also on data availability and interpretability. Therefore, indicators for which country 
coverage is highest are prioritised to improve comparability.
OECD snapshots, newly introduced, provide summary statistics for key indicators in 
the five dimensions listed above. They complement the country dashboards by visualising:
●● the latest OECD average (for quick comparison with country figures in the dashboards)
●● the distribution of top and bottom values (for a general sense of the dispersion surrounding 
each indicator)
●● the overall OECD trend since 2005 (to highlight changes over time)
The snapshots complement the country dashboards, helping the reader make a first 
assessment of a country’s performance vis-à-vis the OECD average and value range before 
delving into the more detailed indicator chapters of the publication.
Country dashboards, in the form of summary tables, compare a country’s performance 
to one another and the OECD average. Countries are classified for each indicator into three 
colour-coded groups:
●● Blue, when the country’s performance is within close distance of the OECD average
●● Green, when the country’s performance is considerably better than the OECD average
●● Red, when the country’s performance is considerably worse than the OECD average
The only exception to this grouping is for the dashboard on health care resources 
(Table 1.5), where the indicators presented cannot be strictly classified as better or worse 
performance. For this reason, the colour coding in this dashboard uses a lighter and darker 
shade of blue to signal that a country is considerably below or above the OECD average. 
Values for each indicator are shown for all countries and for the OECD as a whole.
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Health status
life expectancy is a key indicator to understanding the overall health of a population. It 
therefore is the focus of this section, with three indicators reflecting gender and age-specific 
life expectancies. More specific indicators on ischaemic heart mortality and dementia 
prevalence are also shown, two major causes of mortality and morbidity today and in the 
future. Figure 1.1 provides a snapshot on health status across the OECD and Table 1.1 provides 
more detailed country comparisons.
Figure 1.1. Snapshot on health status across the OECD
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Note: the Y-axis for OECD trends is standardised to have fixed height, based on the minimum and maximum values 
of the indicator. The high-low x-axis is standardised with constant distance from the OECD average whenever the 
indicator is not truncated at 0. 
 Methodology, interpretation and use
OECD snapshots
For each indicator, the OECD average, highest and lowest values for the latest available year are shown, 
corresponding to the data presented in the main chapters of the publication. The spark lines on the right 
show OECD-wide trends in recent years. These are calculated based on an unweighted mean of the data 
available for each year (data linearly interpolated when unavailable, for consistency regarding the number 
of countries used for the means). These spark lines are intended to give a broad overview of trends, given 
potential differences in methodology or country composition over time.
Country dashboards
The classification of countries as better, worse or within close distance of the OECD average is based on 
each indicator’s standard deviation. This method is preferred to using a fixed percentage or fixed number of 
countries per category, since it reflects variation (how far a country is from the OECD average) in a dynamic way.
The standard deviation is a common statistical indicator of variation in a distribution, measuring how close 
values are to the central tendency. Countries are classified as “close to the OECD average” (blue) whenever 
the value for any indicator is within one standard deviation from the OECD mean for the latest year. In rare 
cases, particularly large outliers are excluded from the calculation of the standard deviation. These exceptions 
are noted under the relevant dashboards.
For a typical indicator, about 65% of the countries (23 countries) will be close to the OECD average, with 
the remaining 35% performing significantly better (green) or worse (red). When the number of countries that 
are close to the OECD average is higher (lower) than 23, it means that cross-country variation is relatively 
low (high) for that indicator. For example, indicators such as male life expectancy and alcohol consumption 
show that 28 countries are close to the OECD average, meaning that countries show relatively less variation 
compared to other indicators.
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In general, Japan, France and Spain have the best overall health outcomes in terms 
of life expectancy and ischaemic heart mortality. Hungary, latvia, Mexico and the Slovak 
Republic are consistently below the OECD average for these indicators. Across the OECD, life 
expectancy has increased steadily over time, though about half of the countries reported 
slight falls in life expectancy between 2014 and 2015. At the same time, some of the countries 
with the highest rates of dementia prevalence are the countries with longer life expectancies, 
such as Japan and Italy. Dementia prevalence also shows the greatest amount of variation 
across countries, amongst these indicators.
Important variations in life expectancy by gender and age exist. Women in Japan, 
Spain and France live much longer than the OECD average; while male life expectancy 
is particularly high in Iceland. life expectancy at 65 is noticeably lower than the OECD 
average in 12 countries, and noticeably higher than the average in Japan, France and Spain. 
life expectancy is affected by a range of factors within and beyond the health system. 
Higher health spending per capita is positively associated with life expectancy, though 
this relationship is less pronounced in countries with the highest health spending, such as 
luxembourg, Norway, Switzerland and the United States. Differences in risky behaviours 
such as smoking and obesity, which have a major impact on health, can also partly explain 
cross-country variation and differences in life expectancies. Factors beyond the health 
system are also important determinants of health, including income, education and other 
socio-economic factors.
Ischaemic heart disease remains the highest cause of mortality in most OECD countries, 
though there has been an average decline of more than 50% since 1990. Mortality rates 
are considerably above the OECD average in five countries, and are highest in latvia, the 
Slovak Republic and Hungary; whereas they are relatively low in Japan, Korea, France and 
the Netherlands.
The prevalence of dementia, a variety of brain disorders of which Alzheimer’s disease 
is the most common form, is a core indicator to monitor the health of ageing populations. 
Dementia prevalence is noticeably higher than the OECD average in seven countries and 
highest in Japan, Italy and Germany. Countries with younger populations typically have 
lower dementia prevalence, with Mexico, Turkey and the Slovak Republic having the lowest 
rates of dementia.
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Table 1.1. Dashboard on health status
✓ Better than OECD average  Close to OECD average Ð  Worse than OECD average – Missing data
 
LIFE 
EXPECTANCY (M)
LIFE 
EXPECTANCY (F)
LIFE 
EXPECTANCY (65)
ISCHAEMIC  
MORTALITY
DEMENTIA  
PREVALENCE
Years of life at birth,  
males 
Years of life at birth,  
females
Years of life at age 65, 
total
Age-standardised rate 
per 100 000 population
Cases per  
1 000 population
OECD 77.9 83.1 19.5 112 14.8
Australia 80.4   84.5   20.9   85   14.2  
Austria 78.8   83.7    19.7   131   18.0  
Belgium 78.7   83.4    19.9   54   18.0  
Canada 79.6   83.8   20.2   93   13.0  
Chile 76.5   81.7   18.5   64   11.7    
Czech Republic 75.7   81.6   17.7 Ð 237 Ð 10.4 ✓ 
Denmark 78.8   82.7   19.4   60   16.4  
Estonia 73.2 Ð 82.2   18.1 Ð 211 Ð 14.7  
Finland 78.7   84.4   20.1   147   18.5  
France 79.2   85.5 ✓ 21.5 ✓ 39 ✓ 19.7 Ð 
Germany 78.3   83.1     19.5   106   20.2 Ð 
Greece 78.5   83.7   19.9   82   19.6 Ð 
Hungary 72.3 Ð 79.0 Ð 16.4 Ð 288 Ð 10.6  
Iceland 81.2 ✓ 83.8   20.4   100   13.0   
Ireland 79.6   83.4   19.7   127   11.5  
Israel 80.1   84.1   20.2   64   10.5   
Italy 80.3   84.9   20.6   84   22.5 Ð 
Japan 80.8   87.1 ✓ 21.9 ✓ 34 ✓ 23.3 Ð 
Korea 79.0   85.2   20.3   38 ✓ 9.6 ✓ 
Latvia 69.7 Ð 79.5 Ð 16.6 Ð 328 Ð 14.6  
Luxembourg 80.0    84.7   20.4   59   13.3  
Mexico 72.3 Ð 77.7 Ð 17.7 Ð 144   7.2 ✓ 
Netherlands 79.9   83.2   19.8   46 ✓ 16.1  
New Zealand 79.9   83.4   20.4   129   13.5  
Norway 80.5   84.2    20.3   72   15.1  
Poland 73.5 Ð 81.6   17.9 Ð 98   9.9 ✓ 
Portugal 78.1   84.3   19.9   55   19.9 Ð 
Slovak Republic 73.1 Ð 80.2 Ð 16.9 Ð 291 Ð 8.3 ✓ 
Slovenia 77.8    83.9   19.5   82   11.8   
Spain 80.1    85.8 ✓ 21.0 ✓ 53   19.4 Ð 
Sweden 80.4    84.1    20.2    95    18.1    
Switzerland 80.8   85.1    20.9    78   17.2  
Turkey 75.3   80.7 Ð 17.8 Ð 146   8.0 ✓ 
United Kingdom 79.2   82.8   19.7   98    17.1    
United States 76.3    81.2   19.3   113   11.6  
Note: All data refer to 2015 or nearest year, except for dementia prevalence, which refers to 2017. Indicators are taken from Chapter 3 (life 
expectancy, male and female; ischaemic mortality) and Chapter 11 (life expectancy at 65; dementia prevalence).
Source: OECD Health Statistics 2017; OECD analysis of data from the World Alzheimer Report 2015 and the United Nations (for prevalence 
of dementia). 
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Risk factors for health
Smoking, alcohol consumption and obesity are three major risk factors for non-
communicable diseases. Population exposure to air pollution is also a critical non-medical 
determinant of health. Figure 1.2 provides a snapshot on risk factors for health across the 
OECD and Table 1.2 provides more detailed country comparisons.
Figure 1.2. Snapshot on risk factors for health across the OECD
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indicator is not truncated at 0. Air pollution shows data for 2005 and 2010 to 2015. 
In general, Iceland, Norway and Sweden perform well across these indicators. Smoking 
rates are considerably below the OECD average in Mexico, Iceland, Sweden, the United States, 
Norway and Australia; whereas they are much higher in Greece, Turkey, Hungary, Austria and 
latvia. Although most countries have managed to reduce smoking rates in recent decades, 
there is still significant progress to be made. Tobacco smoking has been estimated by the 
World Health Organization to kill 7 million people each year, yet, on average 18.5% of adults 
still report daily smoking across the OECD.
Excessive alcohol consumption is also a considerable health burden, associated to 
increased risk for a range of illnesses, including cancer, stroke, liver disease, as well as social 
problems, with an estimated 2.3 million deaths per year. Populations in Belgium, Austria and 
France consume considerably more litres per capita than the OECD average, while it is relatively 
low in Turkey, Israel, Mexico and Norway. Alcohol consumption has been fluctuating over the 
past 15 years, with a slight reduction across the OECD as a whole in average litres consumed 
(based on sales figures). Binge drinking is of particular concern in certain countries, notably 
Germany, Finland, luxembourg and Denmark, and is more predominant among men.
Obesity is a major risk factor for many chronic diseases, including diabetes, cardiovascular 
diseases and cancer. Obesity rates have been increasing in recent decades in almost all OECD 
countries, with an average of 54% people overweight, of which 19% are obese. Obesity rates 
are considerably higher than the OECD average in five countries, with rates highest in the 
United States and Mexico. Obesity is lowest in Japan, Korea, Italy and Switzerland. The measure 
reported here is for obese adults based on both measured and self-reported data. Caution 
should be taken in comparing countries with reporting differences, since measured data is 
generally much higher (and more accurate).
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Air pollution is a major environmental threat, with health links to lung cancer, respiratory 
and cardiovascular disease, low birth weight, dementia and other health problems. 
Population exposure to fine particulates (PM2.5) is particularly high in Turkey, Korea, Poland 
and Hungary. It is considerably below the OECD average in Australia, New Zealand, Sweden, 
Canada, Finland and Iceland. While the overall trend since 1990 has been downward, there 
have been some increases in population exposure to PM2.5 in more recent years.
Table 1.2. Dashboard on risk factors for health
✓ Better than OECD average  Close to OECD average Ð  Worse than OECD average – Missing data
  SMOKING ALCOHOL OBESITY AIR POLLUTION
% of population who  
smokes daily
Liters per capita consumed  
in a year
% of population  
with BMI > 30
Mean annual exposure  
to PM2.5, mg/m3 
OECD 18.4 9.0 19.4 15.1
Australia 12.4 ✓ 9.7   27.9 Ð 5.9 ✓ 
Austria 24.3 Ð 12.3 Ð 14.7   17.0  
Belgium 18.9   12.6 Ð 18.6   15.6  
Canada 14.0   8.1   25.8   7.2 ✓ 
Chile – 7.2   – 20.9  
Czech Republic 18.2   11.5   18.7   21.4  
Denmark 17.0   9.4   14.9   11.0  
Estonia 21.3   10.3   18.0   9.4  
Finland 17.4   8.5   24.8   7.4 ✓ 
France 22.4   11.9 Ð 17.0   12.4  
Germany 20.9   11.0   23.6   14.0  
Greece 27.3 Ð 7.5   17.0   13.5  
Hungary 25.8 Ð 10.9   30.0 Ð 23.1 Ð 
Iceland 10.2 ✓ 7.5   19.0   7.8 ✓ 
Ireland 19.0   10.9   23.0   9.8  
Israel 19.6   2.6  ✓ 16.6   21.1  
Italy 20.0   7.6   9.8  ✓ 19.9  
Japan 18.2   7.2   3.7  ✓ 13.3  
Korea 17.3   9.1   5.3  ✓ 28.7 Ð 
Latvia 24.1 Ð 10.8   23.2   20.4  
Luxembourg 14.9    11.1   22.6   16.6  
Mexico 7.6  ✓ 5.2  ✓ 33.3 Ð 20.2  
Netherlands 19.0   8.0   12.8   14.6  
New Zealand 14.2   8.9   31.6 Ð 5.5 ✓ 
Norway 12.0  ✓ 6.0  ✓ 12.0  ✓ 9.1  
Poland 22.7   10.5   16.7   24.3 Ð 
Portugal 16.8   9.9   16.6   9.8  
Slovak Republic 22.9   10.2   16.3   20.5  
Slovenia 18.9    11.5   19.2   20.3  
Spain 23.0    9.3   16.7   9.7  
Sweden 11.2  ✓ 7.2   12.3  ✓ 6.2 ✓ 
Switzerland 20.4   9.5   10.3  ✓ 12.9  
Turkey 27.3 Ð 1.4  ✓ 22.3   36.4 Ð 
United Kingdom 16.1   9.5   26.9 Ð 12.4  
United States 11.4  ✓ 8.8   38.2 Ð 8.4  
Note: All data refer to 2015 or nearest year. Indicators are taken from Chapter 4.
Obesity data reports a mix of measured and self-reported weights, with measured data often being higher and more accurate compared 
to self-reported weight. Chapter 4 details the country coverage for each measure.
Source: OECD Health Statistics 2017; World Development Indicators (for air pollution). 
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Access to care
Access to care is a critical measure of health system performance. Indicators presented 
here include population coverage, an overall measure of health care coverage, alongside 
indicators reflecting financial and timely access. The access to care chapter also includes 
geographic accessibility measures, not included here because of the complexity of cross-
country comparisons. Figure 1.3 provides a snapshot on access to care across the OECD and 
Table 1.3 provides more detailed country comparisons.
Figure 1.3. Snapshot on access to care across the OECD
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Note: the Y-axis for OECD trends is standardised to have fixed height, based on the minimum and maximum values 
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In terms of population coverage, most OECD countries have achieved universal (or near-
universal) coverage of health care costs for a core set of services, except for six countries 
which remain considerably below the OECD average – Chile, Greece, Mexico, Poland, the 
Slovak Republic and the United States.
Population coverage, though, is not sufficient by itself. The degree of cost-sharing 
applied to those services also affects access to care. Out-of-pocket (OOP) expenditures and 
consultations skipped due to cost are two indicators measuring financial access, which is 
of particular concern for low-income population groups. OOP expenditures can create 
financial barriers to health care. Across the OECD, they have made up a slightly increasing 
share of household consumption over time, and are relatively high in Korea, Switzerland, 
Greece, Hungary, Mexico, Portugal and Chile. The rate of consultations skipped due to cost is 
particularly high in Poland, the United States and Switzerland (for the subset of 17 countries 
with comparable data).
long waiting times are also an important barrier to access in many OECD countries. They 
are the result of a complex interaction between supply and demand of health services, with 
doctors playing a crucial role on both sides. long waiting times for elective (non-emergency) 
surgery lead to patients suffering unnecessary pain and disability. Waiting times for cataract 
surgery, one of the most commonly reported indicators, are particularly high in Poland and 
Estonia (for the subset of 16 countries with comparable data), while numbers are very low 
for Canada, Italy and the Netherlands.
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Table 1.3. Dashboard on access to care
✓ Better than OECD average  Close to OECD average Ð  Worse than OECD average – Missing data
 
POPULATION  
COVERAGE
SHARE OF OUT OF POCKET 
EXPENDITURE
WAITING TIMES FOR  
CATARACT SURGERY **
CONSULTATIONS SKIPPED  
DUE TO COST *
% of population covered  
by insurance
% of final household  
consumption
Number of days from  
referral to procedure
Age-sex standardised 
rate per 100 population
OECD 97.9 3.0 121 10.5
Australia 100   3.1   93 ✓ 16.2  
Austria 99.9   3.0   – –
Belgium 99.0   3.2   – –
Canada 100   2.2   58 ✓ 6.6  
Chile 92.1 Ð 4.1 Ð 103   –
Czech Republic 100   2.3   – –
Denmark 100   2.6   87 ✓  –
Estonia 94.0   2.7   253 Ð 9.7  
Finland 100   3.0   103   –
France 99.9   1.4 ✓ – 8.5  
Germany 100   1.8 ✓ – 2.6 ✓ 
Greece 86.0 Ð 4.4 Ð – –
Hungary 95.0   4.4 Ð 88 ✓ –
Iceland 100   3.1   – –  
Ireland 100   2.5   – –
Israel 100   3.4   132   4.7  
Italy 100   3.1   50 ✓ 4.8  
Japan 100   2.6   – –
Korea 100   5.1 Ð – –   
Latvia – 3.9 Ð – –
Luxembourg 95.2    1.4 ✓ – –
Mexico 92.3 Ð 3.6   – –
Netherlands 99.9   2.4   37 ✓ 10.3  
New Zealand 100   2.1   73 ✓ 14.5  
Norway 100   2.9    117    5.9  
Poland 91.0 Ð 2.5   464 Ð 33.0 Ð 
Portugal 100   3.8 Ð 104   8.3  
Slovak Republic 93.8 Ð 2.4   – –
Slovenia 100    2.0   – –  
Spain 99.8    3.7   105   2.8 ✓ 
Sweden 100    3.3   – 3.9 ✓ 
Switzerland 100   5.3 Ð – 20.9 Ð 
Turkey 98.4   – – –
United Kingdom 100   1.5 ✓ 72 ✓ 4.2 ✓ 
United States 90.9 Ð 2.5   – 22.3 Ð 
* Poland is excluded from the standard deviation calculation. ** Estonia and Poland are excluded from the standard deviation calculation. 
The values for Australia and Canada are reported in median number of days, rather than mean.
Note: Data on population coverage, share of OOP and waiting times refers to 2015, consultations skipped due to cost refer to 2016. 
Indicators are taken from Chapter 5.
Source: OECD Health Statistics 2017; Commonwealth Fund International Health Policy Survey 2016 and other national sources. 
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Quality and outcomes of care
Measures of the quality and outcomes of care should reflect appropriateness of 
care, clinical effectiveness, patient safety and the person responsiveness of care. The 
appropriateness of care is measured by antibiotics prescribed and asthma/COPD admissions 
as an indicator of avoidable admissions. 30-day mortality following acute myocardial 
infarction (AMI) and colon cancer survival are indicators of clinical effectiveness; obstetric 
trauma is a measure of patient safety. Figure 1.4 provides a snapshot on quality and outcome 
of care across the OECD and Table 1.4 provides more detailed country comparisons.
Figure 1.4. Snapshot on quality and outcomes of care across the OECD
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Asthma and COPD admissions are conditions for which effective treatment at the 
primary care level is well established, but they vary significantly across countries. They 
are considerably higher than the OECD average in Hungary, Turkey, Ireland, Australia, 
New Zealand and latvia; but much lower than the OECD average in Japan, Italy, Portugal, 
Mexico and Chile. The number of antibiotics prescribed is higher than the OECD average in 
Greece, France, Belgium and Italy. Antibiotic prescriptions are considerably below the OECD 
average in the Netherlands, Estonia, Sweden, latvia and Austria. The number of antibiotics 
prescribed has increased slightly over time, with overuse of antibiotics not only a wasteful 
use of resources, but also responsible for increased antimicrobial resistance. 
Mortality following acute myocardial infarction (admission-based) is a long-established 
indicator of the quality of acute care. It has been steadily declining since the 1970s in most 
countries, yet important cross-country differences still exist. Mexico shows very high 
mortality following AMI; rates are also relatively high in latvia, Japan, Chile and Estonia. 
Eight countries have mortality rates considerably below the OECD average, with Norway, 
Australia and Denmark having the lowest rates.
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Colon cancer survival rates vary relatively less than AMI, with only Israel and Korea 
performing better than the average, and five countries performing considerably worse, with 
Chile and Slovenia having the lowest rates.
Obstetric trauma (with instrument) is the most robust measure available for the dimension 
of patient safety. For the subset of 21 countries with comparable data, obstetric trauma is 
highest in Canada, followed by Sweden, Denmark and the United States. In contrast, rates 
of obstetric trauma are considerably lower than the OECD average in Poland, Israel, Italy, 
Slovenia and Portugal.
Table 1.4. Dashboard on quality of care
✓ Better than OECD average  Close to OECD average Ð  Worse than OECD average – Missing data
 
ASTHMA AND COPD 
HOSPITAL ADMISSIONS
ANTIBIOTICS  
PRESCRIBED
 ACUTE MYOCARDIAL 
INFARCTION MORTALITY*
COLON  
CANCER SURVIVAL
OBSTETRIC TRAUMA 
(INSTRUMENT) **
Age-sex standardised 
rate per 100 000 
population
Defined daily dose 
per 1 000 population
Age-sex standardised 
rate per 100 000 
population
Age-standardised 
survival rate in %
Crude rates per 100 
vaginal deliveries
OECD 236 20.6 7.5 62.8 5.7
Australia 371 Ð 23.4   4.0 ✓ 70.6 ✓ 7.2  
Austria 330   14.0 ✓ 7.4   63.7   –
Belgium 286   29.2 Ð 7.0   67.8   3.4  
Canada 247   20.8   5.1 ✓ 67.2   16.9 Ð 
Chile 99 ✓ – 11.3 Ð 51.5 Ð –
Czech Republic 193   19.6   6.9   56.1 Ð –
Denmark 333   16.1   4.0  ✓ 61.6   10.9 Ð 
Estonia 137   12.1 ✓ 10.6 Ð 58.4   3.9  
Finland 184   17.2   5.6   64.8   3.7  
France 150   29.9 Ð 5.6   63.7   –
Germany 284   14.4 ✓ 7.7   64.8   6.4  
Greece – 36.1 Ð – – –
Hungary 428 Ð 17.0   – – –
Iceland 223   19.9   5.9   68.2   –
Ireland 411 Ð 25.6   6.4   60.5   4.2  
Israel 259   21.4   6.7   71.7 ✓ 1.9 ✓ 
Italy 64 ✓ 27.5 Ð 5.4   64.1   1.9 ✓ 
Japan 58 ✓ – 11.7 Ð 67.8   –
Korea 309   24.3   8.1   71.6 ✓ –
Latvia 341 Ð 13.3 ✓ 13.4 Ð 56.4 Ð –
Luxembourg 186    26.3   7.3   – –
Mexico 96 ✓ – 28.1 Ð – –
Netherlands 202   10.7 ✓ 5.4   63.0   3.2  
New Zealand 363 Ð 25.8   4.7 ✓ 64.0   8.5  
Norway 261   15.8    3.7 ✓ 66.6   2.5  
Poland 234   26.2   4.4 ✓ 52.8 Ð 0.7 ✓ 
Portugal 74 ✓ 21.3   7.9   60.9   2.5 ✓ 
Slovak Republic 238    24.5   6.4   51.7 Ð –
Slovenia 146    14.5   6.1   61.9   2.1 ✓ 
Spain 234    21.6   7.9   63.3   4.8   
Sweden 184    12.3 ✓ 4.2 ✓ 64.9    11.3 Ð 
Switzerland 138   – 5.1 ✓ 67.2   7.4  
Turkey 414 Ð 17.3   8.6   54.6 Ð –
United Kingdom 303   20.1   7.1   60.0    6.8    
United States 262    – 6.5   64.9   9.6 Ð 
Note: All data refer to 2015 or nearest year. Indicators are taken from Chapter 6.
* Mexico is excluded from the calculation of the standard deviation. ** Canada is excluded from the calculation of the standard deviation.
Source: OECD Health Statistics 2017. 
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Health care resources
Having sufficient health care resources is critical to the functioning of health systems. 
But higher resources do not automatically translate into better health outcomes – the 
effectiveness of spending is also important. Health care expenditure per capita is the most 
immediate summary measure of health care resources. The supply of health workers (doctors 
and nurses) and hospital beds are also reported, since higher health spending is not always 
closely related to these indicators. Figure 1.5 provides a snapshot on health care resources 
across the OECD and Table 1.5 provides more detailed country comparisons.
Figure 1.5. Snapshot on health care resources across the OECD
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In general, countries with higher health spending and higher numbers of health workers 
and other resources have better health outcomes, quality and access to care. However, the 
absolute number of resources invested is not a perfect predictor of better outcomes – efficient 
use of health resources is also critical.
In terms of overall health care expenditure, the United States spends considerably 
more per person than any other country. Health care spending is also high in Switzerland, 
luxembourg and Norway. Nine countries spend less than the OECD average, with health 
spending per capita lowest in Mexico, Turkey and latvia. Health spending has been 
consistently growing in all countries over the past decades, other than a slowdown following 
the financial crisis. looking at growth rates of spending as a share of GDP, in addition to 
absolute levels of spending, can give a better perspective on how much countries spend 
relative to the general economy.
A large part of health spending is translated into wages for the workforce. The number 
of doctors and nurses in a health system is therefore an important way of monitoring how 
resources are being used. The number of doctors per capita is relatively high in Greece, Austria, 
Portugal and Norway. Among these countries, Greece has one of the lowest numbers of 
nurses per capita, suggesting the potential to decrease the doctors to nurses ratio. This could 
generate significant cost savings in the long run. In contrast, Norway has one of the highest 
numbers of nurses (Austria and Portugal nurses per capita are close to the OECD average). 
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Nurses per capita are particularly high in Switzerland, Germany and Nordic countries. While 
the total number of nurses has grown more than doctors in absolute terms, both have grown 
at similar rates in recent years, at around 13%.
Hospitals also take an important share of health care resources, with hospital beds 
per capita a marker of the physical and technical resources available in a health system. 
Reductions in the number of beds in many OECD countries over the past years have been 
a voluntary effort to encourage a shift to day surgery and primary care. Nevertheless, the 
number of beds per capita remains particularly high in Japan and Korea.
Table 1.5. Dashboard on health care resources
 Above OECD average   Close to OECD average  Below OECD average – Missing data
 
HEALTH CARE  
EXPENDITURE *
DOCTORS PER  
CAPITA
NURSES PER  
CAPITA
BEDS PER  
CAPITA **
Total spending per capita,  
USD PPP    
Number of practising pysicians 
per 1 000 population
Number of practising nurses  
per 1 000 population
Number of beds  
per 1 000 population
OECD 4 003 3.4 9.0 4.7
Australia 4 708   3.5   11.5   3.8  
Austria 5 227   5.1  8.1   7.6  
Belgium 4 840   3.0   10.8   6.2  
Canada 4 753   2.7   9.9   2.6  
Chile 1 977  2.1  2.1  2.1  
Czech Republic 2 544   3.7   8.0   6.5  
Denmark 5 199   3.7   16.7  2.5  
Estonia 1 989  3.4   6.0   5.0  
Finland 4 062   3.2   14.7  4.4  
France 4 600   3.3   9.9   6.1  
Germany 5 551   4.1   13.3  8.1  
Greece 2 223  6.3  3.2  4.3  
Hungary 2 101  3.1   6.5   7.0  
Iceland 4 376   3.8   15.5  3.1   
Ireland 5 528   2.9   11.9   3.0  
Israel 2 822   3.4   4.9   3.0  
Italy 3 391   3.8   5.4   3.2  
Japan 4 519   2.4  11.0   13.2  
Korea 2 729   2.2  5.9   11.5  
Latvia 1 466  3.2   4.7   5.7  
Luxembourg 7 463  2.9   11.9   4.8  
Mexico 1 080  2.4  2.8  1.5  
Netherlands 5 385   3.5   10.5   4.2  
New Zealand 3 590   3.0   10.3   2.7  
Norway 6 647  4.4  17.3  3.8  
Poland 1 798  2.3  5.2   6.6  
Portugal 2 734   4.6  6.3   3.4  
Slovak Republic 2 150  3.5   5.7   5.8  
Slovenia 2 835    2.8   8.8   4.5  
Spain 3 248    3.9   5.3   3.0  
Sweden 5 488   4.2   11.1   2.4  
Switzerland 7 919  4.2   18.0  4.6  
Turkey 1 088  1.8  2.0  2.7  
United Kingdom 4 192   2.8   7.9   2.6  
United States 9 892  2.6   11.3   2.8  
Note: All data refer to 2015 or nearest year, except for health care expenditure, which refers to 2016. Indicators are taken from Chapter 7 
(health expenditure), Chapter 8 (doctors and nurses per capita) and Chapter 9 (beds per capita).
* United States is excluded from the standard deviation calculation. ** Japan and Korea are excluded from the standard deviation 
calculation. For Ireland, private hospitals beds are excluded.
Source: OECD Health Statistics 2017. 
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Chapter 2
What has driven life expectancy gains 
in recent decades? A cross-country 
analysis of OECD member states
Countries with higher national income and health spending tend to have longer 
life expectancies. But these factors can only account for a part of life expectancy 
differences across countries. This chapter analyses the factors contributing to health 
status, including a closer assessment of the determinants of health that go beyond 
the health system. It shows that on average, a 10% increase in health spending per 
capita is associated with a gain of 3.5 months of life expectancy. The same rate of 
improvement in healthier lifestyles (10%) is associated with a gain of 2.6 months 
of life expectancy. Wider social determinants are also important: a 10% increase in 
income per capita is associated with a gain of 2.2 months of life expectancy, and a 
10% increase in primary education coverage with 3.2 months. For income, minimum 
absolute levels are particularly critical to protecting people’s health.
The main policy implication emerging from this analysis is the significant opportunities 
for health improvement from coordinated action across ministries responsible for 
education, the environment, income and social protection, alongside health ministries. 
This includes inter-sectoral action to address health-related behaviours. Collaboration 
with the private sector will also be important, especially with employers in relation to 
working conditions.
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Introduction
life expectancy has risen steadily in most OECD countries, increasing over ten years on 
average since 1970. Mortality rates from the main causes of death, cardiovascular diseases 
and cancer, have generally fallen. Today, countries with higher national income and health 
spending tend to have longer life expectancies. But these factors can only account for a part 
of life expectancy differences across countries. Furthermore, life expectancy varies across 
population groups. For example, life expectancy is lower amongst individuals with lower 
levels of education across all OECD countries (Murtin et al., 2017).
This chapter explores the determinants of life expectancy gains in OECD countries. These 
include drivers beyond the health system – the demographic, economic and social context 
– alongside health system factors. Such analysis complements subsequent chapters in this 
Health at a Glance edition, which focus predominantly on cross-country comparisons of 
health care system performance. Referring back to the conceptual framework underpinning 
Health at a Glance, this chapter analyses the factors contributing to health status, including 
a closer assessment of the determinants of health that go beyond the health system 
(Figure 2.1).
Figure 2.1. Determinants of health and the Health at a Glance  
conceptual framework
Access
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Health care system performance
How does the health system perform? What is the level of quality of care and access to services?
What does the performance cost?
Drivers beyond the health system, including income,
education, working and living conditions
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Analysis is based on country-level data for the time period 1995-2015, and covers all 
35 OECD member states. Empirical findings are complemented by an assessment of the 
mechanisms by which drivers within and beyond the health system affect health.
Understanding the determinants of health
Health outcomes depend on investments both within and beyond the health system
Biological endowment and health service availability are not sufficient to explain 
differences in individuals’ health. But a growing body of evidence has demonstrated that 
an individual’s health also depends on factors that go beyond the medical care received 
(Marmot and Wilkinson, 2006; WHO, 2008). Some of these factors can still be influenced 
by health systems directly, through public health and prevention measures. In particular, 
non-medical determinants related to lifestyle choices are important. These include major 
risk factors such as smoking, alcohol and unhealthy diet, and conversely health-seeking 
activities such as physical activity.
But broader social determinants of health also matter. Income, education, working 
and living conditions are all also important factors. Having a sufficient income allows 
people to purchase essential goods and services that sustain or improve health, such as 
nutritious food and shelter; though higher income can also involve longer work hours 
and greater stress (Fuchs, 2004). The more educated, as well as often being richer, may be 
better informed about health-seeking activities (Mackenbach et al., 2008). Unemployment 
and poor working conditions adversely affect mental health, and certain occupations 
carry a greater risk of injury (Bassanini and Caroli, 2014). living in an unsanitary, unsafe 
or polluted environment also increases the risk of illness or death (Gibson et al., 2011; 
Deguen and Zmirou-Navier, 2010).
The social determinants of health are closely inter-linked. Indeed, this makes it hard 
to empirically disentangle the individual effects of different factors on health (Fuchs, 2004). 
But what is evident is that these factors will, in general, reinforce each other. For example, 
the better educated are also likely to be richer, live in healthier environments, and be less 
likely to smoke. Further, some researchers argue that large income differences not only 
cause health inequalities, but may also be detrimental to population health (Pickett and 
Wilkinson, 2015). Finally, health inequalities are likely to persist over the life cycle and 
across generations, with early life circumstances influencing future health and economic 
prospects.
Further, despite the fact that most OECD countries have achieved universal health 
coverage, individuals from the most disadvantaged groups tend to have worse access to 
health services. For example, some individuals may be unaware or unwilling to use the full 
range of health services available to them. Quality of care may be worse in more socially 
deprived areas; co-payments and other direct payments by users without effective exemption 
mechanisms will disproportionately affect the poor (OECD, 2014, 2015a).
Studies using aggregated data highlight the contribution of socio-economic factors 
to health
A range of studies have estimated an empirical ‘health production function’ using 
aggregated data. Such analyses have been used to assess the contribution of health spending, 
socio-economic and other factors on population health.1
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In general, health spending, income and education have significant beneficial impacts 
on population health (Berger and Messer, 2002; OECD, 2010; Heijink et al., 2013; Moreno-
Serra and Smith, 2015); with pollution and lifestyle factors (particularly smoking and alcohol 
consumption) typically having significant adverse effects (Shaw, 2005; Blázquez-Fernádez 
et al., 2013). Far fewer studies have incorporated variables reflecting unemployment, 
occupational category or income inequality, and when included they have had more mixed 
results (Or, 2000; lin, 2009).
Note that health spending and income have typically had a stronger impact on reducing 
avoidable mortality or infant mortality than on increasing life expectancy (Heijink et al., 2013; 
Nixon and Ulmann, 2006). Dynamic factors may also be important. For example, temporary 
economic downturns have shown more mixed effects on health outcomes, worsening 
mental health but also potentially reducing mortality through reduced traffic fatalities and 
possibly lower pollution (Ruhm, 2012; van Gool and Pearson, 2014; laliotis et al., 2016). More 
generally, differences in the countries analysed explains variability in the impact of different 
factors on health outcomes.
Gains in life expectancy over time reflect increased health spending, 
healthier lifestyles and improving socio-economic conditions
All OECD and partner countries have experienced gains in life expectancy over time, 
but the rate of increase varies markedly across countries
life expectancy at birth increased in all the countries analysed. Gains have been 
particularly rapid in Turkey, India, Korea and China, countries which have had sustained 
periods of economic growth alongside improved health care coverage (Figure 2.2). In the 
United States and Mexico, gains have been more modest. There has also been slower 
progress in South Africa (due mainly to the epidemic of HIV/AIDS), lithuania and the Russian 
Federation (due mainly to the impact of the economic transition in the 1990s and a rise in 
risk increasing behaviors among men). life expectancy at birth is currently the highest in 
Japan, at 83.9 years.
Figure 2.2. Trends in life expectancy at birth, selected countries, 1970-2015
40
45
50
55
60
65
70
75
80
85
90
19
70
19
72
19
74
19
76
19
78
19
80
19
82
19
84
19
86
19
88
19
90
19
92
19
94
19
96
19
98
20
00
20
02
20
04
20
06
20
08
20
10
20
12
20
14
China
Japan Korea
Turkey
United States
India
Years
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933602139 
35HEAlTH AT A GlANCE 2017 © OECD 2017
 2. WHAT HAS DRIVEN lIFE ExPECTANCY GAINS IN RECENT DECADES? A CROSS-COUNTRY ANAlYSIS OF OECD MEMBER STATES
Increased health care spending had a strong positive impact on life expectancy,  
but wider social determinants are also important
New analysis provides estimates of the relative contribution of health systems and 
healthy lifestyles vis-à-vis socio-economic, and environmental factors across OECD countries. 
This analysis uses the latest cross-country data and follows best methodological practices 
(Box 2.1). life expectancy gains from 1995 to 2015 are assessed. Data on explanatory factors 
were lagged by five years (i.e. using data from 1990 to 2010) to account for the delayed effects 
on health.
Results from this analysis show that increased health spending, healthier lifestyles, 
higher incomes and better education coverage over time have positive and statistically 
significant associations with life expectancy gains (Figure 2.3). In particular, a 10% increase 
in health spending per capita (in real terms) is associated with a gain of 3.5 months of life 
expectancy. The same rate of improvement in healthier lifestyles (10%) is associated with 
Box 2.1. Data and methods
The analysis assessed the relative contribution of factors within and beyond the health 
system to life expectancy gains between 1995 and 2015 in all 35 OECD countries. Macro-level 
panel data from OECD Health Statistics and the World Bank Databank was used.
An empirical health production function was developed, taking the following general form:
LE W X Y Z ei t i i t i t i t i t i t, , , , , ,= + + + + +− − − −α β β β β1 5 2 5 3 5 4 5
where LEi,t is the life expectancy at birth for country i in year t; α the country effect; and 
e is the error term. Explanatory variables are 5-year lagged in order to capture the delayed 
effects of key determinants on life expectancy, with variable selection based on key 
determinants identified in the literature. lags of 5 years were chosen to strike a balance 
between accounting for delayed effects on health and maintaining a sufficient number of 
observations for the time-series analysis.
W is a vector of health system variables in year t-5 (health care spending, including both 
curative and preventive care, measured by total health expenditure expressed in per capita 
constant USD PPP; financial protection using the share of out-of-pocket spending in total 
health expenditure as a proxy). X is a vector of lifestyle factors in year t-5 (prevalence of daily 
smokers; alcohol consumption in litres per capita; healthy diet, measured by the share of the 
population consuming vegetables daily). Y is a vector of income and other socio-economic 
variables in year t-5 (income measured by GDP per capita at constant USD PPP, net of total 
health expenditure; education measured as the share of the population attaining above 
primary school education; and the long-term unemployment rate). Z is an environmental 
variable in year t-5 (air pollution measured by the share of the population exposed to fine 
particulates PM2.5).
A Cobb-Douglas production function is used, where all variables are expressed in 
logarithmic form. The general econometric specification is a GlS model with country 
fixed effects, country-specific autocorrelation structures for errors, a correction for 
heteroscedasticity, and lagged explanatory variables. Data gaps in specific years were 
addressed using linear interpolation. Further empirical models are examined in a related 
working paper (James et al., forthcoming). Although the analysis follows best methodological 
practice, associations between life expectancy and explanatory variables do not guarantee 
causality.
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a gain of 2.6 months of life expectancy (fewer smokers with 1.6 months, decreased alcohol 
use with 1.0  month). Wider social determinants also matter. A 10% increase in income 
per capita (in real terms) is associated with a gain of 2.2 months of life expectancy, and a  
10% increase in primary education coverage with 3.2 months.
The share of out-of-pocket spending in total health spending did not have a significant 
association with life expectancy gains, mainly because of its very small reduction over the 
time period studied. Healthy diet had a positive but not significant association with life 
expectancy. This may be explained by the very limited improvements to people’s diet over 
time, and the difficulty to capture nutritional effects at the macro level. The association 
between long-term unemployment rates and life expectancy was also not significant.2 
More surprisingly, air pollution was also not significantly associated with life expectancy 
gains, despite there being clear evidence elsewhere of the adverse effects of air pollution 
on health (OECD 2016). This result reflects the long lag in time before air pollution affects a 
person’s health, and also the relatively small decreases in air pollution over time in many 
OECD countries. These results are explored further in a related working paper (James et al., 
forthcoming).
Figure 2.3. Life expectancy gains associated with a 10% change in the main 
determinants of health
Analysis based on 35 OECD countries for the time period 1995-2015
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While the effect on life expectancy of a 10% change in the main determinants of 
health is useful for comparative purposes, in practice larger changes may be feasible, 
leading to larger life expectancy gains. For example, if smoking rates and alcohol 
consumption could be halved, together these could lead to a gain of 13 months of life 
expectancy. Figure  2.4 illustrates the impact of more ambitious changes for selected 
factors, notably a doubling of health spending and income, primary education coverage 
reaching 100%, and more marked improvements in healthy lifestyles (a halving of 
smoking rates and alcohol consumption).
The actual evolution in the main determinants of health over the past 20 years has 
often been much more substantial than the 10% change used in Figure 2.3. From a policy 
perspective, this is relevant because it means the positive impacts on life expectancy can 
be substantial – given the right investments within and beyond the health system.
37HEAlTH AT A GlANCE 2017 © OECD 2017
 2. WHAT HAS DRIVEN lIFE ExPECTANCY GAINS IN RECENT DECADES? A CROSS-COUNTRY ANAlYSIS OF OECD MEMBER STATES
Figure 2.4. Life expectancy gains from more substantial changes in the main 
determinants of health
Analysis based on 35 OECD countries for the time period 1995-2015
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of-pocket spending and air pollution are excluded because they were not statistically significant.
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Figure 2.5 shows the percentage change of these determinants of health between 
1990 and 2010. For example, while a 10% increase health spending is associated with a 
gain of 3.5 months of life expectancy, health spending actually grew by 98% from 1990 
to 2010 (from USD PPP 1 624 in 1990 to USD PPP 3 212 in 2010 in constant terms). Income 
increased by 42% over the same time period, and education coverage by 44%. Improvements 
in healthy lifestyles have been less marked: smoking rates were reduced by 31%, but 
alcohol use only fell by 8% and the rate of daily vegetable consumption only increased by 
2% from 1990 to 2010.
Figure 2.5. Evolution of the main determinants of life expectancy:  
OECD 1990 to 2010
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As a result of the evolution of these determinants over time, health spending has been 
the major contributing factor to gains in life expectancy over the last two decades, followed 
by education then income (Table 2.1). The contributions of lifestyle factors (smoking, alcohol, 
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healthy diet) have been smaller, largely because there have been smaller improvements in 
these factors over the time period studied. Table 2.1 also shows regression coefficients and 
values for 1990 and 2010, alongside the relative contributions of each of these determinants 
of life expectancy.
Table 2.1. Determinants of life expectancy gains over time: regression 
coefficients, relative contributions, 1990 and 2010 values
Explanatory variables
Regression 
coefficient
Contribution to life 
expectancy (months)
1990 value 2010 value
Health system factors        
Health expenditure (per capita in constant USD PPP) + 0.039* 42.4 1 624 3 212
Out-of-pocket spending (as % of health expenditure) ns ns 22 20
Lifestyle factors        
Smoking (% daily smokers) - 0.018* 5 30.3 21
Alcohol (litres of pure alcohol per capita) - 0.011* 0.4 10.1 9.2
Healthy diet (% daily consumers of vegetables) ns ns 64.2 65.3
Income and other socio-economic factors        
Income (GDP per capita in constant USD PPP) + 0.025* 13.4 22 479 31 900
Education (% with above primary education) + 0.035* 15.1 57 82
Unemployment (% long-term unemployed) ns ns 3.2 3.6
Environmental factors        
Air pollution (% of population exposed to PM2.5) ns ns 75.7 65.2
Note: * statistically significant at the 5% level, ‘ns’ means not significant. Regression based on 718 observations across 
35 countries. The sum of the contributions and the residual (not shown here) is equal to the total gain of life years 
over the studied period. 
Supplementary analyses were carried out to test a range of common econometric 
specification issues, as well as alternative explanatory variables. These analyses showed 
consistent results (see James et al., forthcoming). Additional analysis adding OECD partner 
countries to the sample shows some differences in the determinants of health by a country’s 
level of economic development. For high-income countries, health care spending has been 
the main driver of life expectancy gains, whereas income was the main driver in emerging 
economies. This analysis, though, was limited by data only being available for a shorter 
time period.
Most OECD countries have steadily increased health care spending in recent 
decades, but accompanying gains in life expectancy vary markedly across countries
While empirical analysis showed that health care spending has made a marked 
contribution to life expectancy gains across OECD countries as a whole, there are important 
cross-country differences. These are illustrated in Figure 2.6, which shows the trajectories 
of life expectancy gains alongside increase in health expenditure since 1995 for selected 
high-income countries.
In all OECD countries, both life expectancy and health spending have been increasing 
over time. But these rates of increase vary significantly across countries. The notable outlier 
is the United States, where health spending has increased far more rapidly over time than 
in other OECD countries, yet life expectancy gains have been smaller. On the other hand, 
life expectancy at birth in Japan has reached almost 84 years, but health expenditure per 
capita is less than half of the United States.
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Figure 2.6. Life expectancy gains and increased health spending, selected 
high-income countries, 1995-2015
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These varying trajectories for health expenditure and life expectancy across countries 
over time suggest the critical role healthy lifestyles and the wider social determinants of 
health have in increasing life expectancy. But these trajectories also point to the importance 
of improving value for money in health systems. This includes placing greater emphasis 
on health promotion and other highly cost-effective interventions, but also eliminating 
ineffective spending and waste (see OECD, 2017 for an in-depth discussion).
Unpacking the mechanisms by which socio-economic factors and a person’s 
living environment affect health is essential for policy
The empirical results presented offer insights on the strength and relative contribution 
of different determinants of health. This section complements the macro-level analysis 
by assessing exactly how socio-economic factors and a person’s living environment affect 
health and health-seeking behaviours, drawing on insights from more micro-level evidence.
The nature of income trajectories matter
The positive association between income and health is an important general finding. But 
examining how different income trajectories influence health status offers further guidance 
for policymakers. A first observation is the importance of minimum absolute levels of income. 
Whereas low income and poverty has a clear detrimental effect on health, health differences 
between individuals with average or high income are far less pronounced (Deaton, 2003). In 
other words, there is a non-linear relationship between income and health.
Second, whilst current income matters, long-term income has a much greater impact on health. 
That is, it takes time for higher (lower) incomes to have a beneficial (adverse) effect on health. 
For example, studies in the United Kingdom concluded that persistent poverty carries a much 
greater health risk than occasional episodes, and income level appears more important than 
income change (Benzeval and Judge, 2001; Contoyannis et al., 2004).
Third, income reductions generally seem to have a larger impact on health than income gains, 
irrespective of whether they are temporary or more permanent (O’Donnell et al., 2013). 
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For example, McInerney et al. (2013) found that wealth losses following the 2008 global 
financial crisis led to increased depression and use of antidepressants in the United 
States. In contrast, they observed no health improvements from wealth gains in the 
same study sample. In Sweden, self-assessed health responded to decreases in income 
to a greater extent than to income gains over time (Miething and Aberg-Yngwe, 2014). 
Similarly, most (but not all) studies of sudden wealth gains from inheritance, the stock 
market and lotteries find limited or no evidence of associated improvements in health 
status (O’Donnell et al., 2013).
Indeed, income payments can trigger adverse health events in some circumstances, 
probably reflecting an increase in more risky behaviours. For example, Dobkin and Puller 
(2007) found elevated drug-related admissions and within-hospital mortality in California for 
recipients of federal disability payments around the time of payment. Evans and Moore (2011) 
found increased risks of traffic accidents and heart attacks immediately after social security 
payments, wage payments for military personnel, tax rebates and dividend payments.
Unemployment worsens mental and physical health; employment conditions  
are also important
As discussed earlier, macro-level studies of unemployment on health find mixed effects. 
In contrast, micro-level studies more consistently find that being unemployed adversely affects 
both mental and physical health. For example, a meta-analysis of studies using individual data 
found that unemployment is associated with a 63% higher risk of mortality after controlling 
for age and other control factors (Roelfs et al., 2011), although this may partly reflect pre-
existing health conditions. Unemployment also affects mental health. In Australia, Canada 
and the United Kingdom, evidence from panel data shows that changing from employment 
to unemployment significantly increased mental distress (llena-Nozal, 2009).
Employment conditions also matter. Working longer hours are harmful to health, raising 
general stress levels but also increasing the risk of stroke and coronary heart disease 
(Kivimaki et al., 2015). In extreme cases, it may raise the risk of major accidents (Harrington, 
2001). Choice over working hours has also been shown to be crucial, irrespective of the 
number of hours worked (Bassanini and Caroli, 2014). Other aspects of job quality are also 
important. Exposure to hazardous substances and risk of injury is typically concentrated 
amongst low-skilled menial labour (Clougherty et al., 2013). Job insecurity and job 
dissatisfaction has also been shown to adversely affect health (Caroli and Godard, 2014; 
Datta Gupta and Kristensen, 2008).
Education encourages healthier lifestyles
Better educated individuals and their offspring are healthier, independent of income 
and employment-related effects. A large part of this difference has been attributed to 
healthier lifestyles. In particular, the more educated are typically better informed about the risks 
and benefits of different behaviours, but also more likely to process and act upon this information. 
For example, people with lower education levels are more likely to smoke, be obese, have 
less well-balanced diets and be less physically active (Mackenbach et al., 2008; Cutler and 
lleras-Muney, 2010). The evidence on alcohol, however, is more mixed. A recent OECD report 
found that in general better educated women were more likely to drink excessively, though 
the opposite held true for men (OECD, 2015b). At the same time, alcohol-related harm is 
more prevalent among less educated and low-income groups, partly because of multiple 
comorbidities (coexisting risk factors) and lower access to health care.
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The better educated are also more knowledgeable about exactly which health services are 
available to them, with consequently greater use of certain services. This is particularly 
noticeable in terms of use of preventive health services and specialist consultations (OECD, 
2006). Further, education may improve self-management (and therefore the efficacy) of medical 
treatment, particularly for chronic diseases (Goldman and Smith, 2002).
Disadvantaged population groups are more likely to experience inadequate living 
conditions, and adverse health effects from pollution
Air pollution was not significantly associated with life expectancy changes in the 
empirical analysis presented earlier, principally due to there being rather small decreases 
in air pollution over time in many OECD countries and because of the lagged effects of 
air pollution on health. Nevertheless, air pollution is a major health concern, linked to 
respiratory diseases, lung cancer and cardiovascular diseases.
The level of pollution varies greatly across different neighbourhoods, with consequent 
effects on health. A review found that poorer and less educated populations often (but not 
always) lived in areas with worse air pollution, but also were far more likely to experience 
negative health effects from air pollutants (Deguen and Zmirou-Navier, 2010). The authors 
posit this reflects a greater susceptibility because of factors such as higher prevalence of 
chronic conditions and greater long-term exposure to pollutants. More generally, children 
and the elderly are particularly vulnerable to air pollution.
Alongside pollution, other aspects of a person’s living environment also impact upon 
their health. Poor housing conditions and certain neighbourhood characteristics such as the 
risk of crime have frequently been shown to adversely affect health (Gibson et al., 2011). 
Households with low-incomes and many ethnic minorities are more likely to experience 
these inadequate living conditions. Policies targeting better housing infrastructure (home 
visits, removal of hazards) and rental assistance policies, have had positive health effects 
(Bambra et al., 2010).
Conclusion
Empirical results demonstrate that while life expectancy depends on factors both within 
and beyond the health system, health spending has been a major driver of life expectancy 
gains in recent decades. In particular, a 10% increase in health spending per capita (in real 
terms) is associated with a gain of 3.5 months of life expectancy. Given the notable evolution 
in health spending in the last 20 years, higher health spending is associated with 42.4 months 
of life expectancy gains in this time period.
Education and income have also made significant contributions to life expectancy 
gains. A 10% increase in education coverage is associated with a gain of 3.2 months of life 
expectancy, and a 10% increase in income per capita with 2.2 months. The same rate of 
improvement in healthier lifestyles (10%) is associated with a gain of 2.6 months of life 
expectancy (fewer smokers with 1.6 months, decreased alcohol use with 1 month). Other 
factors – out-of-pocket spending, healthy diet, unemployment, air pollution – had smaller 
effects at the aggregate level. For some of these factors, notably air pollution and healthy 
diet, this may reflect long time lags before they affect an individual’s health.
These empirical results provide a useful aggregate picture of the relative importance of 
investments within and beyond the health system. looking forward, future analysis using 
such macro-level data could include variables that proxy health policies and institutional 
characteristics, and sub-national analysis.
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It is important, though, to reiterate that observed associations between life expectancy 
and explanatory factors at this macro-level does not guarantee causality. Indeed, it is 
important to recognise two-way causality, as ill-health worsens productivity, hinders job 
prospects, and adversely affects human capital development. For this reason, a review of 
more micro-level evidence was also undertaken. Such evidence was generally consistent 
with the macro-level analysis, while also providing further precision on the mechanisms 
by which different socio-economic factors and a person’s living environment affect health. 
For example, the empirical results showed that income has a strong positive association 
with life expectancy. Micro-level evidence adds to this by demonstrating that the nature of 
income trajectories matter: persistent poverty has particularly adverse health effects, and 
falls in income have a larger impact on health than income gains.
Taken together, the main policy implication emerging from this analysis is the significant 
opportunities for health improvement from coordinated action across ministries responsible 
for education, the environment, income and social protection, alongside health ministries. 
This includes inter-sectoral action to address health-related behaviours. In this regard, the 
WHO Health in All Policies (HiAP) framework provides countries with an approach that 
systematically accounts for the health implications of public policies across sectors (WHO, 
2013). Collaboration with the private sector will also be important, especially with employers 
in relation to working conditions. Particular attention should be paid to early childhood, 
since early life circumstances are crucial to future health and economic prospects, as well 
as to shaping health-related behaviours later in life. Such policies can help reduce health 
inequalities and achieve better health outcomes for all.
Notes
1. The studies referenced in the text are based on a systematic review of the literature, based on 
studies from 1995 or later that included OECD and/or BRIICS countries. Note that such econometric 
analyses face some common methodological issues, including two-way causality and delayed effects 
of certain factors on health outcomes. James et al. (forthcoming) explores these methodological 
issues in more detail.
2. A positive association with life expectancy is consistent with other country-level studies that have 
typically shown decreases in mortality (as well as morbidity) during economic downturns, when 
unemployment levels are higher (Ruhm, 2012). However, much of the observed correlation between 
unemployment and life expectancy in these studies has been explained by fewer traffic accidents 
and lower pollution (particularly as decreases in deaths have been concentrated among the elderly), 
rather than unemployment per se (Miller et al., 2009; van Gool and Pearson, 2014). Moreover, auxiliary 
regressions with interaction terms between unemployment and country dummies showed large 
variability in the sign and strength of this coefficient across countries.
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Life expectancy at birth
life expectancy at birth was on average 80.6 years across 
OECD countries in 2015 (Figure  3.1). There have been 
substantial gains in life expectancy over time, with life 
expectancy at birth on average ten years higher today than 
it was in 1970. A number of countries reported slight falls in 
life expectancy between 2014 and 2015, though preliminary 
data for 2016 suggest these reductions were temporary. 
Among OECD countries, Turkey, Korea and Chile have 
experienced the largest gains since 1970, with increases 
of 24, 20 and 17 years respectively. Gains in longevity over 
time can be attributed to a number of factors within and 
beyond the health system. These include rising incomes, 
better education, healthier lifestyles and progress in 
health care (see Chapter 2 for further analysis). Indeed, 
each of these countries has experienced rapid economic 
growth alongside expanded health care coverage in recent 
decades. 
Although the life expectancy in partner countries such 
as India, Indonesia, Brazil and China remains well below 
the OECD average, these countries have also achieved 
considerable gains in longevity over the past decades, with 
the level converging rapidly towards the OECD average. 
There has been less progress in South Africa (due mainly 
to the epidemic of HIV/AIDS), lithuania and the Russian 
Federation (due mainly to the impact of the economic 
transition in the 1990s and a rise in risky health behaviours 
among men). 
Japan, Spain and Switzerland lead a large group of 25 OECD 
countries in which life expectancy at birth now exceeds 
80 years. A second group, including the United States, Chile 
and a number of central and eastern European countries, 
has a life expectancy between 75 and 80 years.
Among OECD countries, latvia and Mexico had the lowest 
life expectancy in 2015, at around 75  years. Since  2000, 
life expectancy in Mexico has increased more slowly than 
in other OECD countries, with a gain of just over a year 
compared with an average gain of more than three years 
across OECD countries. Slow progress in life expectancy in 
Mexico is due to a number of factors, including harmful 
health-related behaviours such as poor nutrition and high 
obesity rates, increasing mortality rates from diabetes and 
a lack of progress in reducing mortality from circulatory 
diseases, high death rates from road traffic accidents and 
homicides, as well as persistent barriers of access to quality 
care. 
In the United States, gains in life expectancy over the past 
few decades have also been more modest than in most 
other OECD countries. While life expectancy in the United 
States used to be one year above the OECD average in 1970, 
it is now almost two years below the average. Many factors 
can explain these lower gains in life expectancy, including: 
1) the highly fragmented nature of the US health system, 
with relatively few resources devoted to public health and 
primary care, and a large share of the population uninsured; 
2)  health-related behaviours, including greater obesity 
rates, higher consumption of prescription and illegal 
drugs, more deaths from road traffic accidents and higher 
homicide rates; and 3) higher rates of poverty and income 
inequality than in most other OECD countries (National 
Research Council and Institute of Medicine, 2013).
Higher national income (as measured by GDP per capita) is 
generally associated with higher life expectancy at birth, 
although the relationship is less pronounced at the highest 
levels of national income (Figure 3.2). There are also notable 
differences in life expectancy between countries with 
similar income per capita. For example, Japan and Spain 
have higher, and luxembourg, the United States and the 
Russian Federation lower, life expectancies than would be 
predicted by their GDP per capita alone.
Figure 3.3 shows the relationship between life expectancy at 
birth and health spending per capita across OECD, candidate 
and partner countries. Higher health spending per capita is 
generally associated with higher life expectancy at birth, 
although this relationship tends to be less pronounced 
in countries with the highest health spending per capita. 
Japan, Spain and Korea stand out as having relatively high 
life expectancies, and the United States and the Russian 
Federation relatively low life expectancies, given their 
levels of health spending.
Definition and comparability
life expectancy at birth measures how long, on 
average, people would live based on a given set of age-
specific death rates. However, the actual age-specific 
death rates of any particular birth cohort cannot be 
known in advance. If age-specific death rates are 
falling (as has been the case over the past decades), 
actual life spans will be higher than life expectancy 
calculated with current death rates.
The methodology used to calculate life expectancy 
can vary slightly between countries. This can change 
a country’s estimates by a fraction of a year.
life expectancy at birth for the total population 
is calculated by the OECD Secretariat for all OECD 
countries, using the unweighted average of life 
expectancy of men and women.
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3.1. Life expectancy at birth, 1970 and 2015 (or nearest year)
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3.2. Life expectancy at birth and GDP per capita, 2015 
(or nearest year)
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3.3. Life expectancy at birth and health spending  
per capita, 2015 (or nearest year)
0 2 000 4 000 6 000 8 000 10 000
65
70
75
80
85
Life expectancy in years
Health spending per capita (USD PPP)
R2 = 0.54
AUS
AUT
BEL
BRA
CAN
CHL
CHN
COL
CRI
CZE DNKEST
FIN
FRA
DEU
GRC
HUN
ISL
IND
IDN
IRL
ISR
ITA JPN
KOR
LVA
LTU
LUX
MEX
NLDNZL
NOR
POL
PRT
RUS
SVK
SVN
ESP SWE
CHE
TUR
GBR
USA
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933602272
50 HEAlTH AT A GlANCE 2017 © OECD 2017 
3. HEALTH STATUS
Life expectancy by sex and education level
There remain large gaps in life expectancy between 
women and men in all OECD countries. On average across 
OECD countries, life expectancy at birth for women was 
83.1 years in 2015, compared with 77.9 years for men, a gap 
of 5.2 years (Figure 3.4). The gender gap in life expectancy 
increased substantially in many OECD countries during 
the 1970s and early 1980s to reach a peak of almost seven 
years in the mid-1980s, but it has narrowed since, reflecting 
higher gains in life expectancy among men than women. 
This can be attributed at least partly to narrowing of 
differences in risk-increasing behaviours such as smoking, 
accompanied by sharp reductions in mortality rates from 
circulatory diseases among men.
In 2015, life expectancy for women in OECD countries 
ranged from less than 80  years in Hungary, latvia and 
Mexico to more than 85 years in Japan, Spain, France, Korea 
and Switzerland. life expectancy for men ranged from 
less than 75 years in latvia, Mexico, Hungary, the Slovak 
Republic, Estonia and Poland to over 80 years in Iceland, 
Japan, Switzerland, Norway, Australia, Sweden, Italy, Israel 
and Spain.
Among OECD countries, the gender gap in life expectancy 
is relatively narrow in Iceland, the Netherlands, New 
Zealand, the United Kingdom, Norway, Sweden, Ireland 
and Denmark (a gap of less than four years), but much 
larger in latvia (around ten  years) Estonia (around 
nine  years), Poland (around eight  years), the Slovak 
Republic and Hungary (around seven years). In this latter 
group of countries, gains in life expectancy of men over 
the past few decades have been much more modest than 
in other countries. For partner countries, the gender 
gap is also large in the Russian Federation, lithuania 
and Colombia (seven years or more), and small in China 
(around three years).
life expectancy in OECD countries varies by socio-economic 
status as measured, for instance, by education level 
(Figure 3.5). A higher education level not only provides the 
means to improve the socio-economic conditions in which 
people live and work, but may also promote the adoption 
of healthier lifestyles and facilitate access to appropriate 
health care. 
On average among 25 OECD countries for which recent data 
are available, people with the highest level of education can 
expect to live around six years longer than people with the 
lowest level of education at age 30 (53.4 versus 47.8 years). 
These differences in life expectancy by education level 
are particularly pronounced for men, with an average gap 
of seven years. Differences are especially pronounced in 
central and eastern European countries (Slovak Republic, 
Estonia, Poland, Hungary, latvia and the Czech Republic), 
where the life expectancy gap between higher and lower 
educated men is more than ten  years. This is largely 
explained by older people in these countries having 
lower levels of education, and the greater prevalence of 
risk factors among men, such as tobacco and alcohol use. 
In other countries such as Turkey, Sweden and Canada, 
inequalities are less pronounced. Differences in lifespan 
between people with low and high education have been 
estimated to account for about 10% of overall inequalities 
in ages at death (Murtin et al., 2017).
Definition and comparability
life expectancy at birth measures how long, on average, 
people would live based on a given set of age-specific 
death rates. However, the actual age-specific death 
rates of any particular birth cohort cannot be known 
in advance. If age-specific death rates are falling (as 
has been the case over the past decades), actual life 
spans will be higher than life expectancy calculated 
with current death rates. Data for life expectancy at 
birth comes from Eurostat for EU countries, and from 
national sources elsewhere. The methodology used to 
calculate life expectancy can vary slightly between 
countries. This can change a country’s estimates by 
a fraction of a year.
Data for life expectancy by education level come from 
national suveys provided for the OECD Health Data 
questionnaire for Israel, Mexico and the Netherlands; 
from the OECD Statistics Directorate project (see 
Murtin et al. below) for Australia, Austria, Belgium, 
Canada, France, latvia, the United Kingdom and the 
United States; and from Eurostat for the remaining 
14 European countries shown in Chart 3.5.
To calculate life expectancies by education level, 
detailed data on deaths by sex, age and education 
level are needed. However, not all countries have 
information on education as part of their deaths data. 
In such cases, data linkage to another source (e.g. a 
census) which does have information on education 
may be required (Corsini, 2010). Note further that 
data disaggregated by education are only available 
for a subset of the population for Belgium, the 
Czech Republic and Norway, and that there are more 
missing data on education among the deceased than 
the population at large. In these three countries, the 
large share of the deceased population with missing 
education (above 40%) could affect the accuracy of 
results.
References
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3.4. Life expectancy at birth by sex, 2015 (or nearest year)
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3.5. Gap in life expectancy at age 30 between highest and lowest education level, by sex, 2015  
(or nearest year)
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Main causes of mortality
Over 10 million people died in 2015 across OECD 
countries, which equates to an average of 793 deaths per 
100  000  population. Diseases of the circulatory system 
and cancer are the two leading causes of death in most 
countries. Across the OECD, more than one in three deaths 
were caused by ischaemic heart diseases, stroke or other 
circulatory diseases; and one in four deaths were related 
to cancer.
Two factors can explain certain commonalities in causes of 
death across OECD and partner countries. First, population 
ageing is important since the main causes of death change 
with age. Among younger adults, cancer-related deaths 
occur more frequently than many other causes. After 
age 50, deaths due to diseases of the circulatory system rise 
steadily, and become one of the major causes of death after 
age 80, along with dementia. Second is the epidemiological 
transition from communicable to non-communicable 
diseases, which has already taken place in high-income 
countries and is rapidly occurring in many middle-income 
countries (GBD, 2013).
Variation across OECD and partner countries is substantial. 
All-cause mortality rates (age-standardised) ranged 
from 583 deaths per 100 000 population in Japan to over 
1  000  deaths per 100  000 in Hungary, latvia, lithuania, 
the Russian Federation and the Slovak Republic in 2015 
(Figure  3.6). looking at specific causes, diseases of the 
circulatory system were the main cause of mortality in 
most OECD countries. They caused over 600  deaths per 
100 000 population in latvia and lithuania, and 869 deaths 
per 100 000 in the Russian Federation. Japan and France had 
the lowest rates, at 152 and 164 deaths per 100 000 population 
respectively. Diet, smoking and alcohol consumption 
play important roles in these diseases, as does access to 
treatment.
Variations in cancer-related deaths was less substantial but 
still significant, ranging from 123 to 286 deaths per 100 000 
in 2015. Other causes of death were particularly important in 
specific countries. For example, respiratory system diseases 
(predominantly chronic obstructive pulmonary diseases) 
caused over 100 deaths per 100 000 in Ireland, the United 
Kingdom, Brazil and Colombia. External causes (predominantly 
assault, accidents and intentional self-harm) accounted for 
over 80 deaths per 100 000 in Brazil, latvia, lithuania, South 
Africa and the Russian Federation. HIV-AIDS caused more 
than 50 deaths per 100 000 population in South Africa.
The main causes of death also differ by gender (Figure 3.7). 
For example, dementia is a more important cause of 
death for women than for men. In contrast, the rates of 
lung cancer and accident-related deaths were higher for 
men than for women. A body of evidence suggests that 
alongside intrinsic gender differences, women are more 
likely to choose healthy behaviours (Gore et al., 2011).
It is also worth noting that the main causes of death 
diverge between socio-economic groups. Social disparities 
are generally larger for the most preventable diseases, as 
deaths are amenable to medical intervention, behaviour 
change and injury prevention (Mackenbach et al., 2015).
Definition and comparability
Mortality rates are based on numbers of deaths 
registered in a country in a year divided by the size 
of the corresponding population. The rates have been 
directly age-standardised to the 2010 OECD population 
(available at http://oe.cd/mortality) to remove variations 
arising from differences in age structures across 
countries and over time. The source is the WHO 
Mortality Database.
Deaths from all causes are classified to ICD-10, Codes 
A00-Y89, excluding S00-T98. The classification of 
causes of death defines groups and subgroups. Groups 
are umbrella terms covering diseases that are related 
to each other; subgroups refer to specific diseases. 
For example, the group diseases of the respiratory 
system comprises 4 subgroups: influenza, pneumonia, 
chronic obstructive pulmonary diseases and asthma.
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3.6. Main causes of mortality per country, 2015 (or nearest year)
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3.7. Main causes of mortality by gender, 2015 (or nearest year)
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Mortality from circulatory diseases
Despite substantial declines in recent decades, circulatory 
diseases remain the main cause of mortality in most OECD 
countries, accounting for more than one-third (36%) of all 
deaths in 2015. Prospects for further reductions may be 
hampered by a rise in certain risk factors such as obesity 
and diabetes (OECD, 2015). Circulatory diseases cover 
a range of illnesses related to the circulatory system, 
particularly ischaemic heart disease (including heart 
attack) and cerebrovascular diseases such as stroke.
Ischaemic heart disease (IHD) is caused by the accumulation 
of fatty deposits lining the inner wall of a coronary artery, 
restricting blood flow to the heart. IHD alone was responsible 
for nearly 12% of all deaths in OECD countries in 2015. 
However, mortality from IHD varies considerably across 
countries (Figure 3.8). Among OECD countries, Central and 
Eastern European countries report the highest IHD mortality 
rates. Rates are also high in the Russian Federation. 
Japan, Korea and France report the lowest rates. Across 
OECD countries, IHD mortality rates in 2015 were around 
82% higher for men than women.
IHD mortality rates have declined in nearly all OECD 
countries, with an average reduction of more than 50% 
since 1990, contributing greatly to gains in life expectancy, 
particularly among men. The decline has been most 
remarkable in Denmark, the Netherlands, Norway and 
Israel, where rates fell by over 70%. Declining tobacco 
consumption contributed significantly to reducing the 
incidence of IHD (see indicator on “Smoking among adults” 
in Chapter  4), and consequently to reducing mortality 
rates. Improvements in medical care have also contributed 
to reduced mortality rates (see indicators on “Mortality 
following acute myocardial infarction” in Chapter 6 and 
“Hospital discharges” in Chapter 9).
In Korea, IHD mortality rates have increased substantially 
since 1990, although they remain low compared with 
nearly all other OECD countries and have started to fall 
after peaking in 2006. The initial rise in IHD mortality rates 
in Korea has been attributed to changes in lifestyle and 
dietary patterns as well as environmental factors at the 
time of birth, with people born between 1940 and 1950 
facing higher relative risks. In 2006, Korea introduced a 
Comprehensive Plan to tackle circulatory diseases that 
encompassed prevention and primary care as well as better 
acute care, contributing to the reduction in mortality in 
recent years (OECD, 2012).
Cerebrovascular disease was the underlying cause 
for about 7% of all deaths in OECD countries in 2015. 
Cerebrovascular disease refers to a group of diseases that 
relate to problems with the blood vessels that supply 
the brain. Common manifestations of cerebrovascular 
disease include ischaemic stroke, which develops when 
the brain’s blood supply is blocked or interrupted, and 
haemorrhagic stroke which occurs when blood leaks from 
blood vessels into the surface of the brain. In addition 
to being an important cause of mortality, the disability 
burden from stroke and other cerebrovascular diseases is 
also substantial (Feigi et al., 2016).
There are large variations in cerebrovascular disease 
mortality rates across countries (Figure 3.9). Among OECD 
countries, latvia, Hungary and the Slovak Republic report 
a cerebrovascular mortality that is more than three times 
higher than that of Switzerland, Canada and France, and have 
the highest mortality rates for both IHD and cerebrovascular 
disease. Rates are also high in the partner countries of the 
Russian Federation and South Africa. The high prevalence 
of risk factors common to both diseases (e.g. smoking and 
high blood pressure) may explain this link. 
Since 1990, cerebrovascular disease mortality has 
decreased in all OECD countries, although to a lesser 
extent in Poland and the Slovak Republic. On average, the 
mortality burden from cerebrovascular disease has halved 
across OECD countries. In Estonia, luxembourg, Portugal, 
the Czech Republic and Austria, the rates have been cut 
by over 70%. As with IHD, the reduction in mortality from 
cerebrovascular disease can be attributed at least partly 
to a reduction in risk factors as well as improvements in 
medical treatments (OECD, 2015; see indicator “Mortality 
following ischaemic stroke” in Chapter 6) but rising obesity 
and diabetes threatens progress in tackling cerebrovascular 
disease (OECD, 2015).
Definition and comparability
Mortality rates are based on numbers of deaths 
registered in a country in a year divided by the size 
of the corresponding population. The rates have been 
directly age-standardised to the 2010 OECD population 
(available at http://oe.cd/mortality) to remove variations 
arising from differences in age structures across 
countries and over time. The source is the WHO 
Mortality Database.
Deaths from ischaemic heart disease are classified to 
ICD-10 codes I20-I25, and cerebrovascular disease to 
I60-I69. 
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3.8. Ischaemic heart disease mortality, 2015 and change 1990-2015 (or nearest year)
0100200300400500 500-50-100
458
424
328
291
288
237
211
175
147
146
144
131
129
127
120
113
112
106
100
98
98
95
93
93
85
84
82
82
78
72
66
64
64
60
59
55
54
53
46
39
38
34
-2
-34
-42
-21
-13
-46
-67
-4
-57
na
1
-42
-56
-62
-47
-55
-52
-52
-60
-67
-33
-65
-60
-37
-68
-38
-54
-37
-52
-73
-40
-61
-71
-81
-61
-53
-55
-49
-75
-56
-40
43
2015
Age-standardised rates per 100 000 population Change in %
Russian Federation
Lithuania
Latvia
Slovak Republic
Hungary
Czech Republic
Estonia
Colombia
Finland
Turkey
Mexico
Austria
New Zealand
Ireland
Costa Rica
United States
OECD35
Germany
Iceland
United Kingdom
Poland
Sweden
Canada
Brazil
Australia
Italy
Slovenia
Greece
Switzerland
Norway
South Africa
Chile
Israel
Denmark
Luxembourg
Portugal
Belgium
Spain
Netherlands
France
Korea
Japan
Change 1990-2015
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933602367
3.9. Cerebrovascular disease mortality, 2015 and change 1990-2015 (or nearest year)
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Mortality from cancer 
Cancer is the second leading cause of mortality in OECD 
countries after circulatory diseases, accounting for 25% of 
all deaths in 2015, up from 15% in 1960. In a number of 
countries such as Denmark, France, Japan, the Netherlands, 
Canada, the United Kingdom, Spain, Belgium and Australia, 
the mortality rate for cancer is higher than for circulatory 
diseases. The rising share of deaths due to cancer reflects 
the fact that mortality rates from other causes, particularly 
circulatory diseases, has been declining more rapidly than 
for cancer.
There are more than 100 different types of cancers. For a 
large number of cancer types, the risk of developing the 
disease rises with age. While genetics is a risk factor, only 
about 5% to 10% of all cancers are inherited. Modifiable 
risk factors such as smoking, obesity, lack of exercise and 
excess sun exposure, as well as environmental exposures, 
explain up to 90-95% of all cancer cases (Anand et al., 
2008). Prevention, early detection and treatment remain 
at the forefront in the battle to reduce the burden of cancer 
(OECD, 2013).
In 2015, the average rate of mortality attributable to 
cancer across OECD countries was  just over 200 per 
100 000 population (Figure 3.10). Mortality due to cancer was 
lowest in Mexico, Turkey, Finland, Switzerland, Japan, Israel 
and Korea, with rates less than 180 per 100 000 population. 
Among partner countries, rates were also less than 180 per 
100 000 in Colombia, Brazil, Costa Rica and South Africa. 
Hungary, the Slovak Republic, Slovenia and latvia bear the 
highest cancer mortality burden, with rates in excess of 240 
per 100 000 population.
In most OECD countries, cancer-related mortality rates have 
fallen since 1990, with the largest reductions in the Czech 
Republic and Switzerland. On average, rates fell by 18% 
between 1990 and 2015. Substantial declines in mortality 
from stomach cancer, colorectal cancer, lung cancer for 
men, breast, cervical and ovarian cancer for women, as well 
as prostate cancer for men contributed to this reduction. 
However, these gains were partially offset by increases in 
the number of deaths due to cancer of the liver, skin and 
pancreas for both sexes, as well as lung cancer for women.
Mortality due to cancer is consistently higher for men than 
for women in all countries (Figure 3.11). The gender gap was 
particularly wide in Korea, Turkey, latvia, Estonia, Spain 
and Portugal, with rates among men more than twice those 
for women. This gender gap can be explained partly by 
the greater prevalence of risk factors among men, notably 
smoking.
Among men, lung cancer imposes the highest mortality 
burden, accounting for 22% of all cancer-related deaths 
(Figure 3.12). For women, lung cancer accounted for 16% 
of all cancer-related deaths. In many countries, lung cancer 
mortality rates for men have decreased over the last 
25 years, in particular in Mexico, the Netherlands, Czech 
Republic, Finland and the United Kingdom where they fell 
by about 50%. But lung cancer mortality has risen for women 
in several countries such as the Netherlands, France and 
Spain where it has more than doubled since 1990. These 
conflicting trends are, to a large degree, explained by the 
high number of females who started smoking several 
decades later than males. 
Breast cancer is the second most common cause of cancer 
mortality in women in many OECD countries. While there 
has been an increase in the incidence of breast cancer over 
the past decade, mortality has declined in most countries 
due to earlier diagnosis and better treatment. Mortality 
from breast cancer increased in Korea and Japan, though 
the rates there remained the lowest in 2015. Mortality rates 
from breast cancer in 2015 were highest in Ireland, Iceland, 
Hungary, Denmark and the Netherlands.
Colorectal cancer is a major cause of cancer mortality 
among both men and women (second-highest cause of 
cancer mortality in men and third in women). In Japan, 
it is the leading cause of cancer mortality in women. In 
2015, colorectal cancer mortality was lowest in Mexico and 
Turkey, and highest in Hungary and the Slovak Republic. 
Prostate cancer has become the most common cancer 
among men in many OECD countries, particularly among 
men aged 65 years and over. 
Definition and comparability
Mortality rates are based on numbers of deaths 
registered in a country in a year divided by the size 
of the corresponding population. The rates have been 
directly age-standardised to the 2010 OECD population 
(available at http://oe.cd/mortality) to remove variations 
arising from differences in age structures across 
countries and over time. The source is the WHO 
Mortality Database.
Deaths from all cancers are classified to ICD-10 
codes C00-C97. The international comparability of 
cancer mortality data can be affected by differences 
in medical training and practices as well as in death 
certification across countries. 
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3.10. Cancer mortality, 1990 and 2015 (or nearest year)
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3.11. Cancer mortality by gender, 2015 (or nearest year)
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3.12. Main causes of cancer mortality by gender, 2015 (or nearest year)
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Infant health
Infant mortality, the rate at which babies and children of 
less than one year of age die, is the most fundamental 
measure of infant health. In OECD countries, around two-
thirds of the deaths that occur during the first year of life 
are neonatal deaths (i.e. during the first four weeks). Birth 
defects, prematurity and other conditions arising during 
pregnancy are the main factors contributing to neonatal 
mortality in developed countries. For deaths beyond a 
month (post-neonatal mortality), there tends to be a 
greater range of causes –  the most common being SIDS 
(sudden infant death syndrome), birth defects, infections 
and accidents.
In most OECD countries infant mortality is low and there 
is little difference in rates (Figure 3.13). In 2015, the average 
in OECD countries was less than four deaths per 1 000 live 
births. Turkey and Mexico still have comparatively high 
infant mortality at above ten deaths per 1 000 live births.
In some large partner countries (India, South Africa and 
Indonesia), infant mortality remains above 20 deaths per 
1 000 live births, although in these three countries infant 
mortality has reduced considerably in recent decades. 
Indeed, infant mortality has fallen significantly in all 
OECD and partner countries, with reductions since 1990 
particularly large in Slovenia, Estonia, Poland, Korea and 
China.
Despite this progress in reduced infant mortality, 
increasing numbers of low birth weight infants is a concern 
in some OECD countries. In a number of countries, this 
has contributed to a levelling-off of the downward trend 
in infant mortality over the past few years. On average, 
one in 15 babies born in the OECD (or 6.5% of all births) 
weighed less than 2 500 grams at birth in 2015 (Figure 3.14). 
In almost all OECD countries, the proportion of low birth 
weight infants has increased over the past two decades, 
mainly due to increases in pre-term births (Euro-Peristat, 
2013). Korea, Spain, Portugal, Greece and Japan have seen 
large increases (50% or more) of low birth weight babies 
since 1990, although the proportions remain below the 
OECD average in Korea.
low birth weight can occur as a result of restricted foetal 
growth or from pre-term birth. low birth weight infants 
have a greater risk of poor health or death, require a longer 
period of hospitalisation after birth, and are more likely 
to develop significant disabilities. Risk factors for low 
birth weight include maternal smoking, excessive alcohol 
consumption, poor nutrition, low body mass index, lower 
socio-economic status, having had in-vitro fertilisation 
treatment and multiple births, and a higher maternal age. 
The increased use of delivery management techniques 
such as induction of labour and caesarean delivery, which 
have increased the survival rates of low birth weight babies, 
may also explain the rise in low birth weight infants. 
Despite the widespread use of a 2 500 grams limit for low 
birth weight, physiological variations in size occur across 
different countries and population groups, and these need 
to be taken into account when interpreting differences 
(Euro-Peristat, 2013).
Comparisons of different population groups within 
countries indicate that both infant mortality and the 
proportion of low birth weight infants may be influenced 
by differences in education level, income and associated 
living conditions. For example, in the United States, black 
women are more likely to give birth to low birth weight 
infants, with an infant mortality more than double that for 
white women (NCHS, 2015). Similar differences have also 
been observed among the indigenous and non-indigenous 
populations in Australia, Mexico and New Zealand, 
reflecting the disadvantaged living conditions of many of 
these mothers.
Definition and comparability
The infant mortality rate is the number of deaths of 
children under one year of age, expressed per 1 000 live 
births. Some of the international variation in infant 
mortality rates is related to variations in registering 
practices for very premature infants. While some 
countries register all live births including very small 
babies with low odds of survival, several countries 
apply a minimum threshold of a gestation period of 
22  weeks (or a birth weight threshold of 500 g) for 
babies to be registered as live births (Euro-Peristat, 
2013). To remove this data comparability limitation, 
the data presented in this section are based on a 
minimum threshold of 22 weeks of gestation period 
(or 500 grams birth weight) for a majority of OECD 
countries that have provided these data. However, the 
data for some countries (e.g., Canada and Australia) 
continue to be based on all registered live births, 
resulting in some over-estimation.
low birth weight is defined by the World Health 
Organization as the weight of an infant at birth of 
less than 2 500 grams (5.5 pounds) irrespective of the 
gestational age of the infant. This threshold is based on 
epidemiological observations regarding the increased 
risk of death to the infant and serves for international 
comparative health statistics. The number of low 
weight births is expressed as a percentage of total 
live births.
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3.13. Infant mortality, 2015 and change 1990-2015 (or nearest year)
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3.14. Low birth weight infants, 2015 and change 1990-2015 (or nearest year)
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Mental health 
Mental illness represents a considerable – and growing – 
proportion of the global burden of disease. An estimated 
one in two people will experience a mental illness in 
their lifetime, and around one in five working-age adults 
suffer from mental ill-health at any given time (OECD, 
2012; OECD, 2015). Depression alone affects millions of 
individuals each year. Figure 3.17 shows self-reported 
prevalence of depression in Europe. On average, 12-month 
prevalence of depression was 7.9% of the population. 
Women reported higher rates of depression in all countries; 
in Spain, lithuania, Hungary, Poland women were more 
than 50% more likely to report experiencing depression 
in the previous year than men, rising to 66% in Portugal. 
People in Iceland or Ireland were close to three times 
more likely to report depression than people in the Czech 
Republic (Figure 3.17). These differences are in part driven 
by different attitudes and understandings around mental 
ill-health and depression. lower stigma around depression 
may contribute to higher rates of self-reported illness, and 
higher rates of diagnosis. 
When people are suffering from a mental disorder, it has 
significant consequences across their lives, contributing 
to poorer educational outcomes, higher rates of 
unemployment, and poorer physical health. In serious 
cases depression and other mental illnesses, such as 
bipolar disorder and schizophrenia, can lead to people 
harming themselves, or even dying from suicide (McDaid et 
al., 2017). There are other complex reasons that contribute 
to the rate of death by suicide. The social context, poverty, 
substance abuse, and unemployment are all associated 
with higher rates of suicide. 
Suicide remains a significant cause of death in many 
OECD countries. Figure 3.15 shows that in 2015 suicide 
rates were lowest in South Africa, Turkey, Greece and 
Colombia with fewer than five  deaths by suicide per 
100 000 population. lithuania had the highest suicide 
rate, with 29 deaths per 100 000, followed by Korea and 
the Russian Federation. Some caution is needed when 
comparing suicide rates. Stigma associated with suicide, 
or problems with recording suicides mean that in some 
countries deaths by suicide may be under-reported. 
Unlike depression prevalence, mortality rates for suicide 
are three-to-four times higher for men than for women. 
Studies suggest that the gender gap for attempted suicide 
is smaller, but men tend to use more lethal means when 
attempting suicide.
Suicide rates have decreased steadily across the OECD, 
falling by close to 30% between 1990 and 2015. In some 
countries the declines have been significant, including in 
Estonia, Finland and Hungary where suicide rates have 
fallen by 40% or more (Figure 3.16). In Finland significant 
declines in suicide can be attributed at least in part to 
targeted mental health promotion and suicide prevention 
programmes, as well as to improved mental health care. 
In some other countries suicides have increased in recent 
years. In Mexico the suicide rate increased from 4.8 per 
100  000  population in 2010 to 5.5 in 2015, while in the 
United States the rate rose from 12.5 to 13.5. A range of 
interventions can both prevent and treat depression, and 
prevent suicide, but in many countries people with mental 
ill-health have difficulties accessing appropriate mental 
health care in a timely way. 
Definition and comparability
The registration of a suicide is a complex procedure, 
which is affected by factors including how intent is 
ascertained, who is responsible for completing the 
death certificate, and cultural dimensions including 
stigma around suicide. Caution is therefore needed 
when comparing suicide rates between countries. 
Mortality rates are based on numbers of deaths divided 
by the size of the corresponding population. The rates 
have been age-standardised to the OECD population. 
The source is the WHO Mortality Database; suicides are 
classified under ICD-10 codes x60-x84, Y870.
Estimates of the prevalence of depression are derived 
from the second wave of the European Health 
Interview Survey. Respondents were asked: “During 
the past 12 months, have you had any of the following 
diseases or conditions?” with the list including 
depression. Self-reported data on depression may 
be subject to under-diagnosis and reporting errors. 
Studies from several European countries show more 
variation between countries in self-reported data on 
mental illness than on other survey methods.
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3.15. Suicide, 2015 (or nearest year)
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3.16. Trends in suicide, selected OECD countries, 1990-2015
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3.17. Prevalence of chronic depression, 2014
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Perceived health status
Most OECD countries conduct regular health surveys which 
allow respondents to report on different aspects of their 
health. A commonly asked question is of the type: “How 
is your health in general?”. Despite the subjective nature 
of this question, indicators of perceived general health are 
a good predictor of people’s future health care use and 
mortality (Palladino et al., 2016).
For the purpose of international comparisons, cross-
country variations in perceived health status are difficult 
to interpret because responses may be affected by the 
formulation of survey questions and responses, and by 
social and cultural factors. For example, a central tendency 
bias in self-reporting health has been noted in Japan and 
Korea (lee et al., 2003). In addition, since older people report 
poor health more often than younger people, countries 
with a larger proportion of aged persons will also have a 
lower proportion of people reporting to be in good health. 
With these limitations in mind, in almost all OECD 
countries a majority of adults report being in good health 
(Figure 3.18). New Zealand, Canada, the United States and 
Australia are the four leading countries, with more than 
85% of people reporting to be in good health. However, the 
response categories offered to survey respondents in these 
four countries are different from those used in European 
countries and Asian OECD countries, which introduce an 
upward bias (see box on “Definition and comparability”).
On the other hand, less than half of adults in Japan, 
Korea, latvia and Portugal rate their health as being good. 
The proportion is also relatively low in Estonia, Hungary, 
Poland and Chile, where less than 60% of adults consider 
themselves to be in good health. In many of these cases, 
though, adults consider themselves to be in fair health. A 
potentially clearer distinction is on adults who consider 
themselves to be in bad health. Across the OECD, on average 
9% of adults consider themselves to be in bad health. The 
share is over 15% in Portugal, Korea, latvia, Israel, Hungary 
and Estonia. 
In all OECD countries, men are more likely than women 
to report being in good health, except in New Zealand, 
Canada and Australia where the proportion is almost equal. 
As expected, people’s rating of their own health tends to 
decline with age. In many countries, there is a particularly 
marked decline in how people rate their health after age 
45 and a further decline after age 65. 
There are large disparities in self-reported health across 
different socio-economic groups. Figure 3.19 shows that, 
in all countries, people with a lower level of income tend 
to report poorer health than people with higher income, 
although the gap varies. On average across OECD countries, 
nearly 80% of people in the highest income quintile report 
being in good health, compared with just under 60% for 
people in the lowest income group. These disparities 
may be explained by differences in living and working 
conditions, as well as differences in smoking and other risk 
factors. People in low-income households may also have 
limited access to certain health services for financial or 
other reasons (see Chapter 5 on “Access to care”). A reverse 
causal link is also possible, with poor health status leading 
to lower employment and lower income.
Greater emphasis on public health and disease prevention 
among disadvantaged groups, and improving access to 
health services may contribute to further improvements 
in population health status in general and reducing health 
inequalities.
Definition and comparability
Perceived health status reflects people’s overall 
perception of their health. Survey respondents are 
typically asked a question such as: “How is your 
health in general?”. Caution is required in making 
cross-country comparisons of perceived health status 
for at least two reasons. First, people’s assessment 
of their health is subjective and can be affected by 
cultural factors. Second, there are variations in the 
question and answer categories used to measure 
perceived health across surveys and countries. The 
response scale used in the United States, Canada, New 
Zealand, Australia and Chile is asymmetric (skewed on 
the positive side), including the following response 
categories: “excellent, very good, good, fair, poor”. 
In most other OECD countries the response scale 
is symmetric, with response categories being: “very 
good, good, fair, poor, very poor”. In Israel, the scale 
is symmetric but there is no middle category related to 
“fair” health. Such differences in response categories 
bias upward the results from those countries that are 
using an asymmetric scale or a symmetric scale but 
without any middle category.
Self-reported health by income level is reported for 
the first quintile (lowest 20% of income group) and the 
fifth quintile (highest 20%). Depending on the surveys, 
the income may relate either to the individual or the 
household (in which case the income is equivalised 
to take into account the number of persons in the 
household).
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3.18. Perceived health status among adults, 2015 (or nearest year)
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3.19. Perceived health status by income level, 2015 (or nearest year)
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Cancer incidence
In 2012, an estimated 5.8 million new cases of cancer were 
diagnosed in OECD countries, 54% (around 3.1  million) 
occurring in men and 46% (around 2.7 million) in women. 
The most common were breast cancer (12.9% of all new 
cancer cases) and prostate cancer (12.8%), followed by lung 
cancer (12.3%) and colorectal cancer (11.9%). These four 
cancers represented half of the estimated overall burden 
of cancer in OECD countries (Ferlay et al., 2014).
large variations exist in cancer incidence across OECD 
countries. Cancer incidence rates are highest in Denmark, 
Australia, Belgium, Norway, United States, Ireland, Korea, 
Netherlands and France registering more than 300  new 
cancer cases per 100 000 population in 2012 (Figure 3.20). 
The lowest rates were reported in some latin American 
and Mediterranean countries such as Mexico, Greece, 
Chile and Turkey, with around 200 new cases or less per 
100  000  population. These variations reflect not only 
variations in the prevalence of risk factors for cancer, 
but also national policies regarding cancer screening and 
differences in quality of reporting.
Cancer incidence was higher for men in all OECD countries 
in 2012 except in Mexico. However, the gender gap varies 
widely across countries. In Turkey, Estonia and Spain, 
incidence among men were around 60% higher than among 
women, whereas in the United Kingdom, Denmark and 
Iceland, the gap was less than 10%.
Breast was by far the most common primary sites in 
women (28% on average), followed by colorectal (12%), 
lung (10%), and cervical (3%). The causes of breast cancer 
are not fully understood, but the risk factors include age, 
family history, breast density, exposure to oestrogen, being 
overweight or obese, alcohol intake, radiation and hormone 
replacement therapy. Incidence rates in 2012 were highest 
in Belgium, Denmark and Netherlands, with rates 25% or 
more than the OECD average (Figure 3.21). Chile and Mexico 
had the lowest rate, followed by Turkey and Greece. The 
variation in breast cancer incidence across OECD countries 
may be at least partly attributed to variation in the extent 
and type of screening activities. Although mortality rates 
for breast cancer have declined in most OECD countries 
since the 1990s due to earlier detection and improvements 
in treatments, breast cancer continues to be one of the 
leading causes of death from cancer among women 
(see indicator “Mortality from cancer” in Chapter 3 and 
“Screening, survival and mortality from breast cancer” in 
Chapter 6). 
Prostate cancer has become the most commonly diagnosed 
cancer among men in almost all OECD countries, except in 
Hungary, Poland, Turkey and Greece where lung cancer is 
still predominant, and in Japan and Korea where colorectal 
cancer is the main cancer among men. On average across 
OECD countries, prostate cancer accounted for 24% of all 
new cancer diagnoses in men in 2012, followed by lung (14%) 
and colorectal (12%). Similar to breast cancer, the causes 
of prostate cancer are not well-understood but age, ethnic 
origin, family history, obesity, lack of exercise and poor 
nutrition are the main risk factors. Incidence in 2012 was 
highest in Norway, Sweden, Australia and Ireland, with rates 
more than 50% higher than the OECD average (Figure 3.22). 
Greece had the lowest rates, followed by Mexico, Korea and 
Japan. Prostate cancer incidence rates have increased in 
most OECD countries since the late 1990s with increased 
use of prostate specific antigen (PSA) tests having led to 
greater detection (Ferlay et al., 2014). Differences between 
countries’ rates can be partly attributed to differences in 
the use of PSA testing. Mortality rates from prostate cancer 
have decreased in some OECD countries as a consequence 
of early detection and improvements in treatments (see 
indicator “Mortality from cancer” in Chapter 3).
Definition and comparability
Cancer incidence rates are based on numbers of 
new cases of cancer registered in a country in a year 
per 100 000 population. The rates have been directly 
age-standardised based on Segi’s world population 
to remove variations arising from differences in age 
structures across countries and over time. The data 
come from the International Agency for Research on 
Cancer (IARC), GlOBOCAN 2012, available at globocan.
iarc.fr. GlOBOCAN estimates for 2012 may differ from 
national estimates due to differences in methods.
Cancer registration is well established in most OECD 
countries, although the quality and completeness 
of cancer registry data may vary. In some countries, 
cancer registries only cover subnational areas. The 
international comparability of cancer incidence data 
can also be affected by differences in medical training 
and practice.
The incidence of all cancers is classified to ICD-
10 codes C00-C97 (excluding non-melanoma skin 
cancer C44). Breast cancer corresponds to C50, and 
prostate cancer to C61.
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3.20. All cancers incidence by gender, 2012
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3.21. Breast cancer incidence in women, 2012
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3.22. Prostate cancer incidence in men, 2012
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Diabetes prevalence
Diabetes is a chronic disease, characterised by high levels of 
glucose in the blood. It occurs either because the pancreas 
stops producing the hormone insulin (Type 1 diabetes), or 
because the cells of the body do not respond properly to the 
insulin produced (Type 2 diabetes). People with diabetes are 
more likely to suffer from cardiovascular diseases such as 
heart attack and stroke, sight loss, foot and leg amputation 
and renal failure.
Across the OECD, over 93 million adults – or 7% of all adults – 
were diabetics in 2015 (Figure  3.23). The International 
Diabetes Federation estimates that a further 33 million 
adults have undiagnosed diabetes in OECD countries. 
Diabetes prevalence is highest in Mexico, where more than 
15% of adults have diabetes. Diabetes prevalence is also 
high in Turkey, the United States and Chile, where 10% 
or more of adults were diabetics. In contrast, less than 
5% of adults suffered from diabetes in Estonia, Ireland, 
luxembourg, Sweden and the United Kingdom. Among 
partner countries, diabetes prevalence is relatively high in 
Brazil and Colombia, at about 10% of the adult population, 
and low in lithuania.
Diabetes prevalence has risen slowly or stabilised in the 
majority of OECD countries, especially in Western Europe, 
but it has increased markedly in Turkey and most partner 
countries (Figure 3.24) These trends mirror partly trends 
in population ageing, as well as the rise of obesity and 
physical inactivity, and their interactions (NCD Risk Factor 
Collaboration, 2016). The share of obese people has been 
increasing strongly all around the world, and especially in 
the BRIICS (see indicators on obesity in Chapter 4). 
Diabetes is slightly more common among men than women 
and the prevalence increases substantially with age. For 
example, in the United States the estimated share of 
diagnosed diabetics was about 3% for those aged 20-44, 12% 
for those aged 45-64 and 21% for those aged 65 years and 
over (Menke et al., 2015). Diabetes also disproportionately 
affects those in lower socio-economic groups and people 
from certain ethnicities. 
Diabetes prevalence among children is much lower 
than among adults (Figure  3.25). Nevertheless, almost 
230 000 children suffered from Type 1 diabetes in OECD 
countries in 2015. In Finland, almost five children per 1 000 
were Type 1 diabetics. Prevalence rates were next highest 
in Sweden (2.6) and Norway (2). Korea and Japan had the 
lowest rates amongst OECD countries. 
Diabetes bears heavy consequences on communities. Over 
700 000 people died partly because of diabetes in OECD 
countries and these countries spent an average of about 
USD  4  600 per diabetic adult in 2015 (IDF, 2015). These 
burdens highlight the need for effective management of 
diabetes and its complications (see indicator on “Diabetes 
care” in Chapter  6), as well as appropriate preventive 
actions (see Chapter 4).
Definition and comparability
The sources and methods of the NCD Risk Factor 
Collaboration is described in the lancet article and 
appendix (lancet, 2016). Sources were selected among 
population-based studies that had collected data on 
measurement of diabetes biomarkers for Type 1 or 
Type 2 diabetics. Prevalence in sources were converted 
to meet the definition of diagnosed diabetes as defined 
in the Global Monitoring Framework for NCDs. Then, 
Bayesian hierarchical models were applied to estimate 
trends in prevalence. Adult’s population covers those 
aged 18 years and over.
The sources and methods used by the International 
Diabetes Federation are outlined in their Diabetes 
Atlas, 7th  edition (IDF, 2015). Sources were only 
included if they met several criteria for reliability. Age-
standardised rates were calculated using the world 
population based on the distribution provided by the 
World Health Organization. Adult’s population covers 
those aged between 20 and 79 years old with Type 1 
or Type 2 diagnosed diabetes. 
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3.23. Share of adults with diabetes, 2015
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3.24. Trends in share of adults with diabetes, 1980-2014
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3.25. Share of children with Type 1 diabetes per 1000 population, 2015
0.
1 0.
1 0.
2
0.
2 0.
3
0.
3 0.
4 0.
5 0.
6 0.
8
0.
8
0.
8
0.
9
0.
9
0.
9
0.
9
1.
0
1.
0
1.
0 1.
1 1.
1 1.
1 1.
1 1.
2
1.
2
1.
2
1.
3
1.
3
1.
3 1.
4
1.
4
1.
4
1.
4 1.
5
1.
5 1.
6
1.
6 1.
7 1.
7 2
.0
2.
6
4.
6
0
1
2
3
4
5
Ko
rea
Co
lom
bia
Ja
pa
n
Ch
ina Ind
ia
La
tvi
a
Me
xic
o
Tu
rke
y
Ch
ile Ita
ly
Gr
ee
ce
Slo
va
k R
ep
ub
lic
Fra
nc
e
Sw
itz
erl
an
d
Lit
hu
an
ia
Po
rtu
ga
l
Br
az
il
Slo
ve
nia
Be
lgi
um
Lu
xe
mb
ou
rg
Ne
w 
Ze
ala
nd
Po
lan
d
Ru
ss
ian
 Fe
de
rat
ion
Au
str
ia
OE
CD
35
Cz
ec
h R
ep
ub
lic
Sp
ain
Hu
ng
ary
Isr
ae
l
Un
ite
d S
tat
es
Ne
the
rla
nd
s
Au
str
ali
a
Es
ton
ia
Ge
rm
an
y
Ice
lan
d
De
nm
ark
Ca
na
da
Un
ite
d K
ing
do
m
Ire
lan
d
No
rw
ay
Sw
ed
en
Fin
lan
d
Per 1 000 children
Note: Data cover those aged under 14 years old.
Source: OECD estimates based on IDF Atlas, 7th Edition, 2015 and the United Nations population statistics.
12 http://dx.doi.org/10.1787/888933602690

69HEAlTH AT A GlANCE 2017 © OECD 2017
4. RISK FACTORS FOR HEALTH
Smoking among adults
Alcohol consumption among adults
Smoking and alcohol consumption among children
Healthy lifestyles among adults
Healthy lifestyles among children
Overweight and obesity among adults
Overweight and obesity among children
Air pollution
 
 
 
The statistical data for Israel are supplied by and under the responsibility of the relevant 
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the 
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of 
international law.
70 HEAlTH AT A GlANCE 2017 © OECD 2017 
4. RISK FACTORS FOR HEALTH
Smoking among adults
The health consequences of tobacco smoking are 
numerous, and include cancers, stroke, and coronary heart 
disease, among others. It is also an important contributory 
factor for respiratory diseases, such as chronic obstructive 
pulmonary disease (COPD), while smoking among pregnant 
women can lead to low birth weight and illnesses among 
infants. Smoking causes the largest share of overall years 
of healthy life lost in 15 OECD countries, and ranks second 
in another 16 OECD countries (Forouzanfar et al., 2016). The 
WHO has estimated that tobacco smoking kills 7 million 
people per year across the world, of which 890,000 are due 
to second-hand smoke. It is the leading cause of death, 
illness and impoverishment.
Across the OECD, just over 18% of adults smoke tobacco 
daily (14% of women and 23% of men) (Figure 4.1). Rates are 
highest in Greece, Hungary and Turkey, as well as Indonesia 
(over 25%), and lowest in Mexico as well as Brazil (under 10%). 
Women smoke the most in Austria, Greece and Hungary, 
where rates exceed 20%, while they smoke the least in Korea 
and Mexico, as well as China, India, and Indonesia, where 
rates are below 5%. In men, rates are highest in Turkey 
as well as China, Indonesia, and the Russian Federation 
(exceeding 40%), while they are below 10% in Iceland as well 
as Brazil. Men smoke more than women in all countries 
except Denmark and Iceland, where the gender gap is about 
one percentage point. In other countries, the gender gap 
ranges from below 2 points in Sweden and the United States, 
to over 30 points in China (46 points), Indonesia (73 points) 
and the Russian Federation (34 points).
Daily smoking has decreased in most OECD countries 
since 2000, although rates have slightly risen in the Slovak 
Republic (+0.8 points), have greatly increased in Indonesia 
(+8.8 points), and have not changed in Austria (Figure 4.2). 
In 2015, an average of 18% of adults smoked daily in the 
OECD, as opposed to 26% in 2000, equivalent to a 28% drop. 
The strongest decreases occurred in Denmark, Iceland, 
luxembourg, the Netherlands, New Zealand and the United 
Kingdom, as well as Brazil, India, lithuania and the Russian 
Federation, where they exceeded 10 percentage points, and 
in Norway, where the drop was 20 points. In 2015, rates were 
highest in Greece, Hungary, Turkey and Indonesia (over 25%), 
while they were lowest in Mexico and Brazil (under 10%).
Raising taxes on tobacco is the most effective way to reduce 
tobacco use (WHO, 2015). High levels of taxes as well as 
stringent policies led to strong reductions in smoking 
rates between 1996 and 2011 in many OECD countries 
(OECD, 2015). In 2014, 29 OECD countries applied tobacco 
advertising bans on at least national television, print media 
and radio, while 26 countries applied taxation rates of at 
least 70% (WHO, 2015). In all OECD countries, packages 
displayed at least a medium-sized a health warning. Every 
year on May 31st, “World No Tobacco Day” advocates for 
effective policies to reduce tobacco consumption, and 
highlights the health and additional risks associated with 
tobacco use. The theme for 2017 was “Tobacco – a threat to 
development”, and focused on the threats of the industry 
to the sustainable development of countries.
Definition and comparability
The proportion of daily smokers is defined as the 
percentage of the population aged 15 years and over 
who report tobacco smoking every day. Other forms 
of smokeless tobacco products, such as snuff in 
Sweden, are not taken into account. This indicator 
is more representative of the smoking population 
than the average number of cigarettes smoked per 
day, as the act of smoking is more determining than 
the quantity. Most countries report data for the 
population aged 15 +, but there are some exceptions 
as highlighted in the data source of the OECD Health 
Statistics database.
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4.1. Adult population smoking daily by gender, 2015 (or nearest year)
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4.2. Adult population smoking daily, 2000 and 2015 (or nearest year)
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Alcohol consumption among adults
Harmful alcohol use is a leading cause of death and 
disability worldwide, particularly in those of working age 
(OECD, 2015). Alcohol use is among the top ten leading risk 
factors in terms of years of healthy life lost in 32 OECD 
countries (Forouzanfar et al., 2016), and consumption in 
OECD countries remains well above the world average. 
In 2015, alcohol use lead to 2.3 million deaths, caused by 
cancers, heart diseases and liver diseases, among others. 
Most alcohol is drunk by the heaviest-drinking 20% of 
the population. Heavy drinking is associated with a lower 
probability of employment, more absence from work, and 
lower productivity and wages.
On average, recorded alcohol consumption has decreased 
in the OECD since 2000 (Figure  4.3), from 9.5  litres per 
capita per year to 9 litres of pure alcohol per capita each 
year, equivalent to 96 bottles of wine. The extent of the 
decrease varies greatly by country, and consumption has 
in fact increased in thirteen OECD countries, as well as 
in China, India, lithuania and South Africa. Consumption 
increased by 0.1 to 1 litre in Canada, Chile, Israel, Korea, 
Mexico, Norway, Slovenia, Sweden and the United States, 
as well as in South Africa. The increase was stronger in 
Belgium, Iceland, latvia and Poland, as well as China, 
India and lithuania (1.1 to 5.3 litres per capita). In all other 
countries, alcohol consumption decreased between 2000 
and 2015. The largest drops occurred in Denmark, Ireland, 
Italy and the Netherlands (more than 2 litres per capita).
Although adult alcohol consumption per capita is a useful 
measure to assess long-term trends, it does not identify 
sub-populations at risk from harmful drinking patterns. 
Heavy drinking and alcohol dependence account for an 
important share of the burden of diseases associated with 
alcohol. Across the OECD, an average of 12% of women 
and 30% of men take part in regular binge-drinking (at 
least once per month) (Figure 4.4). Rates range from 8% 
in Hungary to 37% in Denmark, and display large gender 
gaps, with men exhibiting higher rates in virtually all 
countries. These gaps are lowest in Spain and Greece (8-
10 points), and are highest in Estonia, Finland and latvia 
(over 25 points).
Many policies addressing harmful use of alcohol already 
exist: some target heavy drinkers only, while others are 
more broadly based. While all OECD countries apply taxes 
to alcoholic beverages, the level of taxes may greatly vary 
across countries. New forms of fiscal policies have been 
implemented like minimum pricing of one unit of alcohol in 
Scotland. Regulations on advertising alcoholic products have 
been set up in many OECD countries, but the forms of media 
included in these regulations (e.g. printed newspapers, 
billboards, the internet) and the enforcement of the law 
vary a lot across countries. All OECD countries have legally 
set maximum levels of blood alcohol concentration for 
drivers, but the enforcement of these regulations may be 
haphazard and varies widely across and within countries. 
less stringent policies include health promotion messages, 
school-based and worksite interventions and interventions 
in primary health care settings. Comprehensive policy 
packages including fiscal measures, regulations and less 
stringent policies are shown to be the most effective to 
reduce harmful use of alcohol (OECD, 2015).
Definition and comparability
Recorded alcohol consumption is defined as annual 
sales of pure alcohol in litres per person aged 15 years 
and over. Most countries report data for the population 
aged 15 +, but there are some exceptions as highlighted 
in the data source of the OECD Health Statistics database. 
The methodology to convert alcohol drinks to pure 
alcohol may differ across countries. Official statistics 
do not include unrecorded alcohol consumption, such 
as home production. Unrecorded alcohol consumption 
and low quality of alcohol consumed (beverages 
produced informally or illegally) remain a problem, 
especially when estimating alcohol-related burden of 
disease among low income groups. The WHO reports 
unrecorded alcohol consumption in their Global Health 
Observatory data repository. In some countries (e.g. 
luxembourg), national sales do not accurately reflect 
actual consumption by residents, since purchases by 
non-residents may create a significant gap between 
national sales and consumption. Alcohol consumption 
in luxembourg is thus the mean of alcohol consumption 
in France and Germany as recorded in the WHO-GISAH 
database.
Regular binge drinking is derived from self-reports of 
the European Health Interview Survey 2014. Regular 
binge drinking is defined as having six or more 
alcoholic drinks per single occasion at least once a 
month over the past 12 months.
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4.3. Recorded alcohol consumption among adults, 2000 and 2015 (or nearest year)
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4.4. Regular binge-drinking (at least once a month) by gender, 2014
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4. RISK FACTORS FOR HEALTH
Smoking and alcohol consumption among children
Smoking and excessive drinking during adolescence have 
both immediate and long-term health consequences. 
Establishing smoking habits early on increases the risk 
of cardiovascular diseases, respiratory illnesses, and 
cancer (Currie et al., 2012). Smoking during adolescence 
has immediate adverse health consequences, including 
addiction, reduced lung function and impaired lung growth, 
and asthma (Inchley et al., 2016). It is also associated with 
an increased likelihood of experimenting with other drugs, 
as well as engaging in other risky behaviours (O’Cathail et 
al., 2011). Early and frequent drinking and drunkenness 
is associated with detrimental psychological, social and 
physical effects, such as dropping out of high school 
without graduating (Chatterji and DeSimone, 2005).
Results from the Health Behaviour in School-aged Children 
(HBSC) surveys, a series of collaborative cross-national 
studies, allow for monitoring of smoking and drinking 
behaviours among adolescents. Other national surveys, 
such as the Youth Risk Behavior Surveillance System in 
the United States, or the Escapad survey in France, also 
monitor risky behaviours.
Over 15% of 15-year-olds smoke at least once a week 
in France, Hungary, Italy, luxembourg, and the Slovak 
Republic, as well as lithuania (Figure  4.5). At the other 
end of the scale, fewer than 5% report weekly smoking 
in Iceland and Norway. Across the OECD, the average is 
12%. On average, boys smoke slightly more than girls, but 
girls smoke more than boys in twelve countries (Australia, 
the Czech Republic, Denmark, France, Germany, Hungary, 
Italy, luxembourg, the Slovak Republic, Spain, Sweden and 
the United Kingdom). Gender gaps are particularly high 
in Israel, as well as lithuania and the Russian Federation.
Over 30% of 15-year-olds have been drunk at least twice 
in the Czech Republic, Denmark, Hungary, Slovenia and 
the United Kingdom, as well as lithuania (Figure 4.6). In 
Iceland, Israel, luxembourg, Switzerland as well as the 
Russian Federation, rates drop below 15%. Across the OECD, 
the average is 22.3%, with a small gap between boys (23.5%) 
and girls (21.2%). Gender disparities, with boys more prone 
to drink than girls, are especially high in Austria, Hungary, 
Israel, as well as lithuania and the Russian Federation 
(over 5 points). Only in Canada, Sweden and the United 
Kingdom do girls report repeated drunkenness more often 
than boys. 
Trends for repeated drunkenness and regular smoking 
in 15-year-olds display similar patterns (Figure 4.7). Both 
health behaviours are now at their lowest since 1993-94. 
Regular smoking displays the strongest decrease, as rates 
in boys and girls more than halved between 1997-98 and 
2013-14. The gender gap for drunkenness has also shrunk 
since the 1990s. All countries present a decrease in regular 
smoking since 1997-98, exceeding 60% for both boys and 
girls in Belgium, Canada, Denmark, Ireland, Norway, Sweden 
and the United Kingdom, and for girls in Austria, Finland 
and Switzerland. The decreases are weaker for repeated 
drunkenness, and reach 60% only for boys in Ireland and 
Sweden. Rates have increased since 1997-98 for girls in the 
Czech Republic, Estonia, Hungary, latvia and Poland.
Worldwide, one third of youth experimentation with 
tobacco occurs as a result of exposure to tobacco advertising, 
promotion and sponsorship (WHO, 2013). To reduce youth 
tobacco use, its use in the general population must be 
denormalised. Young smokers are responsive to policies 
aiming to reduce tobacco consumption, including excise 
taxes to increase prices, clean indoor-air laws, restrictions 
on youth access to tobacco, and greater education about 
the effects of tobacco (Forster et al., 2007).
Definition and comparability
Estimates for smoking refer to the proportion of 
15-year-old children who self-report smoking at least 
once a week. Estimates for drunkenness refer to the 
proportions of 15-year-old children who report that 
they have been drunk twice or more in their lives.
The Health Behaviour in School-aged Children (HBSC) 
surveys were undertaken every four years between 
1993-94 and 2013-14, and include up to 29 OECD 
countries, lithuania and the Russian Federation. 
Data are drawn from school-based samples of 1,500 
in each age group (11-, 13- and 15-year-olds) in most 
countries.
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4.5. Smoking among 15-year-olds, 2013-14
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4.6. Drunkenness among 15-year-olds, 2013-14
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4.7. Trends in regular smoking and repeated drunkenness among 15-year-olds for selected OECD countries, 
1994 to 2014
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Healthy lifestyles among adults
low fruit consumption, low vegetable consumption, and 
low levels of physical activity are among the ten leading 
risk factors in terms of years of healthy life lost in 24, 6, 
and 16 OECD countries respectively (Forouzanfar et al., 
2016). Worldwide, diets low in fruit were the cause of nearly 
3 million deaths in 2015, while low vegetable consumption 
caused nearly 2 million deaths, and low physical activity 
caused 1.6 million deaths. Including fruit and vegetables in 
the daily diet reduces the risk of coronary heart disease, 
stroke, as well as certain types of cancer (WHO, 2014). 
They include dietary fibre which lowers blood pressure 
and regulates insulin, possibly impacting the risk of 
type 2 diabetes (InterAct Consortium, 2015). Regular physical 
activity improves muscular and cardiorespiratory fitness, 
and reduces the risk of hypertension, coronary heart disease, 
stroke, diabetes, and various cancers (WHO, 2017). It has also 
been shown to positively impact mental health (lindwall 
et al., 2012). In adults, the WHO recommends at least 150 
minutes of moderate-intensity physical activity per week, at 
least 75 minutes of vigorous-intensity physical activity per 
week, or an equivalent combination of the two (WHO, 2017).
Fifty-seven per cent of adults across the OECD consume fruit 
daily, with values ranging from 30-35% in Finland and latvia, 
to over 70% in Australia, Italy, New Zealand and Portugal 
(Figure 4.8). Women consume more fruit than men in all 
countries, and display the highest rates of consumption 
in Australia, Canada, Italy and New Zealand (over 75%). 
Meanwhile, they display the lowest rates in Finland, latvia, 
Mexico, the Netherlands and Turkey (under 50%). levels of 
consumption for men are highest in Australia, Canada, Italy, 
Korea, New Zealand, Portugal and Spain (over 60%), while 
they are lowest in Finland, and latvia (below 30%). Gender 
gaps are largest in Austria, the Czech Republic, Denmark, 
Finland, Germany, Iceland, latvia, Norway, Slovenia, Sweden 
and Switzerland (15-20  points), and lowest in Australia, 
Mexico and Turkey (under 5 points). Overall, 63% of women 
in the OECD consume fruit daily, while 50% of men do.
Vegetable consumption is higher than fruit consumption 
(Figure 4.9). On average, 60% of people in the OECD consume 
vegetables daily (65% of women, and 55% of men). Rates are 
highest in Australia, Korea, New Zealand and the United 
States, with over 90% of people reporting eating vegetables 
daily, although the methodology differs across countries 
(see Definition and comparability). On the other end of 
the spectrum, fewer than 40% report doing so in Finland, 
Germany and the Netherlands. In the United States, men 
consume slightly more vegetables than women, and in 
Korea and Mexico they consume the same amount; in all 
other countries, women consume more vegetables than 
men. Gender gaps are large in Austria, Denmark, Finland, 
Germany, luxembourg, Norway, Sweden and Switzerland 
(15-19 points).
Over 70% of adults perform at least 150  minutes of 
moderate physical activity weekly in Austria, Denmark, 
Finland, France, Iceland, Ireland, Norway, Slovenia and 
Sweden (Figure 4.10). In Portugal, Italy and Spain, fewer 
than 60% meet the WHO recommendation. Across the 
OECD, an average of 66.5% of people perform 150 minutes 
of moderate physical activity per week, with 70.5% of 
men and 63% of women. Men are more physically active 
than women in all countries but Denmark. The gap is 
particularly high (over 15 points) in the Czech Republic, 
latvia, Turkey and Spain.
Definition and comparability
Fruit and vegetable consumption is defined as the 
proportion of individuals consuming at least one fruit 
or vegetable per day. Data rely on self-reporting and 
are subject to errors in recall.
Data for Australia, Korea and New Zealand are derived 
from quantity-type questions. Data from the United 
States include juice made from concentrate. In these 
countries, values may be overestimated as compared 
with other countries. Most countries report data for the 
population aged 15 +, but there are some exceptions 
as highlighted in the data source of the OECD Health 
Statistics database.
The indicator of moderate physical activity is defined 
as doing at least 150 minutes of moderate physical 
activity per week. Estimates of moderate physical 
activity are based on self-reports from the European 
Health Interview Survey 2014, combining work-related 
physical activity with leisure-time physical activity 
(bicycling for transportation and sport). Walking for 
transportation is not included.
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4.8. Daily fruit eating among adults, 2015 (or nearest year)
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4.9. Daily vegetable eating among adults, 2015 (or nearest year)
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4.10. Moderate weekly physical activity among adults, 2014
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Healthy lifestyles among children
Consuming a healthy diet and performing regular physical 
activity when young can be habit forming, promoting a 
healthy lifestyle in adult life. Daily consumption of fruit 
and vegetables can help reduce the risk of coronary heart 
diseases, strokes, and certain types of cancer (Hartley et al., 
2013; World Cancer Research Fund, 2007). The most common 
guideline recommends consuming at least five portions of 
fruit and vegetables daily. Moderate-to-vigorous physical 
activity is beneficial to adolescents’ physical, mental and 
psycho-social health, as it helps build and maintain healthy 
bones and muscles, reduces feelings of depression and 
anxiety, and improves academic achievement (Janssen and 
leBlanc, 2010; Singh et al., 2012). The WHO recommends 
60 minutes of moderate-to-vigorous daily physical activity 
for those aged 5-17 years.
Over 40% of 15-year-olds consume fruit daily in Canada, 
Denmark, Iceland and Switzerland, while less than 25% 
do so in Finland, Greece, latvia and Sweden (Figure 4.11). 
Rates exceed 50% for girls in Denmark and Switzerland, 
while only boys in Canada reach 40%. Rates are under 30% 
for girls in Greece, Hungary, latvia, Poland and Sweden, and 
under 20% for boys in Finland, latvia, and Sweden. Across 
the OECD, nearly one in three 15-year-olds consumes fruit 
daily, with girls at 37% and boys at 28%. Girls consume more 
fruit than boys in all countries. Gender gaps are largest in 
Denmark, Finland and Switzerland (17-18 points).
Daily vegetable consumption in 15-year-olds exceeds 50% 
in Belgium and 40% in Canada, Denmark, Ireland, Israel, 
the Netherlands and Switzerland (Figure  4.12). Rates 
are under 25% in the Czech Republic, Estonia, Germany, 
Portugal, the Slovak Republic, Slovenia and Spain. Overall, 
the OECD average is 32%, nearly identical to the average 
for fruit consumption. Rates are highest in girls in Belgium 
(over 60%), and Israel and Switzerland (over 50%); they are 
highest for boys in Belgium (over 50%) and Ireland (over 
40%). Daily vegetable consumption is lowest for girls in 
Estonia, Portugal and Spain, and boys in Finland, Germany 
and Spain. In all countries, girls consume more vegetables 
than boys. Gender gaps are largest in Finland, Germany, 
Italy and Switzerland (15 points or over).
Rates of physical activity meeting the WHO guidelines reach 
20% in Canada and Spain, and are lower than 10% in Israel, 
Italy and Switzerland (Figure 4.13). They are consistently 
higher in boys, and by a large margin, as gender gaps range 
from 5 points (Israel, Sweden and Switzerland) to 17 points 
(luxembourg). Physical activity is lowest in girls in Austria, 
Israel, Italy and Portugal (5%), and boys in France, Israel, Italy 
and Switzerland (under 15%). Sufficient physical activity 
is most prevalent in girls in Canada, Iceland and latvia 
(14-15%), and boys in Canada and Spain (nearly 30%). The 
OECD average is just under 15%, with nearly 20% for boys 
and 10% for girls, resulting in a 10 point average gender gap.
Nearly all OECD countries promote fruit and vegetable 
consumption: most widely known is the “5 a day” 
guideline (OECD, 2017). In recent years, children’s daily 
habits have evolved, due to new leisure patterns (TV, 
internet, smartphones) which have led to a decrease in 
physical activity (Inchley et al., 2016). Age-specific policies 
should promote a decrease in screen time and an increase 
in physical activity levels. Furthermore, the gender gap 
between boys and girls has not decreased with time, 
suggesting that girls should be targeted with gender-
sensitive approaches and interventions.
Definition and comparability
Dietary habits are measured here in terms of the 
proportions of children who report eating fruit and 
vegetables at least every day or more than once a 
day, no matter the quantity. No reference to exclude 
juice, soup or potatoes was mentioned in the survey 
questions. In addition to fruit and vegetables, healthy 
nutrition also involves other types of foods.
Data for physical activity consider the regularity of 
self-reported moderate-to-vigorous physical activity 
lasting at least 60 minutes. Moderate-to-vigorous 
physical activity refers to exercise undertaken for at 
least an hour each day which increases the heart rate, 
and sometimes leaves the child out of breath.
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4.11. Daily fruit eating among 15-year-olds, 2013-14
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4.12. Daily vegetable eating among 15-year-olds, 2013-14
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4.13. Moderate-to-vigorous daily physical activity among 15-year-olds, 2013-14
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Overweight and obesity among adults
Overweight and obesity are major risk factors for many 
chronic diseases, including diabetes, cardiovascular 
diseases, and cancer. High body mass index (BMI) led to 
nearly 4 million deaths in 2015, a 19.5% increase since 2005 
worldwide. It is the leading risk factor in terms of healthy 
years of life lost in Turkey, second leading in six other 
OECD countries, and third leading in another 24 member 
countries (Forouzanfar et al., 2016). Obesity has risen 
quickly in the OECD in recent decades, and projections 
show that this trend will continue (OECD, 2017). It has 
affected all population groups, regardless of gender, age, 
race, income or education level, though to varying degrees 
(Sassi, 2010).
Across the OECD, 54% of the population is overweight, 
including 19% who are obese (Figure 4.14). Total overweight 
(BMI≥25) ranges from 24% in Japan and 33% in Korea to just 
over 70% in Mexico and the United States. Obesity (BMI≥30) 
is lowest in Italy, Japan and Korea (under 10%), and highest 
in Hungary, Mexico, New Zealand and the United States 
(30% or over). In most countries, pre-obesity (25≤BMI<30) 
accounts for the largest share of overweight people. 
On average, 20% of women and 19% of men are obese 
(Figure  4.15). Gender gaps are lower than 1 point in 
Canada, France, Germany, Iceland, the Slovak Republic, 
Spain, Sweden and the United Kingdom. Women are more 
obese than men in a majority of countries, with disparities 
10 points and over in Mexico, Turkey, as well as Colombia, 
and 22 points in South Africa. In the countries where men 
are more obese than women (Australia, the Czech Republic, 
Japan, Korea, Ireland and Slovenia), the gender gaps are 
much lower.
Obesity has greatly risen in the past two decades, even 
in countries where rates have been historically low 
(Figure 4.16). Obesity has more than doubled since the late 
1990s in Korea and Norway. Rates seem to have stabilised 
in recent years in Italy and Japan. OECD countries with 
historically high rates of obesity are Canada, Chile, Mexico, 
the United Kingdom and the United States. These countries 
have also shown a great increase since the 1990s: +92% in 
the United Kingdom, and +65% in the United States. The 
increase has been slower in Canada, and Mexico since 2006, 
and the rise in Chile is nearly imperceptible.
OECD countries have increased implementation of a range 
of public health policies to try to slow the obesity epidemic 
(OECD, 2017). Food labelling measures, such as nutrient lists, 
informative logos, or traffic light schemes have been set 
up in Australia, England, France and New Zealand, among 
other countries. Social media and new technologies have 
become tools for public health promotion, through mass 
media campaigns aiming to increase public awareness 
about healthier choices (Goryakin et al., forthcoming). 
Taxation policies have also been increasingly implemented 
to raise the price of potentially unhealthy products such as 
foods high in salt, fat, or sugar. Taxes on sugar-sweetened 
beverages are amongst the most popular, and there is 
reasonable evidence that appropriately designed taxes 
would result in proportional reductions in consumption, 
especially if fixed at 20% of the retail price or more (WHO, 
2016). Comprehensive policy packages that include health 
promotion, education, interventions in primary care 
settings, and broader regulatory and fiscal policies, provide 
affordable and cost-effective solutions to tackle obesity 
(OECD, 2010).
Definition and comparability
Overweight and obesity are defined as excessive 
weight presenting health risks because of the high 
proportion of body fat. The most frequently used 
measure is based on the body mass index (BMI), which 
is a single number that evaluates an individual’s weight 
in relation to height (weight/height2, with weight in 
kilograms and height in metres). Based on the WHO 
classification, adults over age 18 with a BMI greater 
than or equal to 25 are defined as overweight, and 
those with a BMI greater than or equal to 30 as obese. 
Pre-obesity defines people whose BMI is greater than 
or equal to 25 and below 30. Most countries report 
data for the population aged 15 +, but there are some 
exceptions as highlighted in the data source of the 
OECD Health Statistics database.
Overweight and obesity rates can be assessed 
through self-reported estimates of height and weight 
derived from population-based health interview 
surveys, or measured estimates derived from health 
examinations. Estimates from health examinations 
are generally higher and more reliable than from 
health interviews.
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4.14. Overweight including obesity among adults, 2015 (or nearest year)
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4.15. Obesity among adults by gender, 2015 (or nearest year)
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4.16. Evolution of obesity in selected OECD countries, 1990 to 2015 (or nearest year)
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Overweight and obesity among children
Childhood obesity has become one of the most serious 
public health challenges of the 21st century. Obesity can 
affect a child’s physical health, through cardiovascular, 
endocrine, or pulmonary diseases, and psycho-social 
health, through the development of poor self-esteem, 
eating disorders, and depression (Inchley et al., 2016). 
Obesity can also affect educational attainment (Cohen 
et al., 2013). Furthermore, childhood obesity is a strong 
predictor of adult obesity, which has health and economic 
consequences (WHO, 2016).
Overweight (including obesity) based on measured rather 
than self-reported height and weight ranges from 15% in 
Norway to 45% in Chile (Figure 4.17). Across the OECD, the 
average is 25%, with 26% of overweight boys, and 24% of 
overweight girls, although rates are based on different age 
groups. Prevalence of overweight is higher in girls than in 
boys in Ireland, Mexico, New Zealand, Portugal, Sweden, 
Switzerland, Turkey and the United Kingdom (England), as 
well as South Africa. Gender gaps are largest in Denmark, 
Greece, Korea, Poland, Sweden, as well as South Africa 
(larger than 8 points).
Over 20% of 15-year-olds self-report overweight in Canada, 
Greece and the United States, while prevalence drops under 
10% in Denmark (Figure 4.18). The highest rates occur for 
girls in Canada, Greece, Iceland and the United States 
(15% or over), and in boys in Canada, Greece, Israel, Italy, 
Slovenia and the United States (over 20%). Rates are lowest 
in girls in Poland and Norway, as well as lithuania and 
the Russian Federation (6-7%), and in boys in Denmark, 
the Netherlands, France as well as lithuania (10-14%). 
Self-reported overweight is higher in boys than in girls in 
all countries, and the overall OECD average is 16% (19% in 
boys, 12% in girls). Gender gaps are large overall, but are 
highest in Canada, Estonia, Greece, Italy, Norway, Poland 
and the Russian Federation (10-15 points). The gaps remain 
very small in Denmark, the Netherlands, and Portugal 
(1-3 points).
Self-reported overweight in 15-year-olds has increased 
in most OECD countries in the past decade (Figure 4.19). 
Overall across the OECD, overweight increased by 28%, from 
12% in 2001-02 to 16% in 2013-14. The strongest increases 
occurred in the Czech Republic, Israel, latvia, Poland, 
the Slovak Republic and Sweden, where overweight rose 
by more than 50%, as well as Estonia and lithuania and 
the Russian Federation, where they more than doubled. 
Overweight has dropped since 2001-02 in Denmark, as well 
as for boys in Iceland and Spain, and girls in Norway and 
the United Kingdom (England).
Increasingly obesogenic environments have contributed to 
the rise in overweight and obesity in children. Several OECD 
countries have implemented policies aimed at tightening 
regulation of advertisements of unhealthy foods and 
beverages, specifically targeted toward children and young 
adults to prevent obesity (OECD, 2017). Children have been 
found to respond well to school programmes (Veugelers and 
Fitzgerald, 2005), but a systemic approach encompassing a 
broad spectrum of factors leading to obesity and including 
communities, families and individuals is necessary to 
effectively halt the epidemic and decrease prevalence 
(Inchley et al., 2016). 
Definition and comparability
Estimates of overweight and obesity are based on body 
mass index (BMI) calculations using either measured 
or child self-reported height and weight, the latter 
possibly under-estimating obesity and overweight. 
Overweight and obese children are those whose BMI 
is above a set of age- and sex-specific cut-off points 
(Cole et al., 2000).
Measured data are gathered by the World Obesity 
Federation (WOF, former IASO) from different national 
studies. The estimates are based on national surveys 
of measured height and weight among children at 
various ages. Caution is therefore needed in comparing 
rates across countries. Definitions of overweight and 
obesity among children may sometimes vary among 
countries, although whenever possible the IOTF BMI 
cut-off points are used.
Self-reported data are from the Health Behaviour in 
School-aged Children (HBSC) surveys undertaken 
between 2001-02 and 2013-14. Data are drawn from 
school-based samples of 1 500 in each age group (11-, 
13- and 15-year-olds) in most countries. Self-reported 
height and weight are subject to under-reporting, 
missing data and error, and require cautious 
interpretation.
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4.17. Measured overweight (including obesity) among children at various ages, 2010 (or nearest year)
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4.18. Self-reported overweight (including obesity) among 15-year-olds, 2013-14
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Note: International Obesity Task Force cut-offs. Rates for the United States refer to survey year 2009-10 rather than 2013-14.
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4.19. Change in self-reported overweight (including obesity) among 15-year-olds, 2001-02 and 2013-14
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Air pollution
Air pollution is a major environment-related health threat, 
especially to children and the elderly, as it can cause 
respiratory diseases, lung cancer, and cardiovascular 
diseases. It has also been linked to low birth-weight, 
dementia, and damage to DNA and the immune system 
(WHO, 2017). Outdoor air pollution in both cities and 
rural areas was estimated to cause 3 million premature 
deaths worldwide in 2012 (WHO, 2016), and can also have 
substantial economic and social consequences, from 
health costs to building restoration needs and agricultural 
output (OECD, 2015). Of particular concern for outdoor air 
pollution are carbon monoxide, nitrogen oxide and ozone, 
but also fine particulates, or PM2.5, whose diameter is 
2.5 μm or smaller. These are potentially more dangerous 
than the larger particulates (PM10), as they can penetrate 
deeper into the respiratory tract, and cause severe health 
effects. In 2015, particulate matter pollution was the 
cause of over 4.2 million deaths worldwide (Forouzanfar 
et al., 2016). The WHO has claimed that air pollution is 
one of the most pernicious threats facing global public 
health today and on a bigger scale than HIV or Ebola 
(WHO, 2017). 
In 2015, exposure levels to PM2.5 exceeding the WHO 
guidelines were higher than 90% in 21  OECD countries 
(Figure 4.20). In 19 of those countries, 100% of the population 
was exposed. Australia, Canada, Finland, Iceland, New 
Zealand and Sweden display rates of nearly 0%, followed 
by the United States and Norway with rates below 10%. The 
OECD average is 68%.
The mean annual population exposure to PM2.5 has decreased 
in the OECD, on average, from 18.2 microgrammes/m3 in 
1990 to 15.1 microgrammes/m3 in 2015 (Figure 4.21). While 
the overall trend since 1990 has been downward, there have 
been some increases in population exposure in more recent 
years. This is largely due to the concentration of pollution 
sources in urban areas and to increasing use of private 
vehicles for urban trips (OECD, 2015).
In 2015, population exposure was lowest in Australia, 
Canada, Finland, Iceland, New Zealand and Sweden, and 
highest in Korea and Turkey, as well as China, India and 
South Africa. Population exposure has decreased in most 
countries since 1990, except in Israel, Italy, Japan, Korea, 
Turkey, China and India where increases range from 5% 
in Japan to 24% in India. In countries where exposure 
has dropped, the decreases range from 3-8% in Finland, 
Iceland, Spain, Sweden, Switzerland as well as Costa Rica 
and Indonesia, to 30-40% in the Czech Republic, Hungary, 
latvia, Poland, the Slovak Republic as well as lithuania.
The WHO estimates that overall, 92% of the world’s 
population is breathing air above the PM2.5 guidelines 
(WHO, 2017), and indoor and outdoor air pollution cause 
approximately 7 million premature deaths per year (WHO, 
2014). OECD projections estimate that outdoor air pollution 
will cause 6 to 9 million premature deaths by 2060, and cost 
1% of global GDP (OECD, 2016). Policies to limit air pollution 
consist of regulatory approaches, such as air quality 
standards, fuel quality standards or emission ceilings, as 
well as economic instruments, which include fuel taxes, 
road pricing or taxes on emissions.
Definition and comparability
The WHO has established guidelines for air pollution, 
expressed as the average level of exposure of a nation’s 
population (urban and rural) to concentrations of 
suspended particles which must not be exceeded. 
The indicators presented here reflect the estimated 
average level of exposure to concentrations of fine 
particulates, which measure less than 2.5 microns 
in diameter. The WHO guidelines for PM2.5 are an 
annual mean of 10 microgrammes/m3, which is the 
lower range over which adverse health effects have 
been observed.
Data for PM2.5 are made available by the World Bank, 
through the Global Burden of Disease Study. They 
are generated by combining data from different 
sources, including satellite observations of aerosols 
in the atmosphere and round-level monitoring of 
particulates. However, pollutant concentrations 
are sensitive to local conditions, and measurement 
protocols may differ across countries. The data must 
therefore serve as a general indicator of air quality, 
mostly allowing for cross-country comparison.
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4. RISK FACTORS FOR HEALTH
4.20. Population exposed to PM2.5 levels exceeding 10 microgrammes/m
3, 2015
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4.21. Mean annual population exposure to PM2.5, 1990 and 2015
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The statistical data for Israel are supplied by and under the responsibility of the relevant 
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the 
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of 
international law.
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Population coverage for health care 
Health care coverage, through government schemes and 
private health insurance, provides financial security against 
unexpected or serious illness. However, the percentage of 
the population covered by such schemes does not provide 
a complete indicator of accessibility, since the range of 
services covered and the degree of cost-sharing applied to 
those services also affects access to care.
Most OECD countries have achieved universal (or near-
universal) coverage of health care costs for a core set of 
services, which usually include consultations with doctors 
and specialists, tests and examinations, and surgical and 
therapeutic procedures (Figure 5.1). Generally, dental care 
and pharmaceutical drugs are partially covered, although 
there are a number of countries where these services must 
be purchased separately (OECD, 2015). Universal coverage 
has typically been achieved through government schemes 
(national health systems or social health insurance), 
though a few countries (the Netherlands and Switzerland) 
use compulsory private health insurance to cover some or 
all of the population.
Population coverage for a core set of services is below 
95% in seven OECD countries, and lowest in Greece, the 
United States and Poland. In Greece, the economic crisis 
continues to have a significant effect, reducing health 
insurance coverage among the long-term unemployed. 
Many self-employed workers have also decided not 
to renew their health insurance because of reduced 
disposable income. However, since 2014 uninsured people 
are covered for prescribed pharmaceuticals, emergency 
services in public hospitals, and for non-emergency 
hospital care under certain conditions (Eurofound, 2014). 
Further, since 2016 new legislation has sought to close 
remaining coverage gaps. In the United States, coverage is 
provided mainly through private health insurance. Publicly 
financed coverage covers the elderly, and people with low 
income or with disabilities. The share of the population 
uninsured decreased from 14.4% in 2013 to 9.1% in 2015. 
This followed implementation of the Affordable Care Act, 
which was designed to expand health insurance coverage 
(Cohen and Martinez, 2015). However, this Act is under 
review by the current United States administration. 
In Poland, a tightening of the law in 2012 made people 
lose their social health insurance coverage if they fail to 
pay their contribution. But uninsured people who need 
medical care utilise emergency hospital services, where 
they will be encouraged to obtain insurance. In Ireland, 
though coverage is universal, most of the population have 
to pay not insignificant user charges (upwards of EUR50) 
to access primary care (Burke et al., 2016).
Basic primary health coverage, whether provided through 
government schemes or private insurance, generally 
covers a defined “basket” of benefits, in many cases 
with cost-sharing. In some countries, additional health 
coverage can be purchased through voluntary private 
insurance to cover any cost-sharing left after basic 
coverage (complementary insurance), add additional 
services (supplementary insurance) or provide faster 
access or larger choice to providers (duplicate insurance). 
Among OECD countries, nine have private coverage for 
over half of the population (Figure 5.2).
Private health insurance offers 96% of the French 
population complementary insurance to cover cost-sharing 
in the social security system. The Netherlands has the 
largest supplementary market (84% of the population), 
followed by Israel (83%), whereby private insurance pays 
for prescription drugs and dental care that are not publicly 
reimbursed. Duplicate markets, providing faster private-
sector access to medical services where there are waiting 
times in public systems, are largest in Ireland (45%) and 
Australia (56%).
The population covered by private health insurance has 
increased in some OECD countries over the past decade, 
particularly in Denmark, Korea, Slovenia and Belgium. 
But private health insurance coverage has come down in 
other countries, notably Greece, Ireland, New Zealand and 
the United States (Figure 5.3). The importance of private 
health insurance is linked to several factors, including 
gaps in access to publicly financed services, government 
interventions directed at private health insurance markets, 
and historical development.
Definition and comparability
Coverage for health care is defined here as the share 
of the population receiving a core set of health care 
goods and services under public programmes and 
through private health insurance. It includes those 
covered in their own name and their dependents. 
Public coverage refers to national health systems or 
social health insurance. Take-up of private health 
insurance is often voluntary, although it may be 
mandatory by law or compulsory for employees 
as part of their working conditions. Premiums are 
generally not income-related, although the purchase 
of private coverage can be subsidised by government.
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5.1. Population coverage for a core set of services, 2015 
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5.2. Private health insurance coverage, by type, 
2015 (or nearest year)
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5.3. Trends in private health insurance coverage, 2005 and 2015 (or nearest year)
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Unmet needs for health care due to cost
Access to health care may be prevented for a number of 
reasons. These can be due to the functioning of the health 
care system (such as the cost of health care, distance to the 
closest health care facility, or waiting lists) or to personal 
reasons (including fear of not being understood by the 
doctor or not having the time to seek care). People who 
forgo health care when they need it may jeopardise their 
health status.
Unmet needs due to cost is a particularly pressing problem, 
especially among lower-income groups. Consequently, an 
increasing number of countries collect data to measure the 
extent to which health care is foregone due to cost (Fujisawa 
and Klazinga, 2017). This includes whether people skipped 
consultations or prescribed medicines due to cost. 
On average across OECD countries, just over one in ten 
people reported having skipped a consultation due to cost 
in 2016, based on 17 OECD countries (Figure 5.4). Relatively 
high numbers of people reporting to forego consultations 
is somewhat surprising, as in most OECD countries 
consultations are free of charge or with a small co-payment 
(Paris et al., 2016). The share of the population foregoing 
consultations due to cost is high in Poland (33%), and also 
in the United States (22.3%) and Switzerland (20.9%). less 
than 5% of the population in Germany, Spain, Sweden, 
the United Kingdom, Israel and Italy reported skipping 
consultations due to cost.
In most countries, the share of the population who skipped 
a consultation due to cost has not changed much in recent 
years, but there are some exceptions. A large increase was 
observed in Switzerland, with people who have foregone 
consultations concentrated among those younger than 
50 years of age and those with low income (OFSP, 2016). 
In Germany and Estonia, the share of the population who 
skipped consultation due to cost has decreased.
In terms of prescribed medicines, on average 7.1% of 
people reported having skipped prescribed medicines 
due to cost, based on 15 OECD countries (Figure  5.5). 
Most OECD countries have co-payments for prescribed 
medicines, though often with exemptions for specific 
population groups (Paris et al., 2016). Population shares 
reporting foregone prescribed medicines were highest 
in the United States (18%) and Switzerland (11.6%); and 
lowest in Germany (3.2%) and the United Kingdom (2.3%). 
In most countries, the share of the population who skipped 
prescribed medicine due to cost has slightly decreased in 
recent years. large improvements were reported in Israel, 
Estonia and Australia. In Israel, this may be due in part 
to policies to improve accessibility and affordability of 
medicines for chronic patients and the elderly. 
Unmet needs for health care due to cost are consistently 
higher among people in low income groups compared 
with those in high income groups, across OECD countries 
(Figure 5.6). An exception is in the United Kingdom, where 
unmet care needs due to cost are similar for low income 
adults and the rest of the population. Unmet needs are 
particularly large among the low income in the United 
States, where 43% of low income adults reported having 
unmet care needs due to cost in 2016. There were also large 
gaps in unmet care needs between high and low income 
people in France and Canada.
Self-reported unmet care needs should be assessed together 
with other indicators of potential barriers to access, such 
as the extent of health insurance coverage and the amount 
of out-of-pocket payments. Strategies to improve access to 
care for disadvantaged or underserved populations need 
to tackle both financial and non-financial barriers, as well 
as promoting an adequate supply and distribution of the 
health workforce.
Definition and comparability
The OECD collects data on unmet care needs due 
to cost reported by populations from national and 
international sources and a number of countries 
reporting these measures are increasing over time. 
These use questions that are similar to those asked 
in the Commonwealth Fund International Health 
Policy Survey. Rates for Figures 5.4 and 5.5 refer to 
both primary and secondary care and they are age-sex 
standardised to the 2010 OECD population structure, 
to remove the effect of different population structures 
across countries. Due to the change of data source for 
this indicator, data cannot be compared directly with 
those presented in the previous editions of Health at 
a Glance. 
The 2016 Commonwealth Fund’s International Health 
Policy Survey asks whether people did not visit a doctor 
when they had a medical problem, skipped a medical 
test, treatment, or follow-up that was recommended 
by a doctor, or did not fill prescription for medicines or 
skipped doses because of cost in the past year and as 
it also collects socio-economic background including 
income level, it allows analysis on unmet care needs 
by income group. This survey was carried out in 
11 countries.
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5.4. Consultations skipped due to cost, 2016 (or nearest year)
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5.5. Prescribed medicines skipped due to cost, 2016 (or nearest year)
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5.6. Unmet care needs due to cost, by income level, 2016
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Out-of-pocket medical expenditure 
Financial protection through compulsory or voluntary 
health coverage can substantially reduce the amount that 
people need to pay directly for medical care. Yet in some 
countries the burden of out-of-pocket spending can still 
create barriers to health care access and use: households 
that face difficulties paying medical bills may delay or 
even forgo needed health care. On average across OECD 
countries, a fifth of all spending on health care comes 
directly from patients (see indicator “Financing of health 
care”).
Out-of-pocket payments rely on the ability to pay. If the 
financing of health care becomes more dependent on out-
of-pocket payments, the burden shifts, in theory, towards 
those who use services more, and possibly from high to 
low-income earners, where health care needs are usually 
higher. In practice, many countries have safety-nets in 
place to protect vulnerable groups of the population (such 
as the poor, the elderly, or people with chronic diseases 
or disabilities) from excessive out-of-pocket payments. 
These may be partial or total exemptions or a cap on direct 
payments, either in absolute terms or as a share of income 
(Paris et al., 2016).
The burden of out-of-pocket medical spending (that is, 
excluding long-term care services) can be measured either 
as a share of total household income or consumption. The 
share of household consumption allocated to medical care 
varied considerably across OECD countries in 2015, ranging 
from lows of around 1.5% of total household consumption 
in France, luxembourg and the United Kingdom, to more 
than 5% in Korea and Switzerland (Figure 5.7). On average, 
across OECD countries, 3% of household spending goes on 
medical goods and services. 
Health systems in OECD countries differ in the degree of 
coverage for different health services and goods. In most 
countries, a higher proportion of the cost is paid directly 
for pharmaceuticals, dental care and eye care than for 
hospital care and doctor consultations (Paris et al., 2016). 
Taking into account these differences and also the relative 
importance of these different spending categories, it is not 
surprising that there are significant variations between 
OECD countries in the breakdown of the medical costs that 
households have to bear themselves.
In most OECD countries, spending on pharmaceuticals and 
outpatient care (including dental care) are the two main 
spending items for out-of-pocket expenditure (Figure 5.8). 
These two components typically account for almost four-
fifths of all medical spending by households. Co-payments 
and additional services can result in a larger proportion 
of the cost of inpatient care being taken on directly by 
households –Greece, Belgium and the Netherlands report a 
greater share of household spending (20-32%) on inpatient 
care than the OECD average of less than 10%. 
In some Central and Eastern European countries such as 
Poland, the Czech Republic and Hungary, as well as Canada 
and Mexico, expenditure on pharmaceuticals accounts for 
half or more of all out-of-pocket payments. This may be due 
not only to co-payments for prescribed pharmaceuticals, 
but also high levels of spending on over-the-counter 
medicines for self-medication. Therapeutic goods, covering 
among other items, corrective eye products and hearing 
aids, can also account for a significant proportion of 
household spending. In the case of spectacles, compulsory 
coverage is often limited to paying a contribution for the 
cost of the lenses, while private households are left to 
bear the full cost of the frames if they are not covered 
by complementary private insurance. Overall, therapeutic 
goods account for more than 20% of household spending in 
the Netherlands, the United Kingdom, Slovenia, Germany 
and the Slovak Republic. 
Coverage for dental treatment is typically limited and 
as such dental care plays a significant part in outpatient 
and overall household spending, accounting for 20% of 
all out-of-pocket expenditure across OECD countries. In 
Spain, Norway and Estonia, this figure reaches 30% or 
more. This can at least partly be explained by the limited 
compulsory  coverage for dental care in these countries 
compared with a more comprehensive coverage for other 
categories of care. 
Definition and comparability
Out-of-pocket payments are expenditures borne 
directly by a patient where neither compulsory nor 
voluntary insurance cover the full cost of the health 
good or service. They include cost-sharing and other 
expenditure paid directly by private households and 
should also include estimations of informal payments 
to health care providers. Only expenditure for medical 
spending (i.e. current health spending less expenditure 
for the health part of long-term care) is presented here, 
because the capacity of countries to estimate private 
long-term care expenditure varies widely. 
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5.7. Out-of-pocket medical spending as a share of final household consumption, 2015 (or nearest year)
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5.8. Out-of-pocket medical spending by services and goods, 2015 (or nearest year)
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Geographic distribution of doctors 
Access to medical care requires an adequate number and 
proper distribution of doctors in all parts of the country. 
Concentration of doctors in one region and shortages in 
others can lead to inequities in access such as longer 
travel or waiting times. The uneven distribution of doctors 
and the difficulties in recruiting and retaining doctors in 
certain regions is an important policy issue in most OECD 
countries, especially those with remote and sparsely 
populated areas, and those with deprived rural and urban 
regions.
The overall number of doctors per capita varies across 
OECD countries from around two per 1 000 population in 
Turkey, Chile and Korea, to above five per 1 000 population in 
Greece and Austria (see indicators on doctors in Chapter 8). 
Beyond these cross-country differences, the number of 
doctors per capita also varies widely across regions within 
the same country (Figure 5.9). In many countries there is 
a high concentration of physicians in capital cities; this is 
particularly evident in Austria, the Czech Republic, Greece, 
Mexico, Portugal, the Slovak Republic, and the United States. 
Between regions, the United States shows nearly a five-fold 
difference in physician density, while Australia, Belgium 
and Korea show only around a 20 percent difference in 
physician densities between regions. 
The density of physicians is also consistently greater in 
urban regions, reflecting the concentration of specialised 
services such as surgery and physicians’ preferences to 
practice in urban settings. There are large differences in 
the density of doctors between predominantly urban and 
rural regions in Canada, the Slovak Republic and Hungary, 
although the definition of urban and rural regions varies 
across countries. The distribution of physicians between 
urban and rural regions was more equal in Japan and Korea, 
but there are generally fewer doctors in these two countries 
(Figure 5.10).
Doctors may be reluctant to practice in rural regions 
due to concerns about their professional life (including 
their income, working hours, opportunities for career 
development, isolation from peers) and social amenities 
(such as educational options for their children and 
professional opportunities for their spouse). A range of 
policy levers can be used to influence the choice of practice 
location of physicians. These include 1)  the provision of 
financial incentives for doctors to work in underserved 
areas; 2)  increasing enrolments in medical education 
programmes of students coming from specific social or 
geographic backgrounds or decentralising the location of 
medical schools; 3) regulating the choice of practice location 
of doctors (for new medical graduates or foreign-trained 
doctors); and 4) re-organising service delivery to improve 
the working conditions of doctors in underserved areas. 
Many OECD countries provide different types of financial 
incentives to attract and retain doctors in underserved 
areas, including one-time subsidies to help them set up 
their practice and recurrent payments such as income 
guarantees and bonus payments (Ono et  al., 2014). A 
number of countries have also introduced measures to 
encourage students from under-served regions to enrol 
in medical schools. Japan established in 1973 the Jichi 
Medical University specifically to educate physicians 
for service in rural communities, which contributed to 
improving access to care in underserved rural regions 
(Ikegami, 2014).
The effectiveness and cost of different policies to promote 
a better distribution of doctors can vary significantly, 
with the impact depending on the characteristics of each 
health system, the geography of the country, physician 
behaviours, and the specific policy and programme design. 
Policies should be designed with a clear understanding 
of the interests of the target group in order to have any 
significant and lasting impact (Ono et al., 2014).
Definition and comparability
Regions are classified in two territorial levels. The 
higher level (Territorial level 2) consists of large regions 
corresponding generally to national administrative 
regions. These broad regions may contain a mix 
of urban, intermediate and rural areas. The lower 
level is composed of smaller regions classified as 
predominantly urban, intermediate or rural regions, 
although there are variations across countries in the 
classification of these regions. The data on geographic 
distributions are from the OECD Regional Database. 
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5.9. Physician density, by level 2 regions, 2015 (or nearest year)
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5.10. Physician density, rural vs urban areas, 2015 (or nearest year)
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Waiting times for elective surgery 
long waiting times for health services is an important 
policy issue in many OECD countries (Siciliani et al., 2013), 
although less relevant in some (e.g. Belgium, France, 
Germany, Japan, Korea, luxembourg, Switzerland, United 
States). long waiting times for elective (non-emergency) 
surgery, such as cataract surgery, hip and knee replacement, 
generates dissatisfaction for patients because the expected 
benefits of treatments are postponed and the pain and 
disability remain.
Waiting times are the result of a complex interaction between 
the demand and supply of health services, with doctors 
playing a critical role on both sides. The demand for health 
services and elective surgeries is determined by the health 
status of the population, progress in medical technologies 
(including the simplification of many procedures, such as 
cataract surgery), patient preferences, and the burden of 
cost-sharing for patients. However, doctors play a crucial 
role in converting the demand for better health from 
patients into a demand for medical care. On the supply 
side, surgical activity rates are influenced by the availability 
of different categories of surgeons, anaesthetists and other 
staff involved in surgical procedures, as well as the supply 
of the required medical equipment.
The measure reported refers to the waiting time from when 
a medical specialist adds a patient to the waiting list for the 
procedure, to the moment the patient receives treatment. 
Both mean and median waiting times are presented. Since 
a number of patients wait for very long times, the median 
is consistently and considerably lower than the mean, and 
might represent a better measure for the central tendency 
of this indicator. The significant difference between the two 
measures, especially in countries such as Chile, Estonia, 
and Poland, highlights the presence of problematic groups 
of patients who wait significantly longer than others to 
receive treatment.
In 2015, the mean waiting time for cataract surgery was just 
over 37 days in the Netherlands, but much longer in Estonia 
and Poland (Figure 5.11), with average waiting times of 253 
and 464 days respectively. Many countries, like the United 
Kingdom, Denmark, Spain and Chile have seen waiting 
times remain relatively stable over recent years. Others, 
shown in the trends graph, have had a general decrease in 
the past decade, but have increased since 2013.
For hip replacement, the mean waiting time was around 
42 days in the Netherlands, but 289 days in Estonia and 
over 400 days in Chile and Poland (Figure 5.12). The median 
waiting times were around 41 days in Denmark, 49 days 
in Italy and 54 days in Israel. It reached between 100 and 
150 days in Spain, Norway, Portugal and Australia, and over 
200 days in Estonia, Poland and Chile. 
Waiting times for knee replacement follows the patterns 
of hip replacement surgery, with Estonia and Poland having 
by far the longest waiting times, with median waiting times 
reaching over 350 days in Poland (Figure 5.13). 
Waiting time guarantees have become the most common 
policy tool to tackle long waiting times in several countries. 
This has been the case in Finland, where a National Health 
Care Guarantee was introduced in 2005, leading to a 
reduction in waiting times for elective surgery (Jonsson 
et al., 2013). In England, since April 2010, the NHS Constitution 
has set out a right to access certain services within specific 
maximum waiting times, or for the NHS to take all reasonable 
steps to offer a range of alternative providers if this is not 
possible (Smith and Sutton, 2013). Such guarantees are 
only effective if they are enforced. There are two main 
approaches to enforcement: setting waiting time targets and 
holding providers accountable for achieving these targets; 
or allowing patients to choose alternative health providers 
(including the private sector) if they have to wait beyond a 
maximum amount of time (Siciliani et al., 2013).
Definition and comparability
There are at least two ways of measuring waiting 
times for elective procedures: 1)  measuring the 
waiting times for patients treated in a given period; 
or 2) measuring waiting times for patients still on the 
list at a point in time. The data reported here relate 
to the first measure (data on the second measure 
are available in the OECD health database). The data 
come from administrative databases rather than 
surveys. 
Waiting times are reported both in terms of the average 
and the median. The median is the value which 
separates a distribution in two equal parts (meaning 
that half the patients have longer waiting times and 
the other half lower waiting times). Compared with 
the average, the median minimises the influence of 
outliers (patients with very long waiting times).
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5.11. Cataract surgery waiting times, averages and selected trends, 2015
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5.12. Hip replacement waiting times, averages and selected trends, 2015
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5.13. Knee replacement waiting times, averages and selected trends, 2015
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Patient experiences with ambulatory care
Prescribing in primary care
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Patient experience with ambulatory care
Delivering health care that is responsive and patient-
centred is playing a greater role in health care policy across 
OECD countries. Considering the health care user as a direct 
source of information is becoming more prevalent. Since 
the mid-1990s, there have been efforts to institutionalise 
measurement and monitoring of patient experiences. 
This empowers patients and the public, involves them 
in decisions on health care delivery and governance, and 
provides insight to the extent to which they are health-
literate and have control over the treatment they receive
In many countries, responsible organisations have been 
established or existing institutions have been identified 
for measuring and reporting patient experiences. They 
develop survey instruments for regular collection of patient 
experience data and standardise procedures for analysis 
and reporting. An increasing number of countries collect 
not only Patient-Reported Experience Measures  (PREMs) 
but also Patient-Reported Outcome Measures  (PROMs) 
which collect patients’ perception on their specific medical 
conditions and general health, including mobility, pain/
discomfort and anxiety/depression, before and after a 
specific medical intervention such as cancer and hip 
and knee replacement. Given the importance of utilising 
people’s voice for developing health systems and improving 
quality of care, international efforts to develop and monitor 
patient-reported measures has been intensified in recent 
years (OECD, 2017a; OECD, 2017b).
Countries use patient-reported data differently to drive 
quality improvements in health systems. To promote quality 
of health care through increased provider accountability 
and transparency, many countries report patient experience 
data in periodic national health system reports or on 
public websites, showing differences across providers, 
regions and over time. Korea and Norway use patient 
experience measures in payment mechanisms or for fund 
allocations to promote quality improvement and patient-
centred care, and Australia, Canada, the Czech Republic, 
Denmark, France and the United Kingdom use them to 
inform health care regulators for inspection, regulation 
and/or accreditation. Patient-reported measures are also 
used in some Canadian jurisdictions, Denmark, France and 
the Netherlands to provide specific feedback for provider’s 
quality improvement (Fujisawa and Klazinga, 2017). 
Patients generally report positive experiences when it 
comes to communication and autonomy in the ambulatory 
health care system. Across countries, the majority of 
patients report that they spent enough time with a doctor 
during consultation (Figure 6.1), a doctor provided easy-to-
understand explanations (Figure 6.2), as well as involved 
them in care and treatment decisions (Figure  6.3). For 
all three aspects of patient experience, Belgium and 
luxembourg score high at above 95% of patients with 
positive experiences while Poland has lower rates and 
for instance, only one in two patients report having been 
involved in their care and treatment during consultation. 
Japan also has a low rate for patient’s perception on time 
spent with doctor, which can be inferred at least partly 
by a high number of consultations both per population 
and doctor (see indicator “Consultations with doctors” in 
Chapter 9). 
In several countries, the proportion of patients with 
positive experience has decreased in recent years. For 
example, in Poland the share of patients reporting that a 
doctor spent enough time with them during consultation 
fell between 2010 and 2016. However, some countries such 
as Australia and Estonia have improved some aspects of 
patient experiences recently.
Definition and comparability
In order to measure and monitor general patient 
experience in the health system, the OECD 
recommends collecting data on patient experience 
with any doctor in ambulatory settings. An increasing 
number of countries have been collecting patient 
experience data based on this recommendation 
through nationally representative population surveys 
while Japan and Portugal collect them through 
nationally-representative service user surveys. About 
half of the countries presented, however, collect 
data on patient experience with a regular doctor. In 
11 countries, the Commonwealth Fund’s International 
Health Policy Surveys 2010 and 2016 were used as a data 
source, even though there are critiques relating to the 
sample size and response rates. Data from this survey 
refer to patient experience with a regular doctor 
rather than any doctor. In 2016, the Netherlands 
which participates in this survey developed a national 
population survey and this resulted in improved 
response rates and data quality. 
Rates are age-sex standardised to the 2010 OECD 
population, to remove the effect of different population 
structures across countries.
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6.1. Doctor spending enough time with patient in consultation, 2010 and 2016 (or nearest year)
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6.2. Doctor providing easy-to-understand explanations, 2010 and 2016 (or nearest year)
69
.5
82
.9
83
.7 85
.9
85
.8
87
.1
88
.9
89
.0
89
.1
89
.4
89
.5
90
.6
90
.7 93
.4
93
.5 96
.3
96
.9
97
.8
25
50
75
100
96
.2
97
.4
2010 2016
Age-sex standardised rate per 100 patients
Confidence Interval 2016
Po
lan
d¹
, ²
Sw
ed
en
²
No
rw
ay
²
Es
ton
ia¹
Ge
rm
an
y²
Ko
rea
¹
OE
CD
17
Ca
na
da
²
Ne
w 
Ze
ala
nd
²
Isr
ae
l¹
Un
ite
d S
tat
es
Un
ite
d K
ing
do
m
Sw
itz
erl
an
d²
Ja
pa
n¹
Au
str
ali
a²
Cz
ec
h R
ep
ub
lic
¹
Po
rtu
ga
l¹
Ne
the
rla
nd
s²
Lu
xe
mb
ou
rg¹
Be
lgi
um
¹
Note: 95% confidence intervals have been calculated for all countries, represented by grey areas.
1 National sources.
2. Data refer to patient experiences with regular doctor.
Source: Commonwealth Fund International Health Policy Survey 2016 and other national sources.
12 http://dx.doi.org/10.1787/888933603374
6.3. Doctor involving patient in decisions about care and treatment, 2010 and 2016 (or nearest year)
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Prescribing in primary care
Prescribing can be used as an indicator of health care quality 
supplementing consumption and expenditure information 
(see Chapter  10). Antibiotics, for example, should be 
prescribed only where there is an evidence based need to 
reduce the risk of resistant strains. likewise, quinolones and 
cephalosporins are considered second-line antibiotics in 
most prescribing guidelines. They should generally be used 
only when first line antibiotics are ineffective. Total volume 
of antibiotics prescribed, and second-line antibiotics as a 
proportion of total volume have been validated as markers 
of quality in the primary care setting. 
Figure 6.4 shows volume of all antibiotics prescribed in 
primary care in 2015, with volumes of second-line antibiotics 
embedded within the total amount. Total volumes vary more 
than three-fold across countries, with the Netherlands, 
Estonia and Sweden reporting the lowest volumes, and 
Greece and France reporting volumes much higher than 
the OECD average. Volumes of second-line antibiotics 
vary almost 16-fold across countries. The Scandinavian 
countries and the Netherlands report the lowest volumes 
of second line antibiotics, whereas Korea, Italy and Turkey 
reported the highest. Variation is likely to be explained, on 
the supply side, by differences in the regulation, guidelines 
and incentives that govern primary care prescribers and, 
on the demand side, by cultural differences in attitudes 
and expectations regarding the natural history and optimal 
treatment of infective illness. There has been some growth 
in the overall volume of antibiotics between 2010 and 2015. 
The highest growth was seen in Ireland and Poland and the 
largest decline in Sweden and Iceland. 
Antibiotic consumption is consistently higher among 
children and young adults and older adults. Volumes of 
antibiotics dispensed to children aged 0-9 years varies 
by 15-fold across countries but only 5-fold across young 
adults aged 10-19 years of age (Figure 6.5). Consumption 
data subdivided by age groups can allow identification of 
specific age groups that are prescribed high proportion of 
certain antibiotics and provide detailed information for 
campaigns or interventions aimed at more prudent use of 
antibiotics in these sub-groups of population.
Benzodiazepines are often prescribed for older adults for 
anxiety and sleep disorders, despite the risk of adverse 
side effects such as fatigue, dizziness and confusion. 
long-term use of benzodiazepines can lead to adverse 
events (falls, road accidents and overdose), tolerance, 
dependence and dose escalation. Beside the period of 
use, there is concern about the type of benzodiazepine 
prescribed, with long-acting types not recommended 
for older adults  because they take longer for the body 
to eliminate. Figures 6.6 and 6.7 indicate that, across the 
OECD, on average around 25 per 1  000  older adults are 
chronic benzodiazepine users (>365 defined daily doses 
in one year), and 64 per 1 000 older adults have received 
at least one prescription for a long-acting benzodiazepine 
or related drugs within the year. The large variation can 
be explained by different reimbursement and prescribing 
policies for benzodiazepines as well as differences in 
disease prevalence and treatment guidelines.
Definition and comparability
Defined daily dose (DDD) is the assumed average 
maintenance dose per day for a drug used for its 
main indication in adults. DDDs are assigned to each 
active ingredient(s) in a given therapeutic class by 
international expert consensus. For instance, the DDD 
for oral aspirin equals 3 grams, which is the assumed 
maintenance daily dose to treat pain in adults. DDDs 
do not necessarily reflect the average daily dose 
actually used in a given country. For more detail, see 
http://www.whocc.no/atcddd. 
Data for Spain, Estonia, United Kingdom, Portugal 
and Sweden include data for primary care physicians 
only. Data for Canada, Ireland, Slovenia and New 
Zealand include only those dispensed by community 
pharmacies. Data for Finland, Italy, and Korea include 
outpatients only. Data for Belgium, Denmark and 
the Netherlands include outpatients and nursing 
homes. Data for Turkey include primary care, nursing 
and residential facilities. Data for Australia include 
prescriptions dispensed at community pharmacies, 
private hospital pharmacies and public hospital 
outpatients and admitted day patients. Results for 
Canada only include data from the provinces of British 
Columbia, Manitoba and Saskatchewan.
Denominators comprise the population held in the 
national prescribing database, rather than the general 
population.
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6.4. Overall volume of antibiotics prescribed, 2015 (or nearest year)
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6.5. Volume of antibiotics prescribed in young people, 2015 (or nearest year)
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6.6. Chronic Benzodiazepine Use: Number of 
patients per 1000, aged 65 years and over who have 
prescriptions for benzodiazepines for more than  
365 days, 2015 (or nearest year)
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6.7. Long-Acting Benzodiazepine use: Number 
of patients per 1000, aged 65 years and over who 
have at least one prescription for long-acting 
benzodiazepines, 2015 (or nearest year)
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Avoidable hospital admissions
Most health systems have developed a ‘primary level’ 
of care whose functions include health promotion and 
disease prevention, managing new health complaints, 
managing long-term conditions and referring patients to 
hospital-based services when appropriate. A key aim is to 
keep people well, by providing a consistent point of care 
over the longer-term, tailoring and co-ordinating care for 
those with multiple health care needs and supporting the 
patient in self-education and self-management. 
Asthma, chronic obstructive pulmonary disease (COPD) 
and congestive heart failure  (CHF) are three widely 
prevalent long-term conditions. Both asthma and COPD 
limit the ability to breathe: asthma symptoms are usually 
intermittent and reversible with treatment, whilst COPD is 
a progressive disease that almost exclusively affects current 
or prior smokers. Asthma may affect up to 334  million 
people worldwide (Global Asthma Network, 2014). About 
3 million people died of COPD in 2015, which is equal to 
5% of all deaths globally that year (WHO, 2016). CHF is a 
serious medical condition in which the heart is unable to 
pump enough blood to meet the body’s needs. CHF is often 
caused by hypertension, diabetes or coronary heart disease. 
Heart failure is estimated to affect over 26 million people 
worldwide resulting in more than 1 million hospitalisations 
annually in both the United States and Europe (Ponikowski 
et al., 2014).
Common to all three conditions is the fact that the 
evidence base for effective treatment is well established 
and much of it can be delivered at a primary care level. 
A high-performing primary care system, where accessible 
and high quality services are provided, can reduce acute 
deterioration in people living with asthma, COPD or CHF 
and reduce unnecessary admissions to hospital. 
Figure 6.8 shows hospital admission rates for asthma 
and COPD together, given the physiological relationship 
between the two conditions. Admission rates for asthma 
vary 15-fold across countries with Italy, Mexico and 
Colombia reporting the lowest rates and latvia, Turkey, 
and Korea reporting rates over twice the OECD average. 
International variation in admissions for COPD is 25-fold 
across OECD countries, with Japan and Italy reporting the 
lowest rates and Hungary and Ireland the highest rates. 
Combined, there is a lower 7-fold variation across countries 
for the two respiratory conditions. 
Hospital admission rates for CHF vary 12-fold, as shown 
in Figure 6.9 Colombia, Costa Rica and Mexico, have the 
lowest rates, while Hungary, Poland and lithuania report 
rates about 2 times the OECD average. 
Figure 6.10 reveals that in Austria, Israel and Ireland a 
reduction in admission rates for CHF has been achieved 
in recent years, whereas in Belgium rates have remained 
relatively stable and in Spain rates have increased. While 
observed improvements may represent advances in the 
quality of primary care for these countries, recent reviews 
undertaken by OECD indicate that investment in primary 
care may not be happening fast enough (OECD, 2017b), 
potentially resulting in wasteful spending on health care 
(OECD, 2017a)
Definition and comparability
The indicators are defined as the number of 
hospital admissions with a primary diagnosis of 
asthma, COPD or CHF among people aged 15 years 
and over per 100 000 population. Rates are age-sex 
standardised to the 2010 OECD population aged 15 
and over. Admissions resulting from a transfer from 
another hospital and where the patient dies during 
the admission are excluded from the calculation 
as these admissions are considered unlikely to be 
avoidable. 
Disease prevalence and availability of hospital care 
may explain some, not all, variations in cross-country 
rates. Differences in coding practices among countries 
may also affect the comparability of data. For example, 
the exclusion of “transfers” cannot be fully complied 
with by some countries. Differences in data coverage 
of the national hospital sector across countries may 
also influence indicator rates.
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6.8. Asthma and COPD hospital admission in adults, 2015 (or nearest year)
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6.9. Congestive heart failure (CHF) hospital admission 
in adults, 2015 (or nearest year)
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6.10. Trends on CHF hospital admission in adults, 
selected countries
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Diabetes care
Diabetes is a chronic disease that occurs when the body’s 
ability to regulate excessive glucose levels in the blood is 
diminished. It is a leading cause of cardiovascular disease, 
blindness, kidney failure and lower limb amputation. 
Globally it is estimated that over 400 million adults had 
diabetes in 2015 and by 2040 it is projected this will grow 
to over 640 million adults. Diabetes caused 5 million deaths 
in 2015 (IDF, 2015).
Ongoing management of diabetes usually involves a 
considerable amount of self-care, and therefore, advice and 
education are central to the primary care of people with 
diabetes. Effective control of blood glucose levels through 
routine monitoring, dietary modification and regular 
exercise can reduce the onset of serious complications and 
the need for hospitalisation. Management of other key risk 
factors such as smoking, blood pressure and lipid levels 
are also important in reducing complications of diabetes. 
In diabetic individuals with hypertension, angiotensin-
converting enzyme inhibitors (ACE-I) or angiotensin 
receptor blockers (ARB) are recommended in most national 
guidelines as first-line medications to reduce blood 
pressure. Figure  6.12 reveals there is broad consistency 
in the proportion of diabetic patients on recommended 
antihypertensive medications, with only Korea, Italy, 
Finland, Belgium and the Slovak Republic with rates less 
than 80%. 
Figure 6.11 shows avoidable hospital admissions for 
diabetes. While admissions have fallen in many countries 
over time, more than a 7-fold variation in the rates is still 
evident across countries. Italy, Iceland and Spain report the 
lowest rates with Austria, Korea and Mexico reporting rates 
at least two times that of the OECD average. Prevalence 
of diabetes may explain some of the variation in rates. A 
positive relationship can be demonstrated between overall 
hospital admissions and admissions for diabetes, providing 
some indication that access to hospital care can also play 
a role in explaining international variation (OECD, 2015).
Hospital admissions for major lower extremity amputation 
reflect the long-term quality of diabetes care. Figure 6.13 
shows the rates of amputation in adults with diabetes. In 
the left panel the rates based on the general population 
are presented. The international variation in rates is over 
14-fold, with Colombia, Korea, Italy, Finland, and the United 
Kingdom reporting rates lower than 3 per 100 000 general 
population and Austria, Israel and Mexico reporting rates 
above 14. In the right panel rates based on the estimated 
diabetic population are presented. The rates based on 
the diabetic population are 9-fold higher than for the 
general population and display differences in the ranking 
of countries, providing an indication that differences in 
disease prevalence across countries may explain some, but 
not all, cross-country variation. In OECD countries, rates of 
amputation have declined significantly since 2000 (Carinci 
et al., 2016).
Definition and comparability
People with diabetes who have first choice 
antihypertensive medication prescriptions is defined 
as the number of people that have one or more 
prescriptions of an angiotensin converting enzyme 
inhibitor (ACE-I) or angiotensin receptor blocker (ARB) 
among people who are long term users of glucose 
regulating medication (people with diabetes) who 
also have one or more prescriptions per year from a 
range of medications often used in the management 
of hypertension.
Diabetes avoidable admission is based on the sum of 
three indicators: admissions for short-term and long-
term complications and for  uncontrolled diabetes 
without complications. The indicator is defined as 
the number of hospital admissions with a primary 
diagnosis of diabetes among people aged 15 years and 
over per 100 000 population. Major lower extremity 
amputation in adults with diabetes is defined as the 
number of discharges of people aged 15 years and over 
per 100 000 population, for the general population and 
the estimated population with diabetes. Rates for 
these indicators have been directly age-standardised 
to the 2010 OECD population.
Differences in data definition and coding practices 
between countries may affect the comparability of 
data. For example, coding of diabetes as a principal 
diagnosis versus a secondary diagnosis varies across 
countries. This is more pronounced for diabetes than 
other conditions, given that in many cases admission 
is for the secondary complications of diabetes rather 
than diabetes itself. Diabetes population estimates 
used to calculate the amputation indicators were self-
reported by countries. Differences in data coverage of 
the national hospital sector across countries may also 
influence indicator rates. 
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6.11. Diabetes hospital admission in adults, 2010 and 2015 (or nearest year)
0
50
100
150
200
250
300
350
400
40 41 48 53
66 69 70 73 73 74
92 94 96 101
110 113
130 133 136 137
141
141 143 148 151
151
171
187 192 197
204 218
222 225
266 281
292
191
2010 2015
Age-sex standardised rates per 100 000 population
Ita
ly
Ice
lan
d¹
Sp
ain
Co
lom
bia
Po
rtu
ga
l
Isr
ae
l
Ne
the
rla
nd
s
Sw
itz
erl
an
d
Un
ite
d K
ing
do
m
No
rw
ay
Ire
lan
d
Ca
na
da
Sw
ed
en
Slo
ve
nia
Hu
ng
ary
De
nm
ark
Es
ton
ia
Ch
ile
Co
sta
 R
ica
OE
CD
33
Au
str
ali
a
Fin
lan
d
Be
lgi
um
Ne
w 
Ze
ala
nd
Fra
nc
e
La
tvi
a
Lu
xe
mb
ou
rg¹
Cz
ec
h R
ep
ub
lic
Ja
pa
n
Un
ite
d S
tat
es
Po
lan
d
Slo
va
k R
ep
ub
lic
Ge
rm
an
y
Tu
rke
y
Lit
hu
an
ia
Au
str
ia
Ko
rea
Me
xic
o
1. Three-year average.
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933603545
6.12 People with diabetes with a prescription 
of recommended antihypertensive medication 
in the past year, 2015 (or nearest year)
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6.13. Major lower extremity amputation  
in adults with diabetes, 2015  
(or nearest year)
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Mortality following ischaemic stroke 
Worldwide an estimated 26 million people have experienced 
a stroke, with over 10 million people having an initial stroke 
each year. Stroke is the second leading global cause of 
death behind heart disease and accounted for just under 
12 percent of total deaths worldwide in 2013 (American 
Heart Association, 2017). Stroke is also the second leading 
cause of disability. A stroke occurs when the blood supply 
to a part of the brain is interrupted, leading to a necrosis 
(i.e. cell death) of the affected part. 
Of the two types of stroke that exist, about 85% are 
ischaemic (caused by clotting) and 15% are haemorrhagic 
(caused by bleeding).Treatment for ischaemic stroke has 
advanced dramatically over the last decade with systems 
and processes now in place in many OECD countries to 
identify suspected ischaemic stroke patients as early as 
possible and to quickly deliver acute reperfusion therapy. 
Figure 6.14 shows the case-fatality rates within 30 days of 
admission for ischaemic stroke where the death occurred 
in the same hospital as the initial stroke admission. 
Figure  6.15 shows the case-fatality rate where deaths 
are recorded regardless of where they occurred (after 
transfer to another hospital or after discharge). This 
indicator is more robust because it captures fatalities 
more comprehensively. Although more countries report 
the same-hospital measure using unlinked data, an 
increasing number of countries are investing in their 
data infrastructure and using linked data to provide more 
comprehensive measures.
Across OECD countries 8.2% of patients in 2015 died within 
30 days in the same hospital in which the initial admission 
for ischaemic stroke occurred (Figure 6.14). The case-fatality 
rates were highest in latvia (18.3%) and Mexico (19.2%). 
Rates were less than 4% in Costa Rica, Korea, and Japan. 
In Japan, many efforts have been dedicated to improving 
the treatment of stroke patients in hospitals, through 
systematic blood pressure monitoring, major material 
investment in hospitals and the establishment of stroke 
units (OECD, 2015a). With the exception of Japan, Korea 
and Germany, countries that achieve better results for 
ischaemic stroke also tend to report good case-fatality rates 
for acute myocardial infarction (AMI). This suggests that 
certain aspects of acute care may be influencing outcomes 
for both stroke and AMI patients. 
Across the 22 countries that reported in- and out-of-hospital 
case-fatality rates, 11.6% of patients died within 30-days 
of being admitted to hospital for stroke (Figure 6.15). This 
figure is higher than the same-hospital based indicator 
because it only counts each patient once and captures 
deaths that occur not just in the same hospital but also in 
other hospitals and out-of-hospital. 
Between 2010 and 2015, case-fatality rates for ischaemic 
stroke have decreased substantially, whereas in Costa Rica 
and latvia rates have increased over this period by more 
than 1% point (Figures 6.14 and 6.15). Across the OECD, case 
fatalities fell from 9.2% to 8.2% when considering same 
hospital rates and from 12.4% to 11.6% when considering 
in- and out-of-hospital rates. Figure 6.16 illustrates the 
evolution of stroke rates for selected countries over this 
period, noting the United Kingdom was able to reduce 
their rates by an average annual reduction of more than 
5% compared to an OECD average of 0.8%. Better access to 
high-quality stroke care, including timely transportation 
of patients, evidence-based medical interventions and 
high-quality specialised facilities such as stroke units have 
helped to reduce 30-day case-fatality rates (OECD, 2015b).
Despite the progress seen so far, there is still room to 
improve implementation of best practice acute care for 
cardiovascular diseases including stroke across countries. 
To shorten acute care treatment time, targeted strategies 
can be highly effective. Advances in technology are now 
leading to models of care to deliver reperfusion therapy 
in an even more speedy and efficient manner, whether 
through pre-hospital triage via telephone, administration 
via telemedicine, or actually administering the therapy 
in the ambulance (Chang and Prabhakaran, 2017). But 
to encourage the use of evidence-based advanced 
technologies in acute care, wider approaches are needed. 
Adequate funding and trained professionals should be 
made available, and health care delivery systems should 
be adjusted to enable easy access (OECD, 2015b).
Definition and comparability
Case-fatality rates are defined in indicator “Mortality 
following acute myocardial infarction” in Chapter 6.
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6.14. Thirty-day mortality after admission to hospital for ischaemic stroke based on unlinked data,  
2010 and 2015 (or nearest years)
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6.15. Thirty-day mortality after admission to hospital for ischaemic stroke based on linked data,  
2010 and 2015 (or nearest years)
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6.16. Thirty-day mortality after admission to hospital for ischaemic stroke based on linked data for selected 
countries
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Mortality following acute myocardial infarction (AMI) 
Mortality due to coronary heart disease  has declined 
substantially since the 1970s (see indicator “Mortality from 
circulatory diseases” in Chapter 3). Important advances in 
both prevention policies, such as for smoking (see indicator 
“Smoking among adults” in Chapter 4), and treatment of 
cardiovascular diseases have contributed to these declines 
(OECD, 2015a). 
A good indicator of acute care quality is the 30-day AMI 
case-fatality rate. The measure reflects the processes of 
care, such as timely transport of patients and effective 
medical interventions. The indicator is influenced by not 
only the quality of care provided in hospitals but also 
differences in hospital transfers, average length of stay 
and AMI severity.
Figure  6.17 shows the case-fatality rates within 30  days 
of admission for AMI where the death occurs in the same 
hospital as the initial AMI admission. The lowest rates are 
found in Australia, Denmark and Norway (all 4% or less). The 
highest rates are in latvia, Hungary and Mexico, suggesting 
AMI patients do not always receive recommended care. In 
Mexico, the absence of a coordinated system of care between 
primary care and hospitals may have contributed to delays in 
repurfusion and low rates of angioplasty (Martínez-Sánchez, 
2017). High rates of uncontrolled diabetes may also be a 
contributing factor in explaining the high AMI case-fatality 
rates (see indicator “Diabetes care” in Chapter 6) as patients 
with diabetes have worse outcomes after AMI compared to 
those without diabetes, particularly if the diabetes is poorly 
controlled. In Japan, people are less likely to die of heart 
disease overall, but are more likely to die once admitted into 
hospital for AMI compared to many other OECD countries. 
One possible explanation is that the severity of patients’ 
admitted to hospital with AMI may be more advanced 
among a smaller group of people across the population, but 
could also reflect underlying differences in emergency care, 
diagnosis and treatment patterns (OECD, 2015b). 
Figure 6.18 shows 30-day case fatality rates where fatalities 
are recorded regardless of where they occur (after transfer 
to another hospital or after discharge). This is a more robust 
indicator because it records deaths more widely than the 
same-hospital indicator, but it requires a unique patient 
identifier and linked data which is not available in all 
countries. The AMI case-fatality rate ranges in 2015 from 
7.1% in Canada to 18% in latvia. 
Case-fatality rates for AMI have decreased substantially 
between 2005 and 2015 (Figures  6.17 and 6.18). Across 
the OECD, case fatalities fell from 8.5% to 7.5% when 
considering same hospital deaths and from 11.3% to 9.9% 
when considering deaths occurred in and out of hospital. 
The rate of decline was particularly striking in Finland, 
the Netherlands and Denmark, when considering deaths 
occurred in and out of hospital, with an average annual 
reduction of over 4% compared to the OECD average of 2.5%. 
Figure 6.19 illustrates the evolution of the decline in AMI 
case fatality rates for selected countries. Better access 
to high-quality acute care for heart attack, including 
timely transportation of patients, evidence-based medical 
interventions and specialised health facilities such as 
percutaneous catheter intervention-capable centres have 
helped to reduce 30-day case-fatality rates (OECD, 2015a). 
For example, Korea had higher case-fatality rates for AMI 
but in 2006 it has implemented a Comprehensive Plan 
for CVD, encompassing prevention, primary care and 
acute CVD care (OECD, 2012). Under the Plan, specialised 
services were enhanced through a creation of regional 
cardio and cerebrovascular centres throughout the country, 
and average waiting time from emergency room arrival 
to initiation of catheterisation fell from 72.3 in 2010 to 
65.8 minutes in 2011, leading to a reduction in case-fatality 
(OECD, 2015a).
Definition and comparability
The case-fatality rate measures the percentage of 
people aged 45 and over who die within 30 days 
following admission to hospital for a specific acute 
condition. Rates based on unlinked data refer to 
a situation where the death occurred in the same 
hospital as the initial admission. Rates based on 
linked data refer to a situation where the death 
occurred in the same hospital, a different hospital, or 
out of hospital. While the linked data based method 
is considered more robust, it requires a unique patient 
identifier to link the data across the relevant datasets 
which is not available in all countries. 
Rates are age-sex standardised to the 2010 OECD 
population aged 45+ admitted to hospital for a specific 
acute condition such as AMI (ICD-10 I21, I22) and 
ischaemic stroke (ICD-10 I63-I64). 
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6.17. Thirty-day mortality after admission to hospital for AMI based on unlinked data, 2010 and 2015  
(or nearest years)
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6.18. Thirty-day mortality after admission to hospital for AMI based on linked data, 2010 and 2015  
(or nearest years)
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6.19. Thirty-day mortality after admission to hospital for AMI based on linked data for selected countries
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Hospital mortality rates
Variations in acute myocardial infarction (AMI) 30-day 
case fatality rates at the national level are influenced 
by the level of within-country variation in rates across 
hospitals. Most OECD countries have established national 
hospital performance measurement and public reporting 
programmes to monitor efforts to improve the cost, quality 
and access of hospital care. 
Figure 6.20 plots the AMI 30-day case fatality rates (where 
the death occurs in the same hospital as the initial AMI 
admission). Rates are presented according to the caseload 
for each hospital and identifies where the rates are higher 
or lower than expected. While most hospitals have rates 
no different than expected, all countries (except Norway) 
had at least one outlier hospital. 
The total number of hospitals and proportion of hospitals 
by number of AMI admissions varies across countries 
(Table 6.1). Countries with a large number of hospitals are 
likely to have more outlier hospitals than countries with 
fewer hospitals. Figure  6.21 presents the differences in 
dispersion of AMI 30-day case fatality rates across hospitals 
within countries. The interquartile range of rates within 
countries varies markedly. For example, the difference 
between the upper and lower rates for Israel is 1.8 deaths 
per 100  admissions, and 4.9 deaths per 100  admissions 
for latvia (based on unlinked data). Using linked data, the 
results are slightly different, with Sweden rather than Israel 
having the least within-country variation.
Multiple factors contribute to variations in outcomes of 
care including hospital structure, processes of care and 
organisational culture. Significant variation in adherence 
to guideline recommendations for cardiac care is observed 
across countries and within countries (OECD, 2015, p. 174). 
In Sweden, a comprehensive national programme of 
quality improvement that includes public reporting, rapid 
diffusion of technology, use of evidence-based practice and 
a system of evaluating and reporting quality and outcomes 
of care is likely to have contributed to a reduced variation 
in hospital care of patients after an AMI (Chung et al., 
2015, p. 7). 
Definition and comparability
The case-fatality rate measures the percentage of 
people aged 45 and over who die within 30 days 
following admission to hospital for a specific acute 
condition. Rates based on unlinked data refer to 
situations where the death occurred in the same 
hospital as the initial admission. Rates based on linked 
data include all deaths irrespective of where they 
occur. While the linked data method is considered 
more robust, it requires a unique patient identifier to 
link the data across the relevant datasets, which is not 
available in all countries. 
The specific methodology used to calculate the 
hospital case fatality rates presented here differs 
from that used for the indicator “Mortality following 
acute myocardial infarction” and is likely to vary 
from the methods used by participating countries 
for national monitoring and reporting purposes. Key 
methodological choices include: unit of measurement, 
type of hospital, patient risk adjustment variables, 
selection of reference population, method of 
standardisation and data issues. 
Different analytical methods can result in quite 
different rates for and rankings of organisations and 
countries, making direct comparison between rates 
problematic. The specific analytical method used here 
is one of several valid options considered during the 
development work of the OECD. For more details on 
the methodology used to calculate these indicators 
see Brownwood et al. (forthcoming). 
Figure 6.20 is a funnel plot and reflects that the 
precision of indicator rates increases as the caseload 
increases. All rates within the 99.7% control limits 
are considered to be no different than expected, 
whereas those outside the 99.7% control limits are 
considered higher or lower than expected. The 
reference population rate was calculated from pooled 
data from selected countries and used to calculate 
the standardised rates. Figure 6.21 is a turnip plot 
that graphically represents the relative dispersion 
of rates but does not give an indication of statistical 
significance of the variations in rates. Countries are 
ordered according to ascending level of dispersion 
as measured by the interquartile range (between the 
25th percentile and the 75th percentile) of rates. 
Hospitals with less than 50 AMI admissions were 
excluded from both figures to improve data reliability.
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6.20. Thirty-day mortality after admission to hospital for AMI based on linked data, 2013-2015  
(or nearest years)
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Table 6.1. Number of hospitals by AMI admissions based on unlinked data, 2013-2015 (or nearest years)
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50-300 158 7 0 5 8 160 83 11 17 7 4 8
< 50 261 1 0 0 6 328 155 5 2 4 0 59
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6.21. Thirty-day mortality after admission to hospital for AMI based on linked and unlinked data,  
2013-2015 (or nearest years)
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Waiting times for hip fracture surgery 
The main risk factors for hip fractures are associated with 
ageing, including an increased risk of falling and loss of 
skeletal strength from osteoporosis. With increasing life 
expectancy across most OECD countries, it is anticipated 
that hip fracture will become a more significant public 
health issue in coming years. 
In most instances following hip fracture, surgical 
intervention is required to repair or replace the hip joint. 
There is general consensus that early surgical intervention 
maximises patient outcomes and minimises the risk of 
complications. General agreement is that surgery should 
occur within two days (48 hours) of hospitalisation. 
Guidelines in some countries call for even earlier 
intervention. For example, the National Institute for Health 
and Care Excellence (NICE) clinical guidelines recommend 
hip fracture surgery to be performed on the day of hospital 
admission or the next day (National Institute for Health 
and Care Excellence, 2014).
The time taken to initiate hip fracture surgery after 
hospital admission is widely considered to be a clinically 
meaningful process indicator of the quality of acute care 
received by patients with hip fracture. In 2015, on average 
across the OECD over 80% of patients admitted for hip 
fracture underwent surgery within two days (Figure 6.22). In 
Norway, Denmark and the Netherlands, the proportion was 
greater than 95%. Countries with the lowest proportion of 
patients operated on within two days of admission include 
Italy (53.2%), Spain (48.4%), Portugal (46.5%), latvia (46.0%) 
and Costa Rica (24.9%). 
Many patients were treated sooner than two days following 
admission, with about a quarter of patients treated on the 
same day and around two thirds of patients treated by the 
end of the next day across the OECD. Rates were higher 
than 40% on the same day in the Netherlands, and 80% by 
the end of the next day in Denmark. 
Figure 6.23 shows the proportion of hip-fracture repairs 
occurring within two days of admission in OECD countries 
between 2005 and 2015. The OECD average increased from 
72% to 81% over that time. The greatest improvement was 
observed in Switzerland, where the proportion increased 
from 46% to 91% and in Italy, where it increased from 28% 
in 2007 to 53% in 2015. A policy of comparative public 
reporting of hospital indicators, including time to surgery 
following hip fracture, implemented by Italian authorities 
may partly explain the improvement observed in that 
country. In Canada, the percentage of patients operated 
on within the two day benchmark increased over time, but 
there is considerable variation in this indicator between 
provinces and hospitals (CIHI, 2015). Only Portugal reported 
a decline of hip fracture repair within two days of admission, 
reducing from 57% in 2008 to 47% in 2015. 
Time to surgery for hip fracture patients is influenced by 
many factors, including hospitals’ surgical theatre capacity, 
flow and access and targeted policy interventions, including 
public reporting and monitoring of performance (Siciliani 
et al, 2013) Improvement in timely surgery for patients with 
a particular diagnosis or injury (e.g. hip fracture) may be 
achieved at the expense of timeliness in others (e.g. hip or 
knee replacements). 
Definition and comparability
This indicator is defined as the proportion of patients 
aged 65 years and over admitted to hospital in a 
specified year with a diagnosis of upper femur fracture, 
who had surgery initiated within two calendar days 
of their admission to hospital. Data are also provided 
for the proportion of those patients who had surgery 
within one day of their admission to hospital, and for 
patients who had surgery on the same day as their 
hospital admission. Some countries supplied results 
for surgery within two calendar days only.
The capacity to capture time of admission and 
surgery in hospital administrative data varies across 
countries, resulting in the inability to precisely record 
surgery within 48 hours. While recent research and 
development data indicates that the impact of 
measuring days rather than hours may only result 
in marginally higher rates, the impact on relative 
performance across countries can be noticeable, given 
the similarity of rates in many countries. 
While cases where the hip fractures occurred during 
the admission to hospital should be excluded, not 
all countries have a ‘present on admission’ flag in 
their datasets to enable them to identify such cases 
accurately. 
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6.22. Hip fracture surgery initiation after admission to the hospital, 2015 (or nearest year)
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6.23. Hip fracture surgery initiation after admission to hospital, 2005 and 2015 (or nearest year)
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Surgical complications
Patient safety remains one of the most prominent issues 
in health policy and public debate. Evidence suggests that 
over 15% of hospital expenditure and activity in OECD 
countries can be attributed to treating safety failures, many 
of which are preventable (OECD, 2017a; OECD, 2017b). In the 
United States an estimated USD 28 billion has been saved 
between 2010 and 2015 by systematically improving safety 
(AHRQ, 2016). 
Robust comparison of performance with peers is 
fundamental to securing improvement. Two types of patient 
safety event can be distinguished for this purpose: sentinel 
or “never” events that should never occur such as failure to 
remove surgical foreign bodies at the end of a procedure; 
and adverse events, such as post-operative sepsis, which 
can never be fully avoided given the high-risk nature of 
some procedures, although increased incidence at an 
aggregate level may indicate a systemic failing.
Figure  6.24 illustrates a never event, rates of foreign 
body left in during procedure. The most common risk 
factors for this never event are emergencies, unplanned 
changes in procedure, patient obesity and changes in 
the surgical team; preventive measures include counting 
instruments, methodical wound exploration and effective 
communication among the surgical team.
Figure 6.25 shows rates for two related adverse events, 
pulmonary embolism (PE) and deep vein thrombosis (DVT) 
after hip or knee replacement surgery. PE and DVT cause 
unnecessary pain and in some cases death, but can be 
prevented by anticoagulants and other measures before, 
during and after surgery. large variations in rates are 
observed, with nearly a 20-fold variation in DVT. Variations 
in DVT rates may be influenced by differences in diagnostic 
practices across countries, with evidence that routine 
ultrasound screening can significantly increase the 
detection of DVT (Kodadek, 2016).
Figure 6.26 shows rates for another adverse event, sepsis 
after abdominal surgery. likewise, sepsis after surgery, 
which may lead to organ failure and death, can in many 
cases be prevented by prophylactic antibiotics, sterile 
surgical techniques and good postoperative care. 
The left panel of Figures 6.24, 6.25 and 6.26 shows the 
rate of the three respective postoperative complications 
based on the “surgical admission”, the hospital admission 
where the surgery took place. The right panel of these 
figures shows rates based on not only the surgical 
admission but all subsequent re-admissions to hospital 
within 30 days, whether at the same hospital or in 
another hospital. 
Caution is needed in interpreting the extent to which 
these indicators accurately reflect international differences 
in patient safety rather than differences in the way that 
countries report, code and calculate rates of adverse events 
(see “Definition and comparability” box).
Definition and comparability
Two methods of calculating surgical complications are 
presented. The surgical admission-based method uses 
unlinked data to calculate the number of discharges 
with ICD codes for the complication in any secondary 
diagnosis field, divided by the total number of discharges 
for patients aged  15 and older. The all admission-
based method uses linked data to extend beyond the 
surgical admission to include all subsequent related 
re-admissions to any hospital within 30 days. While the 
all admission-based method is considered more robust 
and is less affected by variations in the length of stay 
and hospital transfer practices, it requires a unique 
patient identifier and linked data which is not available 
in all countries. While the all admission-based method 
strengthens identification of valid complications, the 
impact on indicator rates is unclear given only one 
admission per patient is counted when multiple 
qualifying admissions are identified.
A fundamental challenge in international comparison 
of patient safety indicators centres on differences 
in the underlying data. Variations in how countries 
record diagnoses and procedures and define hospital 
admissions can affect calculation of rates. In some 
cases, higher adverse event rates may signal more 
developed patient safety monitoring systems and a 
stronger patient safety culture rather than worse care. 
There is a need for greater consistency in reporting of 
patient safety across countries and significant scope 
exists for improved data capture within national 
patient safety programmes. 
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6.24. Foreign body left in during procedure, 2015 (or nearest year)
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6.25. Postoperative pulmonary embolism (PE) or deep vein thrombosis (DVT) in hip and knee  
surgeries, 2015 (or nearest year)
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6.26. Postoperative sepsis in abdominal surgeries, 2015 (or nearest year)
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Obstetric trauma
Patient safety during childbirth can be assessed by 
looking at potentially avoidable tearing of the perineum 
during vaginal delivery (Harvey, 2015). Such tears extend 
to the perineal muscles and bowel wall require surgery. 
They are more likely to occur in the case of first vaginal 
delivery, high baby birth weight, labour induction, occiput 
posterior baby position, prolonged second stage of labour 
and instrumental delivery. Possible complications include 
continued perineal pain and incontinence. These types of 
tears are not possible to prevent in all cases, but can be 
reduced by employing appropriate labour management 
and high quality obstetric care. Hence, the proportion of 
deliveries involving higher degree lacerations is a useful 
indicator of the quality of obstetric care. 
Obstetric trauma indicators are considered to be relatively 
reliable and comparable across countries, particularly given 
they are less sensitive to variations in coding practices across 
countries. Nevertheless, differences in the consistency 
with which obstetric units report these complications may 
complicate international comparison. Fear of litigation, for 
example, may cause under-reporting; conversely systems 
that rely on specially trained administrative staff to identify 
and code adverse events from patients’ clinical records may 
produce more reliable data.
While rates of obstetric trauma may be influenced by 
the overall national rate of caesarean sections, assisted 
vaginal delivery and episiotomy, these remain issues of 
ongoing research. For example, episiotomy is a surgical 
incision of the perineum performed to widen the vaginal 
opening for the delivery of an infant. Wide variation in 
the use of episiotomy during vaginal deliveries currently 
exists across Europe, ranging from around 70% of births in 
Portugal and Poland in 2010 to less than 10% in Sweden, 
Denmark and Iceland (Euro-Peristat, 2013). The selective 
use of episiotomy to decrease severe perineal lacerations 
during delivery remains controversial 
Figure 6.27 shows rates of obstetric trauma with instrument 
and Figure 6.28 shows rates of obstetric trauma after 
vaginal delivery without instrument. Obstetric trauma 
with instrument refers to deliveries using forceps or 
vacuum extraction. As the risk of a perineal laceration is 
significantly increased when instruments are used to assist 
the delivery, rates for this patient population are reported 
separately. 
High variation in rates of obstetric trauma is evident 
across countries. Reported rates of obstetric trauma with 
instrument vary from below 2% in Israel, Italy and Poland 
to more than 10% in Denmark, Sweden and Canada. The 
rates of obstetric trauma after vaginal delivery without 
instrument vary from below 0.5 per 100 deliveries in Poland 
and Israel to over 2.5 per 100 deliveries in Denmark, United 
Kingdom and Canada.
While the average rate of obstetric trauma with instrument 
(5.7 per 100  instrument-assisted vaginal deliveries) 
across OECD countries in 2015 was nearly 4 fold the rate 
without instrument (1.5 per 100 vaginal deliveries without 
instrument assistance), there is a strong relationship 
between the two indicators, with Italy, Israel and Poland 
reporting the lowest rates and Canada, Denmark and New 
Zealand reporting amongst the highest rates for both 
indicators.
No clear trend is evident in the rates of obstetric trauma 
over the five year period 2010-2015, with the OECD average 
remaining relative static for both vaginal deliveries with 
and without instrument. While rates for both indicators 
indicate noticeable improvements in Denmark and Norway 
over this period, rates for some countries including Slovenia 
and Spain would appear to have deteriorated. 
Definition and comparability
The two obstetric trauma indicators are defined as 
the proportion of instrument assisted/non-assisted 
vaginal deliveries with third- and fourth-degree 
obstetric trauma codes (ICD-10 O70.2, O70.3) in any 
diagnosis and procedure field. 
Several differences in data reporting across countries 
may influence the calculated rates of obstetric 
patient safety indicators. These relate primarily to 
differences in coding practice and data sources. Some 
countries report the obstetric trauma rates based on 
administrative hospital data and others based on 
obstetric register data. There is some evidence that 
registries produce higher quality data and report a 
greater number of obstetric trauma events compared 
to administrative datasets (Baghestan et al., 2007).
Careful interpretation of obstetric trauma for 
instrument assisted delivery rates over time is 
required, given the very low number of trauma cases 
in some countries is likely to give rise to significant 
year on year variation. 
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6.27. Obstetric trauma, vaginal delivery with instrument, 2010 and 2015 (or nearest year)
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6.28. Obstetric trauma, vaginal delivery without instrument, 2010 and 2015 (or nearest year)
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Care for people with mental health disorders
The burden of mental illness is substantial, affecting an 
estimated one in four of the OECD population at any time, 
and one in two across the life course (see indicator on 
“Mental health” in Chapter 3; OECD, 2014a). High quality, 
timely care has the potential to improve outcomes and may 
help reduce suicide and excess mortality for individuals 
with psychiatric disorders. 
High quality care for mental disorders in inpatient settings 
is vital, and inpatient suicide is a ‘never event’, which 
should be closely monitored as an indication of how well 
inpatient settings are able to keep patients safe from harm. 
Figure 6.29 shows rates of inpatient suicide amongst all 
psychiatric hospital admissions. Most countries report rates 
below 1 per 1 000 patients, but Costa Rica, the Netherlands, 
Denmark, and Israel are exceptions with rates of over 1. 
Steps to prevent inpatient suicide include identification 
and removal of likely opportunities for self-harm, risk 
assessment of patients, monitoring and appropriate 
treatment plans. 
Suicide rate after hospital discharge can indicate the quality 
of care in the community, and co-ordination between 
inpatient and community settings. Across countries, 
suicide rate among patients who had been hospitalised 
in the previous year was as low as 1 per 1 000 patients 
in the United Kingdom but it was higher than 5 in the 
Netherlands and lithuania (Figure 6.30). Denmark also has 
high suicide rates, but this may reflect that hospitalised 
patients have more severe psychiatric disorders than other 
countries. Patients with milder psychiatric disorders are 
usually treated in ambulatory settings.
Patients with a psychiatric illness are particularly at risk 
immediately following discharge from hospital. In most 
countries, over one quarter of suicides within the first year 
following discharge occurs in the first month, and in New 
Zealand and Sweden, as many as half of suicides among 
patients discharged in the previous year happen in the 
first month of discharge. It is known that suicide in the 
high-risk days following discharge can be reduced by good 
discharge planning and follow-up, and enhanced levels of 
care immediately following discharge (OECD, 2014a). 
Individuals with a psychiatric illness have a higher mortality 
rate than the general population. An “excess mortality” 
value that is greater than one implies that people with 
mental disorders face a higher risk of death than the rest 
of the population. Figures 6.31 and 6.32 show the excess 
mortality for schizophrenia and bipolar disorder, which is 
above two in most countries. In order to reduce their high 
mortality, a multifaceted approach is needed for people 
with mental disorders, including primary care prevention 
of physical ill health, better integration of physical and 
mental health care, behavioural interventions, and changing 
professional attitudes. In view of improving quality of 
health care for people with mental disorders, these efforts 
can be assessed regularly. For example, Sweden monitors 
the use of inpatient physical care for patients with a mental 
disorder that could have been avoided if primary care and/
or primary or secondary prevention was sufficient (OECD, 
2014a; OECD, 2014b). 
Definition and comparability
The inpatient suicide indicator is composed of a 
denominator of patients discharged with a principal 
diagnosis or first two secondary diagnosis code of 
mental health and behavioural disorders (ICD-10 
codes F10-F69 and F90-99) and a numerator of these 
patients with a discharge code of “suicide” (ICD-10 
codes: x60-x84). Data should be interpreted with 
caution due to a very small number of cases. Reported 
rates can vary over time, so where possible a 3-year 
average has been calculated to give more stability to 
the indicator. 
Suicide within 30 days and within one year of 
discharge is established by linking discharge following 
hospitalisation with a principal diagnosis or first two 
listed secondary diagnosis code of mental health 
and behavioural disorders (ICD-10 codes F10-F69 and 
F90-99), with suicides recorded in death registries 
(ICD-10 codes: x60-x84). In cases with several 
admissions during the reference year, the follow-up 
period starts from the last discharge.
For the excess mortality indicators the numerator is 
the overall mortality rate for persons aged between 15 
and 74 years old diagnosed with schizophrenia or 
bipolar disorder. Most countries use registry data 
as a data source. The denominator is the overall 
mortality rate for the general population in the same 
age group. The relatively small number of people with 
schizophrenia or bipolar disorder dying in any given 
year can cause substantial variations from year-to-
year, so three-year averages were presented. 
The data have been age-sex standardised to the 2010 
OECD population structure, to remove the effect of 
different population structures across countries. 
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6.29. Inpatient suicide amongst patients  
with a psychiatric disorder, 2014  
(or nearest year)
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6.30. Suicide following hospitalisation  
for a psychiatric disorder, within 30 days  
and one year of discharge, 2015 (or nearest year)
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Screening, survival and mortality for breast cancer
Breast cancer is the cancer with both the highest incidence 
and prevalence for women across OECD countries. One in 
nine women will have breast cancer at some point in their 
life. Risk factors that increase a person’s chance of getting 
this disease include age, family history of breast cancer, 
genetic predisposition, reproductive factors, oestrogen 
replacement therapy, and lifestyles including obesity, 
physical inactivity, diet and alcohol consumption. 
Most OECD countries have adopted breast cancer screening 
programmes as an effective way for detecting the disease 
early (OECD, 2013). However, due to recent progress in 
treatment outcomes and concerns about false-positive 
results, over-diagnosis and overtreatment, breast cancer 
screening recommendations have been re-evaluated 
in recent years. Taking into account recent research 
findings, WHO recommends organised population-based 
mammography screening if women are able to make 
an informed decision based on the benefits and risks of 
mammography screening (WHO, 2014). 
Screening rates range from less than 20% in Mexico to 
over 80% in a few countries including Sweden, Portugal, 
Denmark, Finland and Slovenia (Figure  6.33). Screening 
coverage increased substantially among countries with 
low rates a decade ago. Mexico had an increase of more 
than ten-fold, and lithuania an almost four-fold increase. 
On the other hand, several countries that had the highest 
screening rates in the mid-2000s experienced some 
reductions, including Finland, the Netherlands, and the 
United States. 
Breast cancer survival reflects early diagnosis as well as 
improved treatments. All OECD countries have attained 
five-year net breast cancer survival of 80% except Chile, 
the Slovak Republic, Poland and Estonia (Figure 6.34). Net 
survival of people with colon and rectal cancers is also 
low in these countries (see indicators on “Survival and 
mortality for colorectal cancer”). 
Over the last decade, the five-year net breast cancer 
survival has improved in OECD countries. Net survival 
has increased considerably in some Central and Eastern 
European countries such as Estonia and the Czech 
Republic, although survival after breast cancer diagnosis 
is still below the OECD average. Improvements may 
be related to strengthening of cancer care governance 
in these countries. For instance, the Czech Republic 
intensified its effort to tackle the burden of breast cancer 
through the introduction of a screening programme and 
a National Cancer Control Programme in the early 2000s 
(OECD, 2014).
With respect to mortality rates, most OECD countries 
showed a decline over the past decade (Figure  6.35). 
The reduction is a reflection of improvements in early 
detection and treatment of breast cancer. Improvements 
were substantial in the Czech Republic and Denmark with 
a decline of over 20% in a decade but Denmark still has 
one of the highest rates. On the other hand, within the 
OECD, in Iceland and Korea, the mortality rate from breast 
cancer increased by more than 10% over the past decade. 
In Iceland the mortality is the highest in the OECD while 
in Korea, it remains the lowest. 
Definition and comparability
Screening rates are based on surveys or encounter 
data, which may influence the results. Survey-based 
results may be affected by recall bias. Programme data 
are often calculated for monitoring national screening 
programmes and differences in target population 
and screening frequency may lead to variations in 
screening coverage across countries.
Five-year net survival is the cumulative probability 
that cancer patients survive their cancer for at least 
5 years, after controlling for the risks of death from 
other causes. Net survival is expressed as a percentage. 
Net survival for patients diagnosed during 2000-2004 
is based on a cohort approach, since all patients had 
been followed up for at least 5 years by the end of 
2014. For patients diagnosed during 2010-2014, the 
period approach is used, which allows estimation of 
five-year survival, though 5 years of follow-up are not 
available for all patients. Cancer survival estimates 
are age-standardised with the International Cancer 
Survival Standard (ICSS) weights. 
Data collection, quality control and analysis were 
performed centrally as part of the CONCORD 
programme, the global programme for the surveillance 
of cancer survival, led by the london School of Hygiene 
and Tropical Medicine (Allemani et al., 2015). In some 
countries, not all regional registries participated, but 
survival estimates from the CONCORD programme 
are considered the best available data from those 
countries for international comparisons. 
See indicator “Mortality from cancer” in Chapter 3 for 
definition, source and methodology underlying cancer 
mortality rates.
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6.33. Mammography screening in women aged 50-69 within the past 2 years, 2005 and 2015 (or nearest years)
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6.34. Breast cancer five-year net survival, 2000-2004 and 2010-2014
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6.35. Breast cancer mortality in women, 2005 and 2015 (or nearest years)
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6. QUALITY AND OUTCOMES OF CARE
Survival and mortality for colorectal cancer
Colorectal cancer is the third most commonly diagnosed 
form of cancer after prostate and lung cancers, for men, 
and the second most common cancer after breast cancer, 
for women, across OECD countries (see indicator “Mortality 
from cancer” in Chapter 3). There are several factors that 
place certain individuals at increased risk for the disease, 
including age, ulcerative colitis, a personal or family history 
of colorectal cancer or polyps, and lifestyle factors such as 
a diet high in fat and low in fibre, lack of physical activity, 
obesity, and tobacco and alcohol consumption. Incidence is 
significantly higher for men than women across countries. 
Generally, rectal cancer is more difficult to cure than colon 
cancer due to a higher probability of spreading to other 
tissue, recurrence and postoperative complications. 
Following screening for breast and cervical cancers, 
colorectal cancer screening has become available, and 
an increasing number of countries have introduced free 
population-based screening, targeting people in their 50s 
and 60s (OECD, 2013). Partly because of uncertainties about 
the cost-effectiveness of screening (lansdorp-Vogelaar et al., 
2010), countries are using different methods. In most 
countries that provide faecal occult blood test, screening 
is available every two years and the screening periodicity 
schedule is less frequent with colonoscopy and flexible 
sigmoidoscopy, generally every ten years. These differences 
make screening coverage difficult to compare across 
countries.
Advances in diagnosis and treatment of colorectal cancer 
including improved surgical techniques, radiation therapy 
and combined chemotherapy and their wider and timelier 
access have contributed to increased survival over the last 
decade. In general, OECD countries showed improvement 
in five-year net survival for colon and rectal cancers. On 
average across OECD countries, five-year colon cancer 
survival improved from 57.0% to 62.8% for patients with 
colon cancer between 2000-04 and 2010-14 periods while 
survival for rectal cancer also improved from 55.1% to 
61.0% during the same periods (Figures 6.36 and 6.37). Some 
countries show a considerable improvement including 
Chile, lithuania, Korea, Denmark and Estonia for colon 
cancer, and latvia, lithuania, Slovenia, Denmark, Ireland 
and Korea for rectal cancer. Generally, countries with 
low survival estimates for colon cancer tend to have low 
estimates also for rectal cancer. Among OECD countries, 
net survival estimates are low for both cancers in countries 
such as Chile, the Czech Republic, Poland, the Slovak 
Republic and Turkey. 
In terms of mortality rates, most countries experienced 
a decline in recent years, with the average rate across 
OECD countries falling from  26.8 to 23.9  deaths per 
100 000 population between 2005 and 2015 (Figure 6.38). 
The decline was particularly large in Austria, the Czech 
Republic, Denmark and Israel with a reduction of over 
30%. Despite some progress, Central and Eastern European 
countries, particularly the Czech Republic, Slovenia and the 
Slovak Republic continue to have higher mortality rates 
than other OECD countries.
However, in some OECD countries, the mortality rate from 
colorectal cancer increased during the same period. For 
instance, Hungary which had the highest mortality rate a 
decade ago, reported even higher rates. In latin American 
countries including Chile and Mexico, the increase was 
particularly large, by more than 10%, over the last decade, 
although the rate remains much lower than the OECD 
average. Despite increases, some of these countries 
have made progress in strengthening their systems to 
reduce the burden of colorectal cancer. For example, in 
2013, Chile included treatment for colorectal cancer as 
part of its guaranteed health care coverage plan, which 
assures improved access, quality, financial protection and 
timeliness of care for priority diseases, and this may lead 
to improved outcomes of colorectal cancer in the future 
(OECD, 2018).
Definition and comparability
Net survival and mortality rates are defined in indicator 
“Screening, survival and mortality for breast cancer” 
in Chapter 6. See indicator  “Mortality from cancer” 
in Chapter 3 for definition, source and methodology 
underlying cancer mortality rates. Mortality rates of 
colorectal cancer are based on ICD-10 codes C18-C21 
(colon, rectosigmoid junction, rectum, and anus) while 
survival estimates are based on C18-C19 for colon 
cancer and C20-C21 for rectum cancer. 
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6.36. Colon cancer five-year net survival, 2000-04 and 2010-14
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6.37. Rectal cancer five-year net survival, 2000-04 and 2010-14
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6.38. Colorectal cancer mortality, 2005 and 2015 (or nearest years)
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6. QUALITY AND OUTCOMES OF CARE
Survival and mortality for leukaemia in children 
leukaemia is the most common childhood cancer and 
accounts for over 30% of all cancers diagnosed in children 
aged below 15 years old in the world (IARC, 2012). Causes 
of leukaemia are not well known, but some known risk 
factors include inherited factors such as Down syndrome 
and a family history of leukaemia and non-inherited 
factors including exposure to inonising radiation. There are 
different types of leukaemia but about three-quarters of 
cases among children are acute lymphoblastic leukaemia 
(All). The second most frequent type is acute myeloid 
leukaemia. Prognosis of leukaemia is different depending 
on various factors including age, initial white blood cell 
count, gender, initial reaction to induction treatment and 
type of leukaemia. Children with acute leukaemia who are 
free of the disease for 5 years are considered to have been 
cured as remission after 5 years is rare.
On average across OECD countries, there were 4.7 new 
cases of leukaemia per 100 000 children aged between 
0 and 14 in 2012. Cross-country variations are large and 
incidence rates in Germany and Finland are high at around 7 
per 100  000 children while they are as low as around 3 
in Iceland and Greece. South Africa, India and China also 
have low incidence rates, below 3.0 per 100 000 children 
(Figure 6.39). 
Five-year net survival of acute lymphoblastic leukaemia 
among children is on average 86.7% during the period of 
2010-2014 across OECD countries. Although prognosis of 
All is considered better among girls than among boys, 
the difference in net survival is not statistically significant 
for most countries with the exception of Estonia where 
survival for girls is slightly better. 
Over time, five-year net survival for children with All 
has improved across OECD countries (Allemani et al., 
2015). This improvement is mainly due to progress in 
chemotherapy and stem cell transplantation technology. 
However, countries have not benefited equally from 
progress in medical technologies. Survival estimates are 
high in Finland (95.2%) and Denmark (94.0%) but they 
are low in Mexico (52.7%) and Chile (63.9%). Net survival 
is low also in China (57.7%), Brazil (66.0%) and Colombia 
(68.9%) (Figure 6.40). In these countries, survival prospect 
of children with All may improve through better 
access to effective treatment, by expanding health care 
coverage and providing high quality care by accredited 
professionals at specialised centres. Some of these 
countries are making progress in improving access 
and quality of care for childhood cancer. For example, 
Chile included access to care for childhood cancer as 
part of its guaranteed health care coverage plan and 
although a shortage of qualified professionals still exist 
at specialised centres, quality of care has become similar 
across providers (OECD, 2018). 
Across OECD countries, the mortality rate of childhood 
leukaemia has also improved over time (la  Vecchia 
et al., 2009; Malvezzi et al., 2013) and it was less than 
1 per 100 000 children in most OECD countries in 2012 
(Figure 6.41). The rate is particularly low at less than 0.3 in 
Australia, and Austria. However, the mortality rate is high 
in Turkey at 3.0 per 100 000 children and Mexico at 2.6. 
Definition and comparability
Incidence and mortality rates come from the 
International Agency for Research on Cancer (IARC), 
GlOBOCAN 2012, available at www.globocan.iarc.fr. 
They refer to crude rates and are not age-standardised. 
GlOBOCAN estimates for 2012 may differ from 
national estimates due to differences in methods. 
For example, the incidence reported by the German 
Centre for Cancer Registry Data (ZfKD) and German 
Children’s Cancer Registry is about 5 per 100 000. Net 
survival is defined in indicator “Screening, survival 
and mortality for breast cancer” in Chapter 6. 
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6. QUALITY AND OUTCOMES OF CARE
6.39. Leukaemia incidence in children aged 0-14, 2012
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6.40. Acute lymphoblastic leukaemia five-year net survival, 2010-14
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6.41 Leukaemia mortality in children aged 0-14, 2012
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Vaccinations
All OECD countries have established vaccination 
programmes based on their interpretation of the risks 
and benefits of each vaccine. For children, vaccination 
rates for diphtheria, tetanus and pertussis (DTP), measles, 
and hepatitis B at age 1 are high across OECD countries 
(Figures 6.42 and 6.43). On average, over 95% of children 
receive the recommended DTP or measles vaccinations, 
while almost 94% receive a recommended hepatitis B 
vaccination. Vaccination rates for DTP are below 90% 
in Indonesia, Mexico, and India. Vaccination rates for 
measles are below 90% in Italy, Indonesia, and India while 
vaccination rates for hepatitis B are below 90% in Mexico, 
France, Indonesia, India, and Germany. 
Overall rates of vaccination among children are increasing. 
Between 2005 and 2015, vaccination rates among children 
have increased 1 percentage point for DTP vaccination, 
more than 2 percentage points for measles, and nearly 
12 percentage points for hepatitis B among OECD countries. 
large increases in hepatitis B vaccination can be seen over 
this period in a number of OECD countries including France 
and the Netherlands, reflecting the introduction of national 
programmes. However, vaccination rates have dropped 
in recent years in some countries, notably for measles 
coverage in Australia and Italy. Even small decreases in 
vaccination can result in large increases in disease cases 
(lo et al. 2017). While national vaccination coverage rates 
are high, some populations remain under-covered. A 2015 
outbreak of measles in the United States was caused by a 
number of unvaccinated individuals, while in Europe 1020 
cases of measles were reported between February 2016 and 
January 2017 in Italy alone. (CDC, 2017; ECDC, 2017).
Not all countries follow WHO recommendations to 
incorporate hepatitis B into national immunisation 
programmes, including Denmark, Finland, Sweden, and 
the United Kingdom, where vaccination is not part of the 
general infant vaccination programme, but is provided to 
high-risk groups. Other OECD countries that do not include 
vaccination against hepatitis B in their infant programmes 
are Iceland, Hungary, Japan, Slovenia and Switzerland. In 
Canada, the Hepatitis B immunisation schedule varies by 
jurisdiction.
Influenza is a common infectious disease responsible for 
3 to 5 million severe cases worldwide, including 250 000 
to 500 000 deaths. Hospitalisation and death occur mainly 
among high-risk groups and in industrialised countries 
most deaths associated with influenza occur among people 
age 65 or older (WHO, 2016). Safe and effective vaccination 
is available for influenza and most countries recommend 
annual vaccination among older adults. 
In 2003, countries participating in the World Health 
Assembly committed to the goal of attaining vaccination 
coverage against influenza among the elderly of at least 
75% by 2010. Figure 6.44 shows vaccination among adults 
over 65 for 2005 and 2015. Over this period, the average 
vaccination rate against influenza among the elderly 
population decreased among OECD countries from 49% to 
43%. large decreases can be seen in Germany, Slovenia, 
and Italy. Some countries did show increased vaccination 
over this time period including Mexico, Israel, the United 
States, Portugal, Denmark, Greece, and New Zealand. Only 
two countries attained the 75% target: Mexico and Korea, 
with the United Kingdom coming close to meeting the 
target. 
Definition and comparability
Vaccination rates reflect the percentage of children 
that receives the respective vaccination in the 
recommended timeframe. The age of complete 
immunisation differs across countries due to 
different immunisation schedules. For those countries 
recommending the first dose of a vaccine after age 
one, the indicator is calculated as the proportion of 
children less than two years of age who have received 
that vaccine. Thus, these indicators are based on the 
actual policy in a given country.
Some countries administer combination vaccines 
(e.g. DTP for diphtheria, tetanus and pertussis) while 
others administer the vaccinations separately. Some 
countries ascertain vaccinations based on surveys and 
others based on encounter data, which may influence 
the results.
Influenza vaccination rates refer to the number of 
people aged 65 and older who have received an annual 
influenza vaccination, divided by the total number of 
people over 65 years of age. In some countries, the 
data are for people over 60 years of age. The main 
limitation in terms of data comparability arises from 
the use of different data sources, whether survey or 
programme, which are susceptible to different types of 
errors and biases. For example, data from population 
surveys may reflect some variation due to recall errors 
and irregularity of administration.
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6.42. Percent of children aged 1 vaccinated for diphtheria, tetanus and pertussis (DTP) and measles, 2015  
(or nearest year)
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6.43. Percent of children aged 1 vaccinated for hepatitis B, 2005 and 2015
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6.44. Percent of population aged 65 and over vaccinated for influenza, 2005 and 2015
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The statistical data for Israel are supplied by and under the responsibility of the relevant 
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the 
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of 
international law.
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Health expenditure per capita
The financial resources that a country devotes to health 
care, both for individuals and for the population as a whole, 
and how this changes over time is the result of a wide array 
of social and economic factors, as well as the financing 
and organisational structures of a country’s health system.
In 2016, the United States is estimated to have outspent 
all other OECD countries by a wide margin, spending the 
equivalent of USD 9 892 for each resident (Figure 7.1). This 
level of health spending is almost two-and-a-half times 
the average of the 35 OECD countries (USD  4  003) and 
25% above Switzerland, the next highest spender (adjusted 
for the different purchasing powers – see box “Definition 
and comparability”). Compared with the other G7 countries, 
the United States spends almost 80% more than Germany 
and more than twice as much on health care per person as 
Canada, France and Japan. OECD countries spending half or 
less of the OECD average include many of the Central and 
Eastern European members of the OECD, such as Estonia 
and Poland, together with Chile. lowest per capita spenders 
on health in the OECD were Mexico and Turkey with levels 
around a quarter of the OECD average, and similar to 
spending in key emerging economies such as the Russian 
Federation, South Africa and Brazil. China spent around 
20% of the OECD per capita spending level, while both India 
and Indonesia spent less than 10% of the OECD average 
based on latest available figures.
Figure 7.1 also shows the split of health spending based 
on whether it is paid from government sources or some 
kind of compulsory insurance, or through voluntary means 
such as voluntary health insurance or direct payments 
(see indicator on “Financing of health care”). In general, 
the ranking of per capita expenditure of government and 
compulsory schemes is comparable to that of total spending. 
Even if voluntary insurance in the United States continues 
to play a significant role in financing health care, the level 
of spending from federal and state programmes (such as 
Medicaid) and Medicare is still greater on a per capita basis 
in the United States than in most other OECD countries, with 
the exceptions being luxembourg, Norway and Switzerland.
Per capita spending on health across the OECD continued 
to grow in 2016 following the trend of recent years. This 
comes after the abrupt slowdown in health spending 
growth between 2009 and 2011 in the wake of the global 
financial and economic crisis. On average, annual health 
spending growth across the OECD since 2009 has been 
1.4% compared with 3.6% in the six years up to 2009 (Figure 7.2). 
In a number of countries there have been significant 
turnarounds in annual growth rates in health spending in 
the years before, compared with after the financial crisis. 
In Greece, strong annual growth increases were reversed 
after 2009 (5.4% vs. -5.0%). A similar if less dramatic picture 
is also observed in Portugal (2.2% vs. -1.3%). In general, 
health spending growth slowed down in the vast majority 
of OECD countries and preliminary figures or estimations 
for 2016 still point to negative or near-zero growth in a few. 
Only four countries –  Iceland, Hungary, Switzerland and 
Chile – have recorded higher average growth in the period 
since 2009 compared to the period before. Indeed, health 
spending in Hungary together with Poland and Estonia has 
remained relatively resilient since 2009 with annual growth 
of between 2.7-3.6% 
Away from Europe, Korea and Chile have continued to report 
annual health spending increases above 5% in real terms 
since 2009. Preliminary country estimates for 2016 suggest 
further strong spending growth of 6.3% in Korea and 4.5% 
in Chile. In the United States, health spending grew by 4.1% 
in real terms in 2015, the fastest rate for more than ten 
years, with a preliminary estimate by the OECD suggesting 
a further increase of 2.7% in 2016. In the medium-term, the 
US Centers for Medicare & Medicaid Services (CMS) expect 
health spending growth above that of GDP in the United 
States, driven on by faster growing medical prices.
Definition and comparability
Expenditure on health measures the final consumption 
of health goods and services (i.e. current health 
expenditure). This includes spending by both public 
and private sources on medical services and goods, 
public health and prevention programmes and 
administration. 
To compare spending levels between countries, 
per capita health expenditures are converted to a 
common currency (US dollar) and adjusted to take 
account of the different purchasing power of the 
national currencies, in order to compare spending 
levels. Economy-wide  (GDP) PPPs are used as the 
most available and reliable conversion rates. For the 
calculation of growth rates in real terms, economy-
wide GDP deflators are used for all countries. In some 
countries (e.g. France and Norway), health specific 
deflators exist, based on national methodologies, but 
these are not used in this publication due to limited 
comparability.
Note that data for 2016 are based on preliminary 
figures either provided by the country or estimates 
made by OECD Secretariat.
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7.1. Health expenditure per capita, 2016 (or nearest year)
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7.2. Annual average growth rate in per capita health expenditure, real terms, 2003 to 2016 (or nearest year)
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Health expenditure in relation to GDP
How much a country spends on health care over time 
relative to spending on all other goods and services in the 
economy can be down to both growth in health spending 
itself as well as how well the economy is performing overall. 
In 2016, health spending is estimated to have accounted 
for 9.0% of GDP on average across OECD countries, largely 
unchanged in recent years. This comes after a period of 
health spending growth above that of the overall economy 
in the 1990s and 2000s that saw health expenditure as a 
share of GDP rise sharply in many OECD countries.
In 2016, the United States spent 17.2% of GDP on health, 
almost five percentage points above Switzerland, the next 
highest country, and more than eight percentage points 
above the OECD average (Figure 7.3). A group of ten high-
income OECD countries, including Germany, France, Japan 
and Canada, follow with around 11% of GDP going on 
health services. Another large group of countries spanning 
Europe, as well as Australia and New Zealand (and South 
Africa) fit roughly within a band of between 8-10% of GDP. A 
similar sized group of mainly Central and Eastern European 
countries, such as Hungary, the Czech Republic and Poland 
allocate between 6-8% of their GDP to health. Only Mexico, 
latvia and, notably Turkey at 4.3%, spend less than 6% of 
GDP on health services. Turkey’s health spending as a share 
of GDP is at a similar level to that in India.
looking at changes over time, the average health spending 
to GDP ratio jumped sharply in 2009 as overall economic 
conditions deteriorated rapidly in many countries while 
health spending growth was sustained at around 3% on 
average in 2008 and 2009 (Figure 7.4). While subsequent 
health spending growth also significantly declined – 
approaching zero growth on average in 2010/11 – this step 
increase in the health spending to GDP ratio has been 
largely maintained as the rate of health spending growth 
has tended to closely track the growth in the overall 
economy since 2012. 
However, behind the overall OECD average, some different 
patterns emerge on a country by country basis. In the 
United States, after a number of years (2009-14) when the 
ratio of health spending to GDP has been stable at around 
16.4%, 2015 and 2016 have seen this increase again to reach 
the 17.2% in 2016 (Figure 7.5). This mirrors the period before 
the economic crisis when health spending rose almost a 
percentage point between 2003 and 2008. Korea has seen the 
most notable increase in the share of economic resources 
allocated to health over time with a significant progression 
in the ratio over many years on the back of growing wealth 
and increased health coverage for the population. In 2003, 
health spending in Korea accounted for only 4.3% whereas 
in 2016 it was estimated to have reached 7.2%. At the other 
end of the scale, no discernible impact can be seen for 
Mexico which has seen its health spending to GDP ratio 
remain relatively constant throughout the period at around 
6% of GDP.
In Europe, Germany has seen its health spending to GDP 
ratio stabilise since 2009 as health spending growth has 
aligned with economic growth with a slow but steady 
increase to reach 11.3% in 2016, almost one percentage 
point above the level in 2003. Greece, on the other hand, 
where there have been significant cuts in health spending 
since 2009, has seen the health spending to GDP ratio 
fluctuate  –  approaching close to 10% in 2010  – before 
returning to a similar level to that in the early 2000s at 
around 8% of GDP.
Definition and comparability
See indicator on “Health expenditure per capita” for a 
definition of expenditure on health.
Gross Domestic Product (GDP) = final consumption + 
gross capital formation + net exports. Final 
consumption of households includes goods and 
services used by households or the community 
to satisfy their individual needs. It includes final 
consumption expenditure of households, general 
government and non-profit institutions serving 
households.
In countries, such as Ireland and luxembourg, where a 
significant proportion of GDP refers to profits exported 
and not available for national consumption, GNI may 
be a more meaningful measure than GDP.
Note that data for 2016 are based on preliminary 
figures provided by the country or estimates made by 
OECD Secretariat.
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7.3. Health expenditure as a share of GDP, 2016 (or nearest year)
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7.4. Average annual growth in per capita  
health expenditure and GDP, 2003-16  
(OECD average)
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Financing of health care
Health care can be paid for through a variety of financing 
arrangements. In some countries, health care might be 
predominantly covered by government schemes by which 
individuals are automatically entitled to care based on their 
residency. In other cases, compulsory health insurance 
schemes (either through public or private entities) 
finance the bulk of health spending. In addition to these, 
a varying proportion of health care spending consists of 
payments by households (either as standalone payments 
or as part of co-payment arrangements) as well as various 
forms of voluntary health insurance intended to replace, 
complement or supplement automatic or compulsory 
coverage. 
In all but one OECD country, government schemes and 
compulsory health insurance constitute the main health 
care financing arrangements. Together they accounted, 
on average, for almost three-quarters of all health care 
spending across the OECD in 2015 (Figure 7.6). In Denmark, 
Sweden and the United Kingdom, central, regional or local 
government financed 80% or more of all health spending. 
In Germany, Japan, France and the Slovak Republic more 
than 75% of all health expenditure was paid for through 
compulsory health insurance. Only in the United States 
was less than half of all health spending financed by 
government or compulsory health insurance. By contrast, 
a large proportion of health spending (35%) was paid for 
via voluntary health insurance.
Governments provide a multitude of public services out of 
their overall budgets. Hence, health care is competing with 
many other sectors such as education, defence and housing. 
The size of public funds allocated to health is determined 
by a number of factors including, among others, the type of 
system in place and the demographic composition of the 
population. Relative budget priorities may also shift from 
year to year as a result of political decision-making and 
economic effects. In 2015, health spending by government 
schemes and compulsory insurance stood at around 15% of 
total government expenditure across the OECD (Figure 7.7). 
In Japan, Switzerland, New Zealand, the United States and 
Germany more than 20% of public spending was dedicated 
to health care. On the other hand, less than one out of 
every ten euros spent by governments or compulsory 
health insurance was allocated to health care in latvia 
and Greece.
After government schemes and compulsory health 
insurance, the main source of funding tends to be out-
of-pocket payments. On average across the OECD, private 
households directly financed around one-fifth of all health 
spending in 2015. This share is above a third of health 
spending in Greece (35%), Korea (37%), Mexico (41%) and 
latvia (42%), while in France it is below 10%. With the 
implementation of universal health coverage in some OECD 
countries over previous decades, there have been some 
significant reductions in the share of health care costs 
payable by households. More recently, the share of out-of-
pocket spending has been generally stable but with some 
notable increases in some European countries (Figure 7.8). 
In Greece (+6.2 percentage points) and Spain (+4.7 pp) 
the share of health spending payable by households has 
increased since 2009 due to the implementation of reforms 
to balance public budgets which shifted some financing 
responsibilities to patients. On the other hand, this share 
has been reduced in Mexico (-6.0 pp) and Chile (-2.3 pp) 
over the same time period.
Definition and comparability
Health care financing can be analysed from the point 
of view of financing schemes (financing arrangements 
through which health services are paid for and 
obtained by people, e.g. social health insurance), 
financing agents (organisations managing the financing 
schemes, e.g. social insurance agency), and types of 
revenues (e.g. social insurance contributions). Here 
“financing” is used in the sense of financing schemes 
as defined in the System of Health Accounts (OECD, 
Eurostat and WHO, 2011) and includes government 
schemes, compulsory health insurance as well as 
voluntary health insurance and private funds such 
as households’ out-of-pocket payments, NGOs and 
private corporations. Compulsory health insurance can 
be offered by private insurers, in some cases without 
an obligation to contract individuals (e.g. in Chile and 
Germany). Out-of-pocket payments are expenditures 
borne directly by patients and include cost-sharing 
arrangements and any informal payments to health 
care providers. 
Total government expenditure is as defined in the 
System of National Accounts and includes intermediate 
consumption, compensation of employees, interest, 
social benefits, social transfers in kind, subsidies, other 
current expenditure and capital expenditure payable by 
central, regional and local governments as well as social 
security funds. Relating spending from government 
financing schemes and compulsory insurance schemes 
to total government expenditure is overestimated to 
a certain extent for those countries with compulsory 
health insurance provided by private insurers.
Spending by private health insurance companies in 
the United States are considered under voluntary 
health insurance although the Affordable Care Act 
(ACA) constitutes a mandate for individuals to buy 
health insurance or pay a penalty since 2014.
References 
Mueller, M. and D. Morgan (2017), “New Insights into 
Health Financing: First Results of the International Data 
Collection Under the System of Health Accounts 2011 
Framework”, Health Policy, Vol. 121, No. 7, pp. 764–769.
OECD/Eurostat/WHO (2017), A System of Health Accounts 
2011: Revised edition, OECD Publishing, Paris, http://dx.doi.
org/10.1787/9789264270985-en.
137HEAlTH AT A GlANCE 2017 © OECD 2017
Financing of health care
7. HEALTH EXPENDITURE
7.6. Health expenditure by type of financing, 2015 (or nearest year)
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7.7. Health spending by government schemes and compulsory health insurance as share of total government 
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7.8. Change in out-of-pocket expenditure as a share of expenditure on health,  
2009 to 2015 (or nearest years)
%
0
10
20
30
40
50
41.6
41.4
36.8
35.5
32.2
29.0 28.3 27.7
24.2 23.3
23.2
22.8 22.8
22.7
20.2 19.9 19.6 17.9
17.6
17.0 16.9 15.3 15.2
14.6 14.3 13.7 13.1 12.6 12.5 12.5
12.3
11.4 11.1 10.6
10.6
6.8
2015 (or nearest year)2009 (or nearest year)
La
tvi
a
Me
xic
o
Ko
rea
Gr
ee
ce
Ch
ile
Hu
ng
ary
Sw
itz
erl
an
d
Po
rtu
ga
l
Sp
ain
Slo
va
k R
ep
ub
lic
Po
lan
d
Ita
ly
Es
ton
ia
Isr
ae
l
OE
CD
35
Fin
lan
d
Au
str
ali
a
Au
str
ia
Be
lgi
um
Ice
lan
d
Tu
rke
y
Cz
ec
h R
ep
ub
lic
Sw
ed
en
Ca
na
da
No
rw
ay
De
nm
ark
Ja
pa
n
Ne
w 
Ze
ala
nd
Ge
rm
an
y
Slo
ve
nia
Ne
the
rla
nd
s
Ire
lan
d
Un
ite
d S
tat
es
Lu
xe
mb
ou
rg
Un
ite
d K
ing
do
m
Fra
nc
e
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933604324
138 HEAlTH AT A GlANCE 2017 © OECD 2017 
7. HEALTH EXPENDITURE
Sources of health care financing
In all OECD countries, the various schemes that pay for the 
health care goods and services rely on a mix of different 
sources of revenues. Government schemes, for example, 
typically receive budget allocations out of the overall 
government revenues (e.g. from income and corporate 
taxation, value-added tax, etc.). Social health insurance 
is usually financed out of social contributions payable by 
employees and employers. However, these schemes may 
also receive a varying proportion of their revenues from 
governmental transfers. The main sources of revenue 
for private health insurance are either compulsory or 
voluntary prepayments, which typically take the form 
of regular premium payments as part of an insurance 
contract. Out-of-pocket payments are exclusively financed 
from households’ own revenues. Some health financing 
schemes (e.g. non-profit or enterprise schemes) may also 
receive donations or additional income from investments 
or rental. Resident financing schemes can also receive 
transfers from abroad as part of bilateral co-operations 
with foreign governments or other development partners. 
However, these transfers play no role in the vast majority 
of OECD countries. 
The composition of revenues is strongly correlated with a 
country’s system of health care financing. Hence, when 
analysing the overall revenue structure in, say, Denmark 
– where health care activities are predominantly financed 
through local government schemes (see indicator on 
“Financing of health care”)  – governmental transfers are 
the most important revenue (Figure  7.9). Comparing the 
structure of financing schemes with the types of revenues 
that these schemes receive can give important insights into 
how financing works in different health systems: in many 
countries, the government’s role is typically larger than as just 
a simple purchaser of health services (Mueller and Morgan, 
2017). In Japan, for example, the government is directly 
responsible for only 9% of all health spending but government 
transfers to the different schemes existing in the country 
constitute 42% of all revenues for health care financing. 
The role governments play as a financing source can 
be highlighted more clearly when only analysing the 
composition of revenues for compulsory health insurance, 
which in most OECD countries consists of social health 
insurance (SHI) (Figure  7.10). In the countries analysed, 
governmental transfers are a source of revenue in each 
case but the importance differs significantly. In Japan, more 
than 40% of the revenues of SHI stems from governmental 
transfers. The shares are similar in Chile and Finland but 
account for less than 5% in Estonia, Poland and Slovenia. 
In those countries, SHI funds finance their outlays nearly 
exclusively via social contributions. Yet, even here, 
substantial variations exist when analysing this stream 
of revenues in more detail. In Poland, employees bear 
the brunt of social contributions, whereas in Estonia the 
financing responsibility falls on employers.
Some countries are planning to reduce their reliance on 
wage-based contributions in the face of shrinking labour 
markets and financial shocks, and are increasingly looking 
for ways to diversify their revenue base (OECD, 2015). While 
there is little year-to-year change in the health financing 
structure and composition of revenues, some trends can 
be discerned over a longer time horizon (Figure 7.11). In 
Belgium, for example, the share of social contributions in 
all revenues has fallen from over 50% to around 43% over 
the last decade. At the same time, governmental transfers 
have gained importance. The latter is also true for the United 
States where the share from government transfers increased 
from 34% to 41% over the same time period. In Korea, on the 
other hand, government transfers have stagnated while the 
share through social contributions has increased.
Definition and comparability
Health financing schemes have to raise revenues in 
order to pay for health care goods and service for the 
population they are covering. There are different types 
of revenues which can however be closely correlated 
with the financing scheme. In general, financing 
schemes can receive transfers from the government, 
social insurance contributions, voluntary or 
compulsory prepayments (e.g. insurance premiums), 
other domestic revenues and revenues from abroad 
as part of development aid. 
In reality, the revenues of a health financing scheme 
are typically not identical to its expenses in a given 
year leading to a surplus or deficit of funds. In practice, 
most countries only analyse the composition of 
revenues per scheme and apply the resulting shares 
on a pro-rata basis to the expense of each financing 
scheme thus equating revenues with its expenses.
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7.9. Health financing sources by type of revenue, 2015 (or nearest year)
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7.10. Financing sources of compulsory insurance by type of revenue, selected countries, 2015 (or nearest year)
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7.11. Share of government transfers and social insurance contributions in all revenues  
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Health expenditure by type of service
How health spending is split between the various services 
and goods reflects a variety of factors, from disease burden 
and system priorities to organisational aspects and costs. 
Spending on inpatient and outpatient care combined 
accounts for the major part of health expenditure across 
OECD countries –  almost two-thirds of health spending 
on average in 2015 (Figure 7.12). A further 19% of health 
spending was accounted for by medical goods (mainly 
pharmaceuticals), while 14% went on long-term care 
services. The remaining 6% was spent on prevention and 
public health services as well as on the overall governance 
and administration of the health system.
Greece has a particularly high share of spending on inpatient 
care (including day care in hospitals) – accounting for 40% 
of its health spending in 2015. Inpatient care also plays 
an important role in Poland, Austria and France, taking 
up more than a third of total spending. Countries with a 
high share of outpatient spending include Portugal (48%) 
and Israel (47%). The United States also consistently reports 
one of the highest shares of outpatient care. However, this 
includes physicians’ fees in cases where they independently 
bill patients for hospital care.
The third major category of health spending is on medical 
goods. Variations can be due to a number of factors such as 
the different distribution channels in place, the extent of 
generic use as well as the relative prices of pharmaceuticals. 
In the Slovak Republic (35%) and Hungary (32%), medical 
goods represent the largest component of health spending. 
The share is also high in latvia, Mexico and Greece, at 
around 30%. In Denmark, luxembourg and Norway, on the 
other hand, spending on medical goods represents only 
10-11% of health spending.
There are also differences between countries in the amount 
of health expenditure on long-term care services (see 
Chapter 11). Norway, Sweden and the Netherlands, with 
their established formal arrangements for the elderly and 
the dependent population, allocate more than a quarter of 
all health spending to long-term care. Whereas in many 
Southern European and Central and Eastern European 
countries with more informal long-term care sectors, 
spending on long-term care services accounts for a much 
smaller share.
The slowdown in health spending experienced in many 
OECD countries following the economic crisis affected 
all parts of the health sector, but to varying degrees 
(Figure 7.13). Expenditure for pharmaceuticals contracted 
annually by 0.5% after positive annual increases of 2.3% 
during the pre-crisis years and even stronger growth in 
the 1990s and early 2000s. Despite initially protecting 
public health budgets, prevention spending growth also 
turned negative in around half of OECD countries after 
2009. On average, spending on preventive care contracted 
by 0.2% on an annual basis, after recording very high 
growth rates during the period 2003-09 (4.6%). Part of 
the reversal in spending growth can be explained by the 
H1N1 influenza epidemic, which led to significant one-off 
outlays for vaccinations in many countries around 2009 
(Gmeinder et al., forthcoming).
While spending on inpatient, outpatient and long-term 
care has continued to grow, the rates have also significantly 
reduced since 2009. Expenditure growth for outpatient care 
nearly halved overall (4% vs 2.3%), but remained positive 
in the majority of OECD countries. Some governments 
decided to protect expenditure for primary care and front-
line services while looking for cuts elsewhere in the health 
system. The annual average growth rate for inpatient care 
dropped to almost half of its previous growth rate, down 
from 2%, and turned negative between 2009 and 2015 in 
around one-quarter of OECD countries. Reducing wages 
in public hospitals, postponing staff replacement and 
delaying investment in hospital infrastructure were among 
the most frequent measures taken in OECD countries to 
balance health budgets.
Definition and comparability
The System of Health Accounts (OECD, Eurostat and 
WHO, 2017) defines the boundaries of the health care 
system from a functional perspective, with health care 
functions referring to the different types of health 
care services and goods. Current health expenditure 
comprises personal health care (curative care, 
rehabilitative care, long-term care, ancillary services 
and medical goods) and collective services (prevention 
and public health services as well as administration – 
referring to governance and administration of the 
overall health system rather than at the health provider 
level). Curative, rehabilitative and long-term care can 
also be classified by mode of provision (inpatient, day 
care, outpatient and home care).
Concerning long-term care, only the health aspect 
is reported as health expenditure, although it is 
difficult in certain countries to separate out clearly 
the health and social aspects of long-term care. Thus, 
estimations of long-term care expenditure continue 
to be one of the main factors limiting comparability 
across countries.
For the calculation of growth rates in real terms, 
economy-wide GDP deflators are used.
References
Gmeinder, M., D. Morgan and M. Mueller (2017, forthcoming), 
“How Much Do OECD Countries Spend on Prevention?”, 
OECD Health Working Paper, OECD Publishing, Paris.
OECD, Eurostat and WHO (2017), A System of Health Accounts 
2011: Revised edition, OECD Publishing, Paris, http://dx.doi.
org/10.1787/9789264270985-en.
141HEAlTH AT A GlANCE 2017 © OECD 2017
Health expenditure by type of service
7. HEALTH EXPENDITURE
7.12. Health expenditure by type of service, 2015 (or nearest year)
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Health expenditure by provider
Across OECD countries, the delivery of health care services 
and goods takes place in many different organisational 
settings, ranging from hospitals and medical practices to 
pharmacies and even private households caring for family 
members. A breakdown by provider allows the tracking of 
health expenditure from an organisational point of view, a 
useful complement to the functional breakdown of health 
expenditure (see indicator “Health expenditure by type of 
service”).
While the way in which health care provision is organised 
across OECD countries varies considerably, hospitals are 
the main health care provider in terms of health spending 
(Figure 7.14). They account for nearly 40% of overall health 
spending on average and represent the main spending 
category for all but a handful of countries. In Turkey, Estonia 
and Italy around half of all health spending is accounted 
for by activities delivered in hospitals. On the other hand, 
hospitals in Canada, Germany and Mexico account for 30% 
or less of health spending.
Ambulatory providers are the second main category with 
regard to health spending. Overall, around one-quarter of 
health spending relates to ambulatory providers, ranging 
from more than 50% in Israel to 20% or less in Ireland, the 
Slovak Republic, the Netherlands and Turkey. The category 
covers a wide range of facilities and depending on the country-
specific organisational set up, most spending relates either 
to medical practices including offices of GPs and specialists 
(e.g. Austria, France and Germany) or ambulatory health 
care centres (e.g. Finland, Ireland and Sweden). On average, 
practices of GPs and specialists together with ambulatory 
health care centres account for around two-thirds of all 
spending on ambulatory providers. Around one-fifth of 
ambulatory provider spending relates to dental practices 
and about 10% to providers of home health care services. 
Other main provider categories include retailers (mainly 
pharmacies selling prescription and over-the-counter 
medicines) and residential long-term care facilities (mainly 
providing inpatient care to long-term dependent people).
The activities performed by providers classified within 
the same category can differ widely across countries. 
This variation is particularly pronounced in hospitals 
(Figure 7.15). Although inpatient curative and rehabilitative 
care accounts for the vast majority of hospital expenditure 
in almost all OECD countries, hospitals are also important 
providers of outpatient care in most countries, for 
example through accident and emergency departments, 
hospital-based specialist outpatient units, or laboratory 
and imaging services provided to outpatients. In Sweden, 
Estonia, Finland and Portugal outpatient care accounts for 
over 40% of hospital expenditure. On the other hand, in 
Greece, Germany and Belgium, less than 10% of hospital 
expenditure goes on outpatient care.
Many countries have seen a growing share of health spending 
going to hospitals in recent years while at the same time 
there has been a tendency to shift medical services from 
inpatient to day care settings (see indicator on “Ambulatory 
surgery” in Chapter 9). The main motivation behind this 
is the generation of efficiency gains and a reduction of 
waiting times. Moreover, for some interventions day 
care procedures are now the most appropriate treatment 
method. Hence, in a number of countries day care now 
accounts for more than 10% of all hospital expenditure. 
Furthermore, the provision of long-term care in hospital 
makes up a sizeable share of hospital expenditure in some 
countries (e.g. Korea, Japan and Iceland).
Definition and comparability
The universe of health care providers is defined in 
the System of Health Accounts (OECD, Eurostat and 
WHO, 2017) and encompasses primary providers, i.e. 
organisations and actors that deliver health care 
goods and services as their primary activity, as well 
as secondary providers for which health care provision 
is only one among a number of activities.
The main categories of primary providers are hospitals 
(acute and psychiatric), residential long-term care 
facilities, ambulatory providers (practices of GPs and 
specialists, dental practices, ambulatory health care 
centres, providers of home health care services), 
providers of ancillary services (e.g. ambulance services, 
laboratories), retailers (e.g. pharmacies), and providers 
of preventive care (e.g. public health institutes).
Secondary providers include residential care 
institutions whose main activities might be the 
provision of accommodation but provide nursing 
supervision as secondary activity, supermarkets that 
sell over-the-counter medicines, or facilities that 
provide health care services to a restricted group of the 
population such as prison health services. Secondary 
providers also include providers of health care system 
administration and financing (e.g. government 
agencies, health insurance agencies) and households 
as providers of home health care.
References
OECD, Eurostat and WHO (2017), A System of Health Accounts 
2011: Revised edition, OECD Publishing, Paris, http://dx.doi.
org/10.1787/9789264270985-en.
143HEAlTH AT A GlANCE 2017 © OECD 2017
Health expenditure by provider
7. HEALTH EXPENDITURE
7.14. Health expenditure by provider, 2015 (or nearest year)
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7.15. Hospital expenditure by type of service, 2015 (or nearest year)
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Capital expenditure in the health sector 
Although health systems remain a highly labour-intensive 
sector, capital has been an increasingly important factor 
of production of health services over recent decades, 
as reflected for example by the growing importance of 
diagnostic and therapeutic equipment or the expansion 
of information and communications technology (ICT) in 
health care (see previous indicator on eHealth adoption 
in general practice and hospital). However, the level of 
resources invested in infrastructure, equipment and ICT 
tends to fluctuate more with economic cycles than current 
spending on health services, as investment decisions are 
often more discrete and can more easily be postponed or 
brought forward depending on economic circumstances. In 
making capital investment decisions, policy-makers need 
to carefully assess not only the short-term costs, but also 
the potential benefits in the short, medium and longer-
term. Slowing down investment in health infrastructure 
and equipment may also reduce the capacity to treat 
patients and contribute to increases in waiting times for 
different types of services. 
In 2016, OECD countries allocated, on average, around 0.5% 
of their GDP for capital expenditure in the health sector 
(Figure 7.16). This compares with the 9% of GDP going on 
current spending, that is on medical care, pharmaceuticals, 
etc. (see indicator “Health spending as a share of GDP”). 
As is the case with current spending, there are significant 
differences in the current levels of investment expenditure 
between countries and in the recent trends observed 
following the economic crisis.
As a proportion of GDP, Japan was the highest spender 
on capital investment in 2015 with more than 1% of its 
GDP going on construction, equipment and technology 
in the health and social sector. A number of European 
countries  –  Belgium, Austria and Germany  – were also 
relatively high capital spenders in 2015, with between 0.7-
0.8% of GDP invested. For the most part, OECD countries 
find themselves within a relatively narrow band of 
between 0.4-0.6% of GDP each year. However, either due 
to the economic conditions or the peculiarities of a small 
economy (luxembourg and Iceland) capital spending can 
be significantly lower. Greece, for example, spent just under 
0.15% of its GDP on capital investment in the health sector 
in 2015.
By its very nature, capital spending fluctuates from year 
to year more than current spending as capital projects 
on construction (i.e. building of hospitals and other 
health care facilities) and investment programmes on 
new equipment (e.g., medical and ICT equipment) are 
implemented. Decisions on capital spending also tend to be 
more affected by economic cycles, with spending on health 
system infrastructure and equipment often a prime target 
for reduction or postponement in economic downturns. 
Figure  7.17 shows that a number of hard-hit European 
countries have seen annual investment in the health sector 
fall in real terms post-crisis. Greece, in particular, reported 
capital spending in the health sector at around a third of 
the level reported ten years before. Portugal and Italy have 
both seen investment drop by 30% or more from the peaks 
in 2010. The United Kingdom is also notable in seeing a 
significant reduction in investment: up to 2009, capital 
spending was increasing rapidly year-on-year whereas 
between 2011 and 2014 it was back to 2003 levels. 
Outside of Europe a number of countries reported a 
continual increase in capital expenditure. Korea and Japan 
have seen recent investment in the health care sector 
around 50% higher, in real terms, than the levels of ten 
years earlier (Figure 7.18).
Definition and comparability
Gross fixed capital formation in the health sector is 
measured by the total value of the fixed assets that 
health providers have acquired during the accounting 
period (less the value of the disposals of assets) and 
that are used repeatedly or continuously for more 
than one year in the production of health services. 
The breakdown by assets includes infrastructure (e.g. 
hospitals, clinics, etc.), machinery and equipment 
(including diagnostic and surgical machinery, 
ambulances, and ICT equipment), as well as software 
and databases.
Gross fixed capital formation is reported by many 
countries under the System of Health Accounts. 
It is also reported under the National Accounts 
broken down by industrial sector according to the 
International Standard Industrial Classification (ISIC) 
Rev. 4 using Section Q: Human health and social work 
activities or Division 86: Human health activities. The 
former is normally broader than the SHA boundary 
while the latter is narrower.
145HEAlTH AT A GlANCE 2017 © OECD 2017
Capital expenditure in the health sector 
7. HEALTH EXPENDITURE
7.16. Gross fixed capital formation in the health care sector as a share of GDP, 2015 (or nearest year)
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1. Refers to gross fixed capital formation in ISIC 86: Human health activities (ISIC Rev. 4).
2. Refers to gross fixed capital formation in ISIC Q: Human health and social work activities (ISIC Rev. 4).
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7.17. Gross fixed capital formation, constant prices, 
selected European OECD countries, 2003-15
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7.18. Gross fixed capital formation, constant prices, 
selected non-European OECD countries, 2003-15
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Doctors by age, sex and category
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The statistical data for Israel are supplied by and under the responsibility of the relevant 
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the 
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of 
international law.
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Health and social care workforce 
Employment in health and social care represents a large 
and growing share of the labour force in many countries 
across the world (UN High-level Commission on Health 
Employment and Economic Growth, 2016). In the OECD, 
health and social work activities constituted around 10% 
of total employment on average in 2015 (Figure 8.1). The 
employment share is particularly pronounced in the 
Scandinavian countries, Finland and the Netherlands, 
where jobs in health and social work represent 15-20% of 
these countries’ workforces. 
Moreover, the percentage of workers employed in health 
and social work has steadily risen across much of the OECD 
between 2000 and 2015. For the OECD overall, there was an 
average percentage point increase of 1.7 from 2000 to 2015. 
Some of the greatest increases have taken place in Japan, 
Ireland, Korea, luxembourg and the Netherlands. Four 
countries experienced a decrease in share of employment 
in health and social work: latvia, Mexico, Poland and the 
Slovak Republic.
The rapid employment growth in health and social care 
contrasts markedly with the experience in other sectors 
(Figure  8.2). Across the OECD, employment in health 
and social work grew on average by 42% (with a median 
value of 34%) between 2000 and 2015. Over the same 
time period, there was an overall decline in the number 
of jobs in agriculture and industry in the OECD countries. 
Employment growth in health and social work was also 
noticeably higher than employment growth in the services 
sector, and was significantly above the growth in total 
employment. 
Past and current experiences show that employment in 
the health and social sector tends to be less sensitive to 
cyclical fluctuations than employment in other sectors in 
the economy. While the total employment declined slightly 
in the United States during the economic recessions of the 
early 1990s and significantly in 2008-09, employment in the 
health and social sector continued to grow steadily over 
this same period. In most OECD countries, the number of 
doctors and nurses continued to rise through the recession 
period (see indicators on doctors and nurses).
looking forward, employment in health and social care 
sector is likely to increase, but the type of skills and 
functions are expected to change. This reflects a number 
of factors. Ageing populations will change the pattern of 
demand for health and social services. This could include 
greater demand for long-term care and related social 
services, which are particularly labour-intensive (OECD, 
2011). Over time, rising incomes and availability of new 
technologies will raise expectations on the quality and 
scope of care (OECD, 2015). 
Many countries have also started to introduce new care 
delivery models that will involve greater integration of 
health and social services in order to meet the needs of 
ageing societies. These changes are expanding the roles 
of non-physician providers (such as nurse practitioners 
and pharmacists and community health workers) into 
health care, aimed at maintaining access to services and 
increasing the productivity of the health workforce, as 
well as improving the continuity and quality of care for 
the patients. These changes will likely lead to significant 
transformations in staffing profile and skills requirements 
in the health and social care sector.
Definition and comparability
Health and Social Work is one of the economic 
activities defined according to the major divisions of 
the International Standard Industrial Classification 
of All Economic Activities (ISIC). Health and Social 
Work is a sub-component of the Services sector, and 
is defined as a composite of human health activities, 
residential care activities (including long-term care), 
and social work activities without accommodation. 
The employment data are taken from the OECD 
National Accounts (SNA) database for the 35 OECD 
member countries, except for Iceland and Turkey 
where the source is the OECD Annual labour Force 
Statistics (AlFS) database. 
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8.1. Employment in health and social work as a share of total employment, 2000 and 2015 (or nearest year)
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Source: OECD National Accounts; OECD Annual labour Force Statistics for Iceland and Turkey.
12 http://dx.doi.org/10.1787/888933604533
8.2. Employment growth by sector between 2000 and 2015 (or nearest year), OECD average¹
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Doctors (overall number)
The number of doctors per capita varies widely across 
OECD countries. In 2015, Greece had the highest number 
with 6.3 doctors per 1 000 population, but this number is an 
over-estimation as it includes all doctors who are licensed 
to practice but may no longer be practising for various 
reasons. Greece was followed by Austria (5.1 doctors per 
1 000 population). Turkey, Chile and Korea had the lowest 
number among OECD countries at around two  doctors 
per 1 000 population. The OECD average was 3.4 doctors 
per 1 000 population. Among the partner countries, the 
number of doctors per capita is significantly lower: there 
was less than one doctor per 1 000 population in Indonesia, 
India and South Africa. In China, the number of doctors per 
capita is still about half the OECD average, but it has grown 
by 44% since 2000 (Figure 8.3).
Since 2000, the number of doctors has increased in nearly 
all OECD countries, both in absolute number and on a per 
capita basis. The growth rate was particularly rapid in some 
countries which started with lower levels in 2000 but have 
grown at a significantly faster rate than the OECD average 
growth rate, such as Korea, Mexico and the United Kingdom 
(Figure 8.4).
At the same time, countries with high physician density 
such as Australia and Austria have also continued to show 
a high rate of increase over the same period. The number 
of doctors has continued to increase strongly in Australia, 
driven by a strong rise in the number of graduates from 
domestic medical education programmes (see the indicator 
on “Medical graduates”).
In the United Kingdom, concerns were raised in the early 
2000s about possible surpluses in certain categories of 
doctors. This resulted in policies to reduce student intakes 
and to some tapering of the growth rate in the number 
of doctors. More recently, though, funding for additional 
student places at medical schools was announced to meet 
the growing demand for care (Department of Health, 2016). 
The number of physicians per capita remained fairly stable 
between 2000 and 2015 in France, Israel, Poland and the 
Slovak Republic. In Israel, the number of doctors increased 
at nearly the same pace as the population size.
Overall, most OECD countries have shown a steady increase 
in the number of doctors, and did not show much effect of 
the global recession. In countries such as Australia, there 
were about 30% more employed doctors in 2015 than in 
2008. There were some exceptions: the 2008-09 recession 
appears to have had an impact in Greece, where the 
number of doctors increased between 2000 and 2008, but 
has stopped growing afterwards and has even shown some 
decline since 2012.
Projecting the future supply and demand of doctors is 
challenging given the high levels of uncertainty concerning 
their retirement and migration patterns as well as changes 
in their demand (Ono et al., 2013). Many OECD countries 
have anticipated the upcoming retirement of a significant 
number of doctors by increasing their training efforts over 
the past decade to ensure that there would be enough new 
doctors to replace those who will retire. But the impact of 
this increase into medical education will take several years 
for the effects to be felt. The difficulties in anticipating 
the actual number of practicing doctors have resulted in 
countries continually having to revise and adjust their 
policies. However, in most OECD countries, there is a 
shared concern on the shortages of general practitioners 
(see the indicator “Doctors by age, sex and category”) and 
the undersupply of doctors in rural and remote regions (see 
the indicator on the “Geographic distribution of doctors” 
in Chapter 5).
Definition and comparability
The data for most countries refer to practising 
doctors, defined as the number of doctors who are 
providing care directly to patients. In many countries, 
the numbers include interns and residents (doctors 
in training). The numbers are based on head counts. 
Several countries also include doctors who are active 
in the health sector even though they may not 
provide direct care to patients, adding another 5-10% 
of doctors. Greece and Portugal report the number of 
physicians entitled to practice, resulting in an even 
larger over-estimation of the number of practicing 
doctors. Belgium sets a minimum threshold of 
activities for doctors to be considered to be practising, 
thereby resulting in an under-estimation compared 
with other countries which do not set such minimum 
thresholds. Data for India may be over-estimated as 
they are based on medical registers which are not 
updated to account for migration, retirement or death, 
nor do they take into account doctors registered in 
multiple states. 
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8.3. Practising doctors per 1 000 population, 2000 and 2015 (or nearest year)
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8.4. Evolution in the number of doctors, selected OECD countries, 2000 to 2015 (or nearest year)
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Doctors by age, sex and category
The age and gender composition of the medical workforce 
and the mix between different categories of doctors have 
important implications on the availability of medical 
services. The ageing of doctors in OECD countries has, for 
many years, raised concerns that there may not be sufficient 
new recruits to replace them, although there is evidence 
that the retirement of doctors often only occurs gradually 
and that their retirement age is increasing (OECD, 2016). 
The growing imbalance in favour of greater specialisation 
over general medicine raises concerns in many countries 
about access to primary care for all the population.
In 2015, on average across OECD countries, one-third of 
all doctors were over 55 years of age, up from one-fifth in 
2000 (Figure 8.5). Between 2000 and 2015, France, Italy, Spain 
and Austria more than doubled the share of doctors over 
55 years of age. While these doctors might be expected to 
retire over the next ten years, a growing number of them 
will likely continue to practice after 65 years. In Israel and 
Italy, half (or more) of all doctors were over 55 years of age 
in 2015. It should be noted that the high share in Israel may 
be due partly to the fact that these numbers are based on 
all doctors licensed to practice, which may include some 
who may no longer be practicing. At the other end, only 13-
17% of doctors in the United Kingdom and Korea were aged 
over 55. This is consistent with the large numbers of new 
graduates entering medical practice over the past decade 
(see the indicator on “Medical graduates”). 
Several OECD countries have reformed their pension systems 
and increased the retirement age to take into account 
longer life expectancy. While few studies have examined 
the impact of these pension reforms specifically on doctors, 
it is possible that these pension reforms may prolong the 
working lives of doctors after age 65, which could have a 
significant impact on the future replacement needs. 
In 2015, 46% of doctors on average across OECD countries 
were women, up from 39% in 2000 (Figure  8.6). At least 
half of all doctors now are women in 11 countries, with 
latvia and Estonia showing the highest share at over 70%. 
Between 2000 and 2015, the share of women doctors rose 
most rapidly in the Netherlands (49%) and Belgium (47%). 
By contrast, only about one-in-five doctors in Japan and 
Korea were women in 2015, although Japan showed a 
significant increase of 42% over the 2000 figure. 
On average across OECD countries, generalists made up 
about 30% of all physicians in 2015 (Figure 8.7), a similar 
share to 2005. Greece, Hungary and the United States 
showed the lowest share of generalists, while countries 
such as France, Canada and Australia have been able to 
maintain a more equal balance between specialists and 
generalists. It should be noted that in Ireland and Portugal, 
most generalists are not general practitioners but rather 
non-specialist doctors working in hospitals or other settings. 
In the United States, general internal medicine doctors are 
categorised as specialists although their practice is often 
very similar to that of general practitioners, resulting in 
some underestimation of the capacity to provide generalist 
care.
In response to concerns about shortages of general 
practitioners, many countries have taken steps to improve 
the number of training places in general medicine. In 
Canada, the number of post-graduate training places in 
family medicine more than doubled between 2000 and 2013, 
as part of a national effort to improve access to primary 
care (CAPER, 2015). However, in most OECD countries, 
specialists earn more than general practitioners, providing 
financial incentives for doctors to specialize (see indicator 
on the “Remuneration of doctors”).
Definition and comparability
The definition of doctors is provided under the 
previous indicator. In some countries, the data are 
based on all doctors licensed to practice, not only 
those practising (e.g., Greece and Portugal). Not all 
countries are able to report all their physicians in the 
two broad categories of specialists and generalists. 
This may be due to the fact that specialty-specific data 
are not available for doctors in training or for those 
working in private practice.
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8.5. Share of doctors aged 55 years and over, 2000 and 2015 (or nearest year)
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8.6. Share of female doctors, 2000 and 2015 (or nearest year)
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8.7. Generalists and specialists as a share of all doctors, 2015 (or nearest year)
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Medical graduates
The number of new medical graduates in a given year 
reflects to a large extent government decisions taken a 
few years earlier on the number of students admitted in 
medical schools (so-called numerus clausus policies). Since 
2000, most OECD countries have increased the number 
of students admitted to medical education in response 
to concerns about current or possible future shortages of 
doctors (OECD, 2016), but large variations remain across 
countries. 
In 2015, there were on average about 12  new medical 
graduates per 100 000 population across OECD countries 
(Figure  8.8). This proportion was highest in Ireland at 
24 new medical graduates per 100 000. At the other end, 
Israel and Japan had the lowest number of new medical 
graduates relative to their population. In Ireland, the 
number of medical graduates increased strongly in 2013 
due at least partly to the opening of new Graduate Entry 
Programmes a few years earlier, allowing students with 
an undergraduate degree in another discipline to obtain a 
medical degree in four years only.
In Israel, the low number of domestic medical graduates 
is compensated by the high number of foreign-trained 
doctors. About one-third of foreign-trained doctors in Israel 
are people who were born in Israel but have pursued their 
study abroad before coming back. The situation is quite 
different in Japan, where there are very few foreign-trained 
doctors. Since 2008, the Japanese government decided 
to increase intakes in medical education in response to 
current and projected shortages of doctors; however, this 
policy has not yet translated into an increase in the number 
of medical graduates. 
The expansion of the numerus clausus in many of the OECD 
countries over the past fifteen years has resulted in an 
increase in the number of medical graduates, although 
they are occurring at varying paces (Figure 8.9). Australia 
has shown the fastest rate of increase in the number of 
medical graduates, growing by 2.7  times between 2000 
and 2015. While most of this growth reflects an increase 
in the number of domestic students, it should be noted that 
this figure also reflects a growing number of international 
students in medical schools in Australia.
In the United Kingdom, the number of medical graduates 
doubled between 2000 and 2015, reflecting an effort to 
increase the domestic supply and rely less on foreign-
trained doctors. While there was a slight decrease in the 
number of graduates from 2013, in 2016 the government 
announced the intent to provide funding for additional 
1  500  students to meet the growing demand for care 
(Department of Health, 2016). By contrast, there has been 
a continued slow-down in the growth in number of medical 
graduates in the Netherlands (ACMMP, 2014).
In France, the number of medical graduates increased 
steadily since 2006 following a large increase in the numerus 
clausus between 2000 and 2006. However, the number of 
graduates is expected to stabilize in the coming years, as 
admission quotas have remained fairly stable over the past 
few years. Spain showed a slight decline in the number 
of medical students until 2012, when the numbers have 
begun to increase rapidly again, growing by 36% between 
2012 and 2015.
In the United States, the increase in admission intakes to 
medical schools also took place after 2005, and the number 
of medical graduates has shown a gradual increase over 
the past decade, which included a growing number of 
American students who study abroad (notably in Caribbean 
countries), with the intention of coming back to complete 
their post-graduate training and practice in the United 
States. This is expected to create additional pressures 
to increase the number of residency posts to allow both 
domestic graduates and foreign-trained US national 
graduates to complete their post-graduate training. 
There has also been a strong rise in the number of medical 
graduates in the Czech Republic and Poland. This increase 
since around 2009 can be explained partly by the growing 
number of international students choosing these countries 
to purse their medical studies. International students 
accounted for about 30% of all medical graduates in the 
Czech Republic in recent years. The internationalisation 
of medical education combined with migration makes it 
more challenging for national governments to set their own 
domestic policies (OECD, 2016).
Definition and comparability
Medical graduates are defined as the number of 
students who have graduated from medical schools 
in a given year. The data for Australia, Austria and 
the Czech Republic include foreign graduates, but 
other countries may exclude them. In Denmark, the 
data refer to the number of new doctors receiving 
an authorisation to practice, which may result in an 
over-estimation if these include a certain number of 
foreign-trained doctors.
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8.8. Medical graduates, 2015 (or nearest year)
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8.9. Evolution in the number of medical graduates, selected OECD countries, 2000 to 2015 (or nearest year)
50
100
150
200
250
300
50
100
150
200
250
300
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
Index (2000 = 100)
Countries above OECD average per capita Countries below OECD average per capita
Index (2000 = 100)
Spain
Australia
Netherlands
United Kingdom
Ireland
Japan
Canada
United States
Poland
France
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933604685
156 HEAlTH AT A GlANCE 2017 © OECD 2017 
8. HEALTH WORKFORCE
Remuneration of doctors (general practitioners and specialists)
The remuneration level for different categories of doctors has 
an impact on the financial attractiveness of different medical 
specialties. In many countries, governments influence the 
level and structure of physician remuneration by being one 
of the main employers of physicians or purchaser of their 
services, or by regulating their fees. With the increasing 
international mobility of doctors across national borders 
(see the indicator on migration of doctors and nurses), the 
relative levels of remuneration across countries can play an 
important role in influencing these movements. 
OECD data on physician remuneration distinguish 
between salaried and self-employed physicians. In some 
countries this distinction is increasingly blurred, as 
some salaried physicians are allowed to have a private 
practice and some self-employed doctors may receive 
part of their remuneration through salaries. A distinction 
is also made between general practitioners and all other 
medical specialists combined, although there may be wide 
differences in the income of different medical specialties.
In the OECD countries where data are available, the 
remuneration of doctors (both general practitioners and 
specialists) is much higher than that of the average worker 
(Figure 8.10). In 2015, self-employed general practitioners 
in Austria, Canada, France and the United Kingdom earned 
around three times the average wage in the country while 
in Germany they earned over four times the average wage. 
In Australia, self-employed general practitioners earned 
about two times the average wage in 2015, but it should 
be noted that this is an under-estimation since the figure 
includes the remuneration of physicians in training. 
In most countries, specialists earned significantly 
more than the average worker, and more than the 
general practitioners. In 2015, the income gap between 
specialists and general practitioners was particularly 
high in Australia, Belgium and luxemburg, where the self-
employed specialists earned over twice the remuneration 
earned by general practitioners. In comparison with the 
average worker, self-employed specialists in Belgium 
and luxembourg earned six times the average wage, and 
in France and Germany they earned around five times 
the average wage. It should be noted that in Belgium 
the remuneration included practice expenses, thereby 
resulting in an over-estimation. 
In many OECD countries, the income gap between general 
practitioners and specialists has continued to widen over 
the past decade, reducing the financial attractiveness of 
general practice (Figure 8.11). Since 2005, the remuneration 
of specialists has risen faster than that of generalists in 
Canada, Finland, France, Hungary, Israel, luxembourg and 
Mexico. On the other hand, in Austria, Belgium, Estonia 
and the Netherlands, the gap has narrowed slightly, as the 
income of general practitioners grew faster than that of 
specialists.
In some OECD countries, the economic crisis of 2008-09 
had an impact on the remuneration of doctors and other 
health workers. Several European countries hard hit by the 
recession either froze or reduced the wages or fees of doctors 
in efforts to reduce cost while protecting access to care for 
the population. This has been the case in Estonia, Ireland, 
Italy and Slovenia, where doctors saw their remuneration 
decrease for some years after the crisis. However, in more 
recent years, the remuneration of doctors and other health 
workers has started to rise again (OECD, 2016).
Definition and comparability
The remuneration of doctors refers to average gross 
annual income, including social security contributions 
and income taxes payable by the employee. It should 
normally exclude practice expenses for self-employed 
doctors.
A number of data limitations contribute to an under-
estimation of remuneration levels in some countries: 
1)  payments for overtime work, bonuses, other 
supplementary income or social security contributions 
are excluded in some countries (Austria for GPs, 
Ireland for salaried specialists and Italy); 2) incomes 
from private practices for salaried doctors are not 
included in some countries (e.g. Czech Republic, 
Hungary, Iceland, Ireland and Slovenia); 3)  informal 
payments, which may be common in certain countries 
(e.g. Greece and Hungary), are not included; 4) data 
relate only to public sector employees who tend to 
earn less than those working in the private sector in 
Chile, Denmark, Greece, Hungary, Iceland, Ireland, 
Norway, the Slovak Republic and the United Kingdom; 
and 5) physicians in training are included in Australia.
The data for some countries include part-time 
workers, while in other countries the data refer only to 
doctors working full time. In Belgium, the data for self-
employed doctors include practice expenses, resulting 
in an over-estimation.
The income of doctors is compared to the average 
wage of full-time employees in all sectors in the 
country. The source for the average wage of workers in 
the economy is the OECD Employment Database. For the 
calculation of growth rates in real terms, economy-
wide GDP deflators are used.
Reference
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8.10. Remuneration of doctors, ratio to average wage, 2015 (or nearest year)
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8.11. Growth in the remuneration of GPs and specialists, 2005-15 (or nearest year)
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Nurses
Nurses greatly outnumber physicians in most OECD 
countries, and they play a critical role in providing health 
care not only in traditional settings such as hospitals and 
long-term care institutions but increasingly in primary care 
settings (especially to manage the care of the chronically 
ill) and in home care settings.
There are growing concerns in many OECD countries about 
possible future shortages of nurses, given that the demand 
for nurses is expected to rise in a context of population 
ageing and the retirement of the current “baby-boom” 
generation of nurses. These concerns have prompted 
actions in many countries to increase the training of 
new nurses (see the indicator on “Nursing graduates”), 
combined with efforts to increase the retention rate of 
nurses in the profession. The retention rate of nurses has 
increased in recent years in many countries either due 
to the impact of the economic crisis that have prompted 
more nurses to stay or come back in the profession, or 
following deliberate efforts to improve their working 
conditions (OECD, 2016). 
On average across OECD countries, the number of nurses on 
per capita basis has gone up from 7.3 per 1 000 population 
in 2000 to nine nurses per 1  000  population in 2015 
(Figure 8.12). In 2015, the number of nurses per capita was 
highest in Switzerland, Norway, Denmark, Iceland and 
Finland, with more than 14 nurses per 1 000 population. 
The number of nurses per capita in OECD countries was 
lowest in Turkey, Chile and Mexico (with less than 3 
per 1  000  population). With regards to OECD partner 
countries, the number of nurses per capita was generally 
low compared with the OECD average. In 2015, Colombia, 
Indonesia, South Africa, India and Brazil had fewer than 
1.5 nurses per 1 000 population, although numbers have 
been growing quite quickly in Brazil in recent years.
The number of nurses per capita increased in almost 
all OECD countries since 2000. Korea and Portugal had a 
relatively low density of nurses but have now converged 
towards the OECD average. France has also increased from 
a relatively low density to a level above the OECD average. A 
significant increase was registered in countries that already 
had a high density of nurses in 2000, such as Switzerland, 
Finland and Denmark. In Ireland and Israel, the number of 
nurses per capita declined between 2000 and 2015 as the 
size of the population grew more rapidly than the number 
of nurses. In the Slovak Republic, the number of nurses 
declined both in absolute numbers and on a per capita 
basis.
In 2015, there were about three nurses per doctor on 
average across OECD countries, with about half of the 
countries reporting between two to four nurses per doctor 
(Figure  8.13). The nurse-to-doctor ratio was highest in 
Japan, Finland and Denmark (with 4.6 nurses per doctor). 
It was lowest in Chile, Turkey and Mexico with less than 
1.2 nurse per doctor). 
In response to shortages of doctors and to ensure proper 
access to care, some countries have developed more 
advanced roles for nurses. Evaluations of nurse practitioners 
from the United States, Canada and the United Kingdom 
show that advanced practice nurses can improve access 
to services and reduce waiting times, while delivering the 
same quality of care as doctors for a range of patients, 
including those with minor illnesses and those requiring 
routine follow-up. Existing evaluations find a high patient 
satisfaction rate, while the impact on cost is either cost-
reducing or cost-neutral. The implementation of new 
advanced practice nursing roles may require changes 
to legislation and regulation to remove any barrier to 
extensions in their scope of practice (Delamaire and 
lafortune, 2010).
Definition and comparability
The number of nurses includes those employed in 
public and private settings providing services directly 
to patients (“practising”) and in some cases also those 
working as managers, educators or researchers.
In those countries where there are different levels of 
nurses, the data include both “professional nurses” 
who have a higher level of education and perform 
higher level tasks and “associate professional 
nurses” who have a lower level of education but are 
nonetheless recognised and registered as nurses. 
Health care assistants (or nursing aids) who are not 
recognised as nurses are excluded. Midwives are 
excluded, except in some countries where they are 
at least partly included because they are considered 
as specialist nurses or for other reasons (Australia, 
Ireland and Spain).
Austria and Greece report only nurses working in 
hospital, resulting in an under-estimation.
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8.12. Practising nurses per 1 000 population, 2000 and 2015 (or nearest year)
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8.13. Ratio of nurses to doctors, 2015 (or nearest year)
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Nursing graduates
Many OECD countries have taken steps over the past 
decade or so to increase the number of students admitted 
in nursing schools in response to concerns about current 
or possible future shortages of nurses (OECD, 2016). 
Nonetheless, there are wide variations across countries in 
training efforts of new nurses, which may be explained by: 
differences in the current number and age structure of the 
nursing workforce (and hence the replacement needs); in 
the capacity of nursing schools to take on more students; 
and the future employment prospects of nurses.
In 2015, there were on average around 46  new nurse 
graduates per 100 000 population across OECD countries, up 
from less than 40 in 2003. Korea, Switzerland and Denmark 
had the highest number of new nurse graduates relative 
to their population, with these three countries graduating 
more than 90 new nurses per 100 000 population in 2015. 
Mexico, luxembourg and the Czech Republic had the 
lowest number, with less than 16  nurse graduates per 
100 000 population (Figure 8.14).
Over the past decade, the number of nursing graduates 
has increased in all OECD countries, but at different rates 
(Figure 8.15). The number has increased strongly in many 
of the countries which had relatively low number of 
graduates per capita. Mexico has among the lowest number 
of nursing graduates, but between 2000 and 2015 there was 
an eight-fold increase in the number of nursing graduates 
per capita. Over the same period, Italy has also shown a 
four-fold increase in the number of nursing graduates per 
capita.
Among the countries already with above average number of 
nursing graduates per capita, the increase has been more 
modest. Germany has shown an increase in the number 
of nurse graduates since 2012 through the expansion 
of registered nurse training programmes in several 
universities, in addition to the programmes traditionally 
offered in vocational nursing schools (Cassier-Woidasky, 
2013). Norway has also shown a modest increase in the 
last few years. Japan and Finland showed a decline in the 
number of nursing graduates in the earlier part of the 
decade, but has shown some modest increase in recent 
years.
In France, the number of graduates from nursing schools 
increased by 87% between 2000 and 2015. The numerus 
clausus set by the French Ministry of Health to control 
entry in nursing education programmes was expanded 
substantially since 1999. Most of the growth occurred in 
the academic year of 2000/01 when the annual quota was 
increased by 43%, driven by a projected reduction in the 
supply of nurses resulting from the reduction of working 
time to 35  hours per week, as well as a more general 
concern about the anticipated retirement of a large number 
of nurses.
Definition and comparability
Nursing graduates refer to the number of students 
who have obtained a recognised qualification required 
to become a licensed or registered nurse. They include 
graduates from both higher level and lower level 
nursing programmes. They exclude graduates from 
Masters or PhD degrees in nursing to avoid double-
counting nurses acquiring further qualifications. 
The data for Denmark and the United Kingdom are 
based on the number of new nurses receiving an 
authorisation to practice.
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8.14. Nursing graduates, 2015 (or nearest year)
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8.15. Evolution in the number of nursing graduates, selected OECD countries, 2000 to 2015 (or nearest year)
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Remuneration of nurses
The remuneration level of nurses is one of the factors 
affecting their job satisfaction and the attractiveness of 
the profession. It also has a sizeable impact on costs, since 
wages of nurses represent one of the largest spending 
items in health systems. 
The data presented in this section generally focus on the 
remuneration of nurses working in hospitals, although the 
data coverage differs for some countries (see the box below 
on “Definition and comparability”).
The data are presented in two ways. First, it is compared 
with the average wage of all workers in each country, 
providing some indication of the relative financial 
attractiveness of nursing compared to other occupations. 
Second, the remuneration level in each country is converted 
into a common currency, the US dollar, and adjusted for 
purchasing power parity, to provide an indication of the 
relative economic well-being of nurses compared with their 
counterparts in other countries.
In most OECD countries, the remuneration of hospital 
nurses was at or slightly above the average wage of all 
workers in 2015 (Figure  8.16). In Mexico and Chile, the 
hospital nurses earned almost twice the average wage, 
while in Israel, luxembourg and Spain, the wages of 
nurses were respectively 49%, 38% and 28% greater than 
the average wage. In New Zealand, the United States, 
Greece and Australia, it was about 20% greater than the 
average wage. In most of the other countries, the wage of 
hospital nurses was roughly equal to the average wage in 
the economy, while in Hungary it was about 10% and in 
latvia about 20% lower.
When converted to a common currency (and adjusted for 
purchasing power parity), the remuneration of nurses was 
about five times higher in luxembourg than in Hungary and 
latvia (Figure 8.17). Nurses in the United States also had 
relatively high earnings compared with their counterparts 
in other countries, which explains, at least partly, the 
ability of the United States to attract many nurses from 
other countries.
The economic crisis in 2008 has had a varying impact on 
the remuneration of nurses (Figure 8.18). The Netherlands, 
for example, has seen a steady growth in remuneration for 
nurses. Some Central and Eastern European countries have 
introduced a series of measures in recent years to increase 
the retention of nurses and other health workers, including 
pay raises despite tight budget constraints. In Hungary, a 
staged increase of 20% in the salaries of nurses and doctors 
was introduced in 2012, phased over a three-year period. 
In the Czech Republic, nurses also benefitted from a pay 
increase following protests of hospital workers in 2011 
(although their pay raise was lower than that for doctors), 
accompanied by some improvement in other aspects of 
their working conditions (OECD, 2016).
Following the recession, the remuneration of nurses 
was cut down in some countries such as in Italy, which 
has frozen wage increase over the past few years. In 
Greece, the remuneration of nurses has been reduced 
significantly, by as much as 25% in real terms between 
2009 and 2015. 
Definition and comparability
The remuneration of nurses refers to average gross 
annual income, including social security contributions 
and income taxes payable by the employee. It should 
normally include all extra formal payments, such as 
bonuses and payments for night shifts and overtime. 
In most countries, the data relate specifically to 
nurses working in hospitals, although in Canada the 
data also cover nurses working in other settings. In 
some federal states, such as Australia, Canada and 
the United States, the level and structure of nurse 
remuneration is determined at the sub-national 
level, which may contribute to variations across 
jurisdictions.
Data refer only to registered (“professional”) nurses 
in Chile, Ireland and the United States, resulting in 
an over-estimation compared to other countries 
where lower-level nurses (“associate professional”) 
are also included. Data for Canada include registered 
(“professional”) nurses and unregistered nursing 
graduates. Data for New Zealand include all nurses 
employed by publically funded district health boards, 
registered and otherwise, and includes health 
assistants who have a different and significantly lower 
salary structure than registered nurses.
The data relate to nurses working full time, with the 
exception of Belgium where part-time nurses are also 
included (resulting in an under-estimation). The data 
for some countries do not include additional income 
such as overtime payments and bonuses (e.g. Italy 
and Slovenia). Informal payments, which in some 
countries represent a significant part of total income, 
are not reported.
The income of nurses is compared to the average wage 
of full-time employees in all sectors in the country. 
The source for the average wage of workers in the 
economy is the OECD Employment Database. For the 
calculation of remuneration trends in real terms, 
economy-wide GDP deflators are used.
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8.16. Remuneration of hospital nurses, ratio to 
average wage, 2015 (or nearest year)
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8.17. Remuneration of hospital nurses, USD PPP, 2015 
(or nearest year)
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8.18. Trend in the remuneration of hospital nurses in real terms, selected OECD countries, 2005-15
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Foreign-trained doctors and nurses
International migration of doctors and nurses is not a new 
phenomenon, but it has drawn considerable attention in 
recent years due to concerns that it might exacerbate 
shortages of skilled health workers in some countries. The 
Global Code of Practice on the International Recruitment of 
Health Personnel, adopted by the World Health Assembly 
in May 2010, was designed to respond to these concerns. 
It provides an instrument for countries to promote a more 
ethical recruitment of health personnel, encouraging 
countries to achieve greater “self-sufficiency” in the training 
of health workers, while recognising the basic human right 
of every person to migrate.
In 2015, the share of foreign-trained doctors ranged from 
3% or less in Estonia, the Slovak Republic, the Netherlands, 
Poland, Italy and Turkey, to more than 30% in Israel, New 
Zealand, Ireland, Norway and Australia (Figure 8.19). The 
very high proportion of foreign-trained doctors in Israel 
reflects not only the importance of immigration in this 
country, but also that about one third of new licenses 
are issued to people born in Israel but trained abroad. In 
Norway, roughly half of foreign-trained doctors are people 
who were born in the country but went to pursue their 
medical studies in another country. In luxembourg, all 
doctors are foreign-trained, in the absence of a medical 
school in the country.
Since 2000, the number and share of foreign-trained doctors 
has increased in many OECD countries (Figure 8.21). In the 
United States, the share has remained relatively stable over 
time, but the absolute number of doctors trained abroad has 
continued to increase (OECD, 2016). Sweden has experienced 
a strong rise in the number and share of foreign-trained 
doctors, with most of these doctors coming from Germany, 
Poland and Iraq. The number and share of foreign-trained 
doctors has also increased in France and Germany, though 
at a slower pace. In France, the rise is partly due to a fuller 
recognition of qualifications of foreign-trained doctors who 
were already working in the country, as well as the inflow 
of doctors from new EU member states. 
In nearly all OECD countries, the proportion of foreign-
trained nurses is much lower than that of foreign-trained 
doctors. However, given that the overall number of nurses 
is usually much greater than the number of doctors, the 
absolute number of foreign-trained nurses tends to be 
greater than for doctors (OECD, 2016). OECD countries vary 
widely in the number and share of foreign-trained nurses 
working in their health system (Figure 8.20). While there 
were almost no foreign-trained nurses working in Slovenia, 
Turkey, the Netherlands and Estonia in 2015, they make up 
over 25% of the nursing workforce in New Zealand, and 
between 10% and 20% in Switzerland, Australia and the 
United Kingdom. 
The number and share of foreign-trained nurses has 
increased over the past ten years in several OECD countries, 
including New Zealand, Australia and Canada (Figure 8.22). 
In Italy, an increase in the immigration of foreign-trained 
nurses between 2000 and 2008 was primarily driven 
by the arrival of many nurses trained in Romania, who 
now account for nearly half of all foreign-trained nurses. 
In France the share of nurses trained abroad remains 
low, but their numbers have been increasing, and many 
of these foreign-trained nurses are French citizens who 
received their diploma from Belgium. Israel has shown a 
steady decline in the share of nurses trained abroad while 
increasing the number of domestic nursing graduates (see 
the indicator on “Nursing graduates”). 
Definition and comparability
The data relate to foreign-trained doctors and nurses 
working in OECD countries measured in terms of total 
stocks. The OECD health database also includes data 
on the annual flows for most of the countries shown 
here, as well as by country of origin. The data sources 
in most countries are professional registries or other 
administrative sources. 
The main comparability limitation relates to 
differences in the activity status of doctors and 
nurses. Some registries are regularly updated, making 
it possible to distinguish doctors and nurses who are 
still actively working in health systems, while other 
sources include all doctors and nurses licensed to 
practice, regardless of whether they are still active 
or not. The latter will tend to over-estimate not only 
the number of foreign-trained doctors and nurses, but 
also the total number of doctors and nurses (including 
the domestically-trained), making the impact on the 
share unclear. 
The data source in some countries includes interns 
and residents, while these physicians in training are 
not included in other countries. Because foreign-
trained doctors are often over-represented in the 
categories of interns and residents, this may result in 
an under-estimation of the share of foreign-trained 
doctors in countries where they are not included (e.g., 
Austria, France and Switzerland). 
The data for Germany (on foreign-trained doctors) and 
some regions in Spain are based on nationality (or 
place of birth in the case of Spain), not on the place 
of training.
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8.19. Share of foreign-trained doctors, 2015  
(or nearest year)
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8.20. Share of foreign-trained nurses, 2015  
(or nearest year)
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8.21. Evolution in the share of foreign-trained 
doctors, selected OECD countries, 2000 to 2015
%
0
5
10
15
20
25
30
35
40
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
United Kingdom
Norway
France
United States
Sweden
Germany
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933604913
8.22. Evolution in the share of foreign-trained nurses, 
selected OECD countries, 2000 to 2015
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The statistical data for Israel are supplied by and under the responsibility of the relevant 
Israeli authorities. The use of such data by the OECD is without prejudice to the status of the 
Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of 
international law.
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Consultations with doctors 
Consultations with doctors can take place in doctors’ offices 
or clinics, in hospital outpatient departments or, in some 
cases, in patients’ own homes. In many European countries 
(e.g., Denmark, Italy, Netherlands, Norway, Portugal, Slovak 
Republic, Spain and the United Kingdom), patients are 
required or even incentivised to first consult a general 
practitioner (GP) about any new episode of illness. The GP 
may then refer them on to a specialist, if indicated. In other 
countries, patients may approach specialists directly.
In 2015, the number of doctor consultations per person 
ranged from less than 3 in Mexico and Sweden, to almost 
13 and 16 in Japan and Korea respectively (Figure  9.1). 
The OECD  average was 6.9  consultations per person 
per year, with most countries reporting between four 
and eight consultations. Cultural factors can play a role 
in explaining some of the variations across countries, 
although certain health system characteristics may also 
be important. Provider payment methods and the level of 
co-payments are particularly relevant. For example, some 
countries where doctors are paid on a fee-for-service basis 
tend to have above-average consultation rates (e.g. Japan 
and Korea), while countries with mostly salaried doctors 
tend to have below-average rates (e.g. Mexico, Finland and 
Sweden). However, there are examples of countries such 
as Switzerland and the United States where doctors are 
paid mainly by fee-for-service and where consultation rates 
are below average. In these countries, patient co-payments 
can be high, which may result in patients not consulting 
a doctor because of the cost of care (see the indicator on 
“Unmet needs for health care due to cost” in Chapter 5).
In Sweden and Finland, the low number of doctor 
consultations may also be explained partly by the fact 
that nurses and other health professionals play a more 
important role in providing primary care to patients in 
health centres, lessening the need for consultations with 
doctors (Delamaire and lafortune, 2010).
The average number of doctor consultations per person 
across the OECD has remained relatively stable since 2000 
(from 6.5 to 6.9). But in some countries there have been 
large increases over time (Korea, Turkey). In some other 
countries, the number of doctor consultations per person 
fell. This was the case in Japan, the Czech Republic and the 
Slovak Republic, although the numbers remains well above 
average in these three countries.
Information on the number of doctor consultations per 
person can be used to estimate the annual numbers of 
consultations per doctor. This indicator should not be taken 
as a measure of doctors’ productivity, since consultations 
can vary in length and effectiveness, and because it excludes 
the services doctors might deliver for hospital inpatients, 
as well as on administration and research. Keeping this in 
mind, the estimated number of consultations per doctor is 
highest in Korea and Japan, followed by Turkey and Hungary 
(Figure 9.2). On the other hand, the estimated number of 
consultations per doctor was lowest in Sweden and Norway, 
where consultations with doctors in both primary care and 
hospital settings tend to be focused towards patients with 
more severe and complex cases.
The number and type of doctor consultations can vary 
among different socio-economic groups in each country. 
An OECD study found that the probability of a visit to the 
GP tends to be equally distributed in most countries, but in 
nearly all countries, higher income people are more likely 
to see a specialist than those with low income, and also 
more frequently (Devaux and de looper, 2012).
Definition and comparability
Consultations with doctors refer to the number of 
contacts with physicians, including both generalists 
and specialists. There are variations across countries 
in the coverage of these consultations, notably in 
outpatient departments of hospitals. The data come 
mainly from administrative sources, although in some 
countries (Ireland, Italy, Netherlands, New Zealand, 
Spain and Switzerland) the data come from health 
interview surveys. Estimates from administrative 
sources tend to be higher than those from surveys 
because of problems with recall and non-response 
rates.
In Hungary, the figures include consultations for 
diagnostic exams such as CT and MRI scans (resulting 
in an over-estimation). The figures for the Netherlands 
exclude contacts for maternal and child care. The data 
for Portugal exclude visits to private practitioners 
(resulting in an under estimation). In Germany, the 
data include only the number of cases of physicians’ 
treatment according to reimbursement regulations 
under the Social Health Insurance Scheme (a case only 
counts the first contact over a three-month period, 
even if the patient consults a doctor more often, 
leading to an under-estimation). Telephone contacts 
are included in a few countries (e.g. Spain). In Turkey, 
a majority of consultations with doctors occur in 
outpatient departments in hospitals. 
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9.1. Number of doctor consultations per person, 2000 and 2015 (or nearest year)
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9.2. Estimated number of consultations per doctor, 2015 (or nearest year)
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Medical technologies 
New medical technologies are improving diagnosis and 
treatment, but they are also increasing health spending. 
This section presents data on the availability and use 
of two  diagnostic imaging technologies: computed 
tomography  (CT) scanners and magnetic resonance 
imaging  (MRI) units. CT and MRI exams help physicians 
diagnose a range of conditions. Unlike conventional 
radiography and CT scanning, MRI exams do not expose 
patients to ionising radiation.
The availability of CT scanners and MRI units has increased 
rapidly in most OECD countries over the past two decades. 
Japan has, by far, the highest number of MRI and CT scanners 
per capita, followed by the United States for MRI units and 
by Australia for CT scanners (Figures 9.3 and 9.4). Germany, 
Greece, Iceland, Italy, Korea and Switzerland also have 
significantly more MRI and CT scanners per capita than the 
OECD average. The number of MRI units and CT scanners 
per population is the lowest in Mexico, Hungary, Israel and 
the United Kingdom.
There is no general guideline or benchmark regarding the 
ideal number of CT scanners or MRI units per population. 
However, if there are too few units, this may lead to access 
problems in terms of geographic proximity or waiting 
times. If there are too many, this may result in an overuse 
of these costly diagnostic procedures, with little if any 
benefits for patients.
Data on the use of these diagnostic scanners are available 
for a smaller group of countries. Based on this more 
limited country coverage, the number of MRI exams per 
capita is highest in Turkey, Germany, the United States, 
Japan and France, all of which have more than 100 MRI 
exams per 1  000  population (Figure  9.5). In the United 
States, the (absolute) number of MRI exams more than 
doubled between 2000 and 2015. In Turkey, it has grown 
even faster, by three times between 2008 and 2015. In this 
country, there is growing evidence that MRI exams are 
being systematically prescribed for patients with various 
health problems, resulting in overuse of these tests. The 
number of CT exams per capita is highest in the United 
States, followed by Japan and luxembourg (Figure 9.6).
There are large variations in the use of CT and MRI 
scanners not only across countries, but also within 
countries. For example, in Belgium, there was almost 
a two-fold variation in MRI and CT  exams between 
provinces with the highest and lowest rates in 2010. In 
the United Kingdom (England), the utilisation of both 
types of diagnostic exams is generally much lower, but 
the variation across regions is greater, with almost a four-
fold difference between the Primary Care Trusts that had 
the highest rates and lowest rates of MRI and CT exams in 
2010/11. In Canada, there has been a strong rise in the use 
of both MRI and CT exams in all parts of the country over 
the past decade, but there continues to be wide variations 
across provinces (OECD, 2014).
Clinical guidelines have been developed in several OECD 
countries to promote a more rational use of MRI and CT 
exams. In the United Kingdom, the National Institute for 
Health and Clinical Excellence (NICE) has issued a number 
of guidelines on the appropriate use of MRI and CT exams 
(NICE, 2012). In the United States, a “Choosing Wisely” 
campaign has developed clear guidelines for doctors and 
patients to reduce the use of unnecessary diagnostic tests 
and procedures. The guidelines include, for instance, 
avoiding imaging studies such as MRI, CT or x-rays for 
acute low back pain without specific indications (Choosing 
Wisely, 2015). A similar “Choosing Wisely” campaign was 
launched in Canada in 2014, and work has also started 
in several other OECD countries to produce similar clear 
guidelines and recommendations to promote a more 
efficient use of diagnostic tests and other procedures. It is 
still too early to tell to what extent these campaigns will 
succeed in reducing the overuse of MRI and CT exams.
Definition and comparability
The data in most countries cover MRI units and 
CT scanners installed both in hospitals and the 
ambulatory sector, but the coverage is more limited 
in some countries. MRI units and CT scanners outside 
hospitals are not included in Belgium, Portugal, 
Sweden and Switzerland (for MRI units). For the 
United Kingdom, the data only include equipment 
in the public sector. For Australia and Hungary, the 
number of MRI units and CT scanners includes only 
those eligible for public reimbursement. 
Similarly, MRI and CT exams performed outside 
hospitals are not included in Austria, Portugal, 
Switzerland and the United Kingdom. In Australia, the 
data only include exams for private patients (in or out 
of hospitals); while in Korea and the Netherlands they 
only include publicly-financed exams.
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9.3. MRI units, 2015 (or nearest year)
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9.4. CT scanners, 2015 (or nearest year)
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9.5. MRI exams, 2015 (or nearest year)
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9.6. CT exams, 2015 (or nearest year)
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Hospital beds
The number of hospital beds provides a measurement of 
the resources available for delivering services to inpatients 
in hospitals. This section presents data on the number of 
overall hospital beds in 2000 and 2015 and for different 
types of care (curative care, rehabilitative care, long-term 
care and other functions). It also presents an indicator of 
bed occupancy rates over time, focussing on curative care 
beds. 
Among OECD countries, the number of hospital beds per 
capita remains highest in Japan and Korea, with 13.2 and 
11.5 beds per 1 000 population in 2015 (Figure 9.7). In both 
countries, hospitals have so-called “social admissions”, 
that is, a significant part of hospital beds are devoted to 
long-term care to tackle the increasing number of ageing 
population. The number of hospital beds is also well above 
the OECD average in the Russian Federation, Germany 
and Austria. On the other hand, some of the key partner 
countries in Asia (India and Indonesia) have very few 
hospital beds compared to the OECD average. This is also 
the case for countries in latin America (Mexico, Colombia, 
Chile and Brazil).
The number of hospital beds per capita has decreased over 
the past decade in most OECD countries, falling on average 
from 5.6 per 1 000 population in 2000 to 4.7 in 2015. This 
reduction is part of a voluntary effort in most countries, 
partly driven by progress in medical technology, which has 
enabled a move to day surgery for a number of procedures 
and a reduced need for hospitalisation. In many European 
countries, the financial and economic crisis, which started 
in 2008, provided an additional stimulus to reduce hospital 
capacity in line with policies to reduce public spending on 
health. Only in Korea, China and Turkey have the numbers 
of hospital beds per capita grown since 2000. Generally, the 
largest decreases in the number of beds over time have 
been observed in countries with an initially high number 
of beds in 2000.
On average, about three-quarters of hospital beds (77%) are 
allocated for curative care across OECD countries (Figure 9.8). 
The rest are distributed between long-term care (12%), 
rehabilitation (9%), and other types of care (2%). However, in 
some countries, the share of beds allocated for rehabilitation 
and long-term care is much greater than the average. In 
Korea and Japan, for the reasons previously mentioned, 
37% and 20% of hospital beds, respectively, are allocated 
for long-term care. In Finland, this share is also relatively 
high (28%), as local governments (municipalities) use beds 
in health care centres (which are defined as hospitals) for 
at least some of the institutional long-term care needs. In 
France, Germany and Poland, around a quarter of all hospital 
beds are devoted to rehabilitative care.
In several countries, the reduction in the number of 
hospital beds has been accompanied by an increase in 
their occupancy rates. The occupancy rate of curative care 
beds stood at 76% on average across OECD countries in 
2015, only slightly above the 2000 level (Figure 9.9). This is 
because the general increase in occupancy rates (driven 
by the reduction in number of beds) is offset by a few 
large decreases in occupancy rates observed in Norway, 
Japan and latvia, along with some smaller decreases in 
Switzerland, Germany, the Slovak Republic, Korea and 
more. Ireland and Israel had the highest rate of hospital 
bed occupancy at approximately 94%, followed by Canada 
at 92% and the United Kingdom at 84%.
Definition and comparability
Hospital beds are defined as all beds that are regularly 
maintained and staffed and are immediately available 
for use. They include beds in general hospitals, mental 
health and substance abuse hospitals, and other 
specialty hospitals. Beds in residential long-term care 
facilities are excluded (OECD, 2017).
Curative care beds accommodate patients where the 
principal intent is to do one or more of the following: 
cure illness or provide definitive treatment of injury, 
perform surgery, relieve symptoms of illness or 
injury (excluding palliative care), reduce severity of 
illness or injury, protect against exacerbation and/
or complication of illness and/or injury which could 
threaten life or normal functions, perform diagnostic 
or therapeutic procedures, manage labour (obstetric). 
In some countries, these beds include all (curative and 
non-curative) psychiatric care beds. 
Rehabilitative care beds accommodate patients with 
the principal intent to stabilise, improve or restore 
impaired body functions.
long-term care beds are hospital beds accommodating 
patients requiring long-term care due to chronic 
impairments and a reduced degree of independence 
in activities of daily living. They include beds in long-
term care departments of general hospitals, beds for 
long-term care in specialty hospitals, and beds for 
palliative care.
The occupancy rate for curative (acute) care beds is 
calculated as the number of hospital bed-days related 
to curative care divided by the number of available 
curative care beds (multiplied by 365).
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9.7. Hospital beds per 1 000 population, 2000 and 2015 (or nearest year)
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9.8. Hospital beds by function of health care, 2015 (or nearest year)
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9.9. Occupancy rate of curative (acute) care beds, 2000 and 2015 (or nearest year)
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Hospital discharges
Hospital discharge rates measure the number of patients 
who leave a hospital after staying at least one night. 
Together with the average length of stay, they are important 
indicators of hospital activities. Hospital activities are 
affected by a number of factors, including the capacity 
of hospitals to treat patients, the ability of the primary 
care sector to prevent avoidable hospital admissions, 
and the availability of post-acute care settings to provide 
rehabilitative and long-term care services.
In 2015, hospital discharge rates were highest in Austria and 
Germany, followed by lithuania and the Russian Federation 
(Figure 9.10). They were the lowest in Colombia, Mexico, 
Brazil and Canada. In general, those countries that have 
more hospital beds tend to have higher discharge rates. 
For example, the number of hospital beds per capita in 
Austria and Germany is more than two-times greater than 
in Canada and Spain, and discharge rates are also more 
than two-times larger (see indicator on “Hospital beds”).
Across OECD countries, the main conditions leading to 
hospitalisation in 2015 were circulatory diseases, pregnancy 
and childbirth, injuries and other external causes, diseases 
of the digestive system, cancers, and respiratory diseases.
Germany, Austria, Hungary and latvia have the highest 
discharge rates for circulatory diseases; with Austria, Greece, 
Germany and Hungary the highest for cancers (Figures 9.11 
and 9.12). While the high rates of hospital discharges for 
circulatory diseases in Hungary are associated with lots 
of people having heart and other circulatory diseases 
(see indicator on “Mortality from circulatory diseases” in 
Chapter 3), this is not the case for Germany and Austria. 
Similarly, cancer incidence is not higher in Austria, Germany 
or Greece than in most other OECD countries (see indicator 
on “Cancer incidence” in Chapter 3). In Austria, the high 
discharge rate is associated with a high rate of hospital 
readmissions for further investigation and treatment of 
cancer patients (European Commission, 2008).
Trends in hospital discharge rates vary widely across OECD 
countries. Since 2000, discharge rates have increased in 
some countries where discharge rates were low in 2000 
and have increased rapidly since then (e.g. Korea, Turkey 
and China) as well as in other countries such as Germany 
where it was already above-average. In other countries 
(e.g. France, Portugal and the United States), they have 
remained relatively stable, while in other countries (e.g. 
Finland, Hungary, Iceland, Italy and latvia), discharge rates 
fell between 2000 and 2015.
Trends in hospital discharges reflect the interaction of 
several factors. Demand for hospitalisation may grow 
as populations’ age, given that older population groups 
account for a disproportionately high percentage of 
hospital discharges. However, population ageing alone 
may be a less important factor in explaining trends in 
hospitalisation rates than changes in medical technologies 
and clinical practices. The diffusion of new medical 
interventions often gradually extends to older population 
groups, as interventions become safer and more effective 
for people at older ages. But the diffusion of new medical 
technologies may also involve a reduction in hospitalisation 
if it involves a shift from procedures requiring overnight 
stays in hospitals to same-day procedures. In the group 
of countries where discharge rates have decreased since 
2000, there has been a strong rise in the number of day 
surgeries (see indicator  on “Ambulatory surgery”). The 
number of beds available in a hospital might also affect 
the timing of patient discharges, which in turn affects the 
average length of stay (see indicator on “Average length of 
stay in hospitals”). 
Hospital discharge rates vary not only across countries, 
but also within countries. In several OECD countries (e.g., 
Canada, Finland, Germany, Italy, Portugal, Spain and the 
United Kingdom), hospital medical admissions (excluding 
admissions for surgical interventions) vary by more 
than two-times across different regions in the country 
(OECD, 2014).
Definition and comparability
Discharge is defined as the release of a patient who 
has stayed at least one night in hospital. It includes 
deaths in hospital following inpatient care. Same-day 
discharges are usually excluded, with the exceptions 
of Chile, Japan, Norway, the Slovak Republic and 
the United States which include some same-day 
separations.
Healthy babies born in hospitals are excluded 
from hospital discharge rates in several countries 
(Australia, Austria, Canada, Chile, Estonia, Finland, 
Greece, Ireland, luxembourg, Mexico, Norway). 
These comprise around 3 to 10% of all discharges. 
Data for some countries do not cover all hospitals. 
For instance, data for Mexico, New Zealand and the 
United Kingdom are restricted to public or publicly-
funded hospitals only. Data for Ireland cover public 
acute and psychiatric (public and private) hospitals. 
Data for Canada and the United States include only 
acute care/short-stay hospitals.
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9.10. Hospital discharges, 2015 (or nearest year)
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9.11. Hospital discharges for circulatory diseases, 2015 
(or nearest year)
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9.12. Hospital discharges for cancers, 2015 
(or nearest year)
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Average length of stay in hospitals 
The average length of stay in hospitals is often regarded 
as an indicator of efficiency. All else being equal, a shorter 
stay will reduce the cost per discharge and shift care from 
inpatient to less expensive post-acute settings. longer stays 
can be indicative of poor-value care: inefficient hospital 
processes may cause delays in providing treatment; errors 
and poor-quality care may mean patients need further 
treatment or recovery time; poor care co-ordination may 
leave people stuck in hospital waiting for ongoing care 
to be arranged. At the same time, some people may be 
discharged too early, when staying in hospital longer could 
have improved their outcomes or reduced chances of re-
admission.
In 2015, the average length of stay in hospitals for all causes 
across OECD countries was about eight days (Figure 9.13). 
Turkey and Mexico had the shortest stays, with about four 
days, whereas Japan and Korea had the longest stays, with 
over 16 days. In most countries, the average length of stay 
has fallen since 2000, with reductions particularly large 
in Japan, Switzerland, the United Kingdom and Israel. 
However, the average length of stay increased in Korea 
and Hungary, with very slight increases in Italy, Canada 
and South Africa. 
Focusing on specific diseases or conditions can remove 
some of the effect of different case mix and severity. 
Average length of stay following birth by normal delivery 
was slightly less than three  days on average in 2015 
(Figure  9.14). This ranged from less than two  days in 
Mexico, Turkey, the United Kingdom, Canada, Iceland and 
the Netherlands, to around five days in the Slovak Republic 
and Hungary. In almost all OECD countries, the average 
length of stay following a delivery has fallen since 2000.
The average length of stay following acute myocardial 
infarction was 6.5 days on average in 2015. It was shortest 
in Scandinavian countries (Norway, Denmark and Sweden), 
Turkey and the Slovak Republic, at fewer than five days, 
and highest in Chile and Germany, at more than ten days 
(Figure  9.15). Average length of stay following acute 
myocardial infarction has fallen in all OECD countries 
since 2000, with reductions particularly marked in Austria, 
Finland and the Slovak Republic.
Beyond differences in clinical need, several factors can 
explain these cross-country variations. The combination of 
an abundant supply of beds with the structure of hospital 
payments may provide hospitals with incentives to keep 
patients longer. A growing number of countries (France, 
Germany, Poland) have moved to prospective payment 
methods, often based on diagnosis-related groups (DRGs), 
to set payments based on the estimated cost of hospital care 
in advance of service provision. These payment methods 
encourage providers to reduce the cost of each episode of 
care. In Switzerland, cantons which moved from per diem 
payments to DRG-based payments have experienced a 
reduction in their lengths of stay (OECD and WHO, 2011).
Strategic reductions in hospital bed numbers alongside 
development of community care services can also be 
expected to shorten average length of stay, as seen in 
Denmark’s quality-driven reforms of the hospital sector 
(OECD, 2013). Other options include promoting the uptake 
of less invasive surgical procedures, the expansion of early 
discharge programmes which enable patients to return 
home to receive follow-up care, and support for hospitals 
to improve care co-ordination.
A few countries also collect data on delayed discharges – 
the number of days that people stay in hospital after a 
doctor declares them ready to be discharged or transferred. 
This provides a more precise measure of when a stay in 
a hospital is unnecessarily long. Denmark reported just 
under 10 additional bed days per 1 000 population in 2014, 
a figure that has been relatively stable over time. Norway 
saw a sharp drop in delayed discharges, from 28 additional 
bed days per 1 000 population in 2011 to about 12 in 2015. 
Within the United Kingdom, England saw a significant 
increase since 2013, reaching over 30 additional bed days 
per 1  000  population in 2015. In England, this increase 
largely reflects ongoing health or social care services not 
being ready to receive patients (OECD 2017).
Definition and comparability
Average length of stay refers to the average number 
of days that patients spend in hospital. It is generally 
measured by dividing the total number of days 
stayed by all inpatients during a year by the number 
of admissions or discharges. Day cases are excluded. 
The data cover all inpatient cases (including not only 
curative/acute care cases) for most countries, with 
the exceptions of Canada, Japan and the Netherlands 
where the data refer to curative/acute care only 
(resulting in an under-estimation).
Healthy babies born in hospitals are excluded from 
hospital discharge rates in several countries (Australia, 
Austria, Canada, Chile, Estonia, Finland, Greece, 
Ireland, luxembourg, Norway, Mexico), resulting in a 
slight over-estimation of the length of stay (e.g. the 
inclusion of healthy newborns would reduce the AlOS 
by 0.5 days in Canada). These comprise around 3 to 
10% of all discharges. 
Data for normal delivery refer to ICD-10 code O80; for 
AMI they refer to ICD-10 codes I21-I22. 
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9.13. Average length of stay in hospital, 2000 and 2015 (or nearest year)
0
5
10
15
20
25
16
.5
16
.1
11
.4
10
.1
9.
6
9.
5
9.
4
9.
3
9.
1
9.
0
8.
8
8.
5
8.
4
8.
3
7.
9
7.
8
7.
8
7.
6
7.
6
7.
4
7.
3
7.
3
7.
2
7.
0
7.
0
6.
8
6.
8
6.
8
6.
7
6.
5
6.
4
6.
3
6.
2
6.
1
5.
9
5.
7
5.
5
5.
5
5.
5 4
.2
3.
9
2000 2015
Days
Ja
pa
n¹
Ko
rea
Ru
ss
ian
 Fe
de
rat
ion
Fra
nc
e
Ch
ina
Hu
ng
ary
Fin
lan
d
Cz
ec
h R
ep
ub
lic
Lu
xe
mb
ou
rg
Ge
rm
an
y
Po
rtu
ga
l
Au
str
ia
Sw
itz
erl
an
d
La
tvi
a
Lit
hu
an
ia
Ita
ly
OE
CD
35
Be
lgi
um
Es
ton
ia
Ca
na
da
¹
Po
lan
d
Sp
ain
Slo
va
k R
ep
ub
lic
Gr
ee
ce
Un
ite
d K
ing
do
m
Isr
ae
l
Ne
w 
Ze
ala
nd
Slo
ve
nia
No
rw
ay
So
uth
 Af
ric
a
Ire
lan
d
Ice
lan
d
Ne
the
rla
nd
s¹
Un
ite
d S
tat
es
Sw
ed
en
Ch
ile
Au
str
ali
a
De
nm
ark
Co
lom
bia
Me
xic
o
Tu
rke
y
1. Data refer to average length of stay for curative (acute) care (resulting in an under-estimation). In Japan, the average length of stay for all inpatient 
care was 29 days in 2015 (down from 39 days in 2000).
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933605179
9.14. Average length of stay for normal delivery, 2015 
(or nearest year)
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9.15. Average length of stay for acute myocardial 
infarction (AMI), 2015 (or nearest year)
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Hip and knee replacement
Significant advances in surgical treatment have provided 
effective options to reduce the pain and disability associated 
with certain musculoskeletal conditions. Joint replacement 
surgery (hip and knee replacement) is considered the most 
effective intervention for severe osteoarthritis and hip 
fractures, reducing pain and disability and restoring some 
patients to near normal function.
Osteoarthritis is one of the ten most disabling diseases 
in developed countries. Worldwide, estimates show that 
10% of men and 18% of women aged over 60 years have 
symptomatic osteoarthritis, including moderate and 
severe forms (WHO, 2014). Age is the strongest predictor 
of the development and progression of osteoarthritis. It 
is more common in women, increasing after the age of 50 
especially in the hand and knee. Other risk factors include 
obesity, physical inactivity, smoking, excessive alcohol 
consumption and injuries. While joint replacement surgery 
is mainly carried out among people aged 60 and over, it can 
also be performed on people at younger ages.
In 2015, Switzerland, Germany, Austria and Belgium had 
the highest rates for both of hip and knee replacement 
(Figures 9.16 and 9.17). In Mexico and Chile, the rates of hip 
and knee replacement are particularly low, with less than 
40 hip replacements and less than 10 knee replacements 
per 100 000 population. Differences in population structure 
may explain part of this variation across countries, and 
age standardisation reduces it to some extent. Still, large 
differences persist and the country ranking does not 
change significantly after age standardisation (McPherson 
et al., 2013; OECD 2014).
National averages can mask important variation in 
hip and knee replacement rates within countries. In 
Australia, Canada, Germany, France and Italy, the rate 
of knee replacement is more than two  times higher in 
certain regions compared with others, even after age-
standardisation (OECD, 2014). 
The number of hip and knee replacements has increased 
rapidly since 2000 in most OECD countries (Figures 9.18 and 
9.19). On average, the rate of hip replacement increased 
by 30% between 2000 and 2015 and the rate of knee 
replacement nearly doubled. For hip replacement, most 
OECD countries show increasing trends of varying degrees, 
but countries like Ireland and Portugal show much slower 
growth than the average, with Ireland being the only OECD 
country to show a decrease in hip replacement rates from 
2000. Similarly, knee surgeries have seen a large increase in 
the past decades in all OECD countries, with the exception 
of Chile and Estonia, which showed small decreases in the 
past few years.
Definition and comparability
Hip replacement is a surgical procedure in which 
the hip joint is replaced by a prosthetic implant. It is 
generally conducted to relieve arthritis pain or treat 
severe physical joint damage following hip fracture.
Knee replacement is a surgical procedure to replace 
the weight-bearing surfaces of the knee joint in order 
to relieve the pain and disability of osteoarthritis. It 
may also be performed for other knee diseases such 
as rheumatoid arthritis.
Classification systems and registration practices vary 
across countries, which may affect the comparability of 
the data. While most countries include both total and 
partial replacement, some countries only include total 
hip replacement. In Ireland, Mexico, New Zealand and 
the United Kingdom, the data only include activities in 
publicly-funded hospitals, therefore underestimating 
the number of total procedures presented here (for 
example, approximately 15% of all hospital activity 
in Ireland is undertaken in private hospitals). Data 
for Portugal relate only to public hospitals on the 
mainland. Data for Spain only partially include 
activities in private hospitals.
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9.16. Hip replacement surgery, 2015 (or nearest year)
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9.17. Knee replacement surgery, 2015 (or nearest year)
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9.18. Hip replacement surgery trends,  
2000 to 2015 (or nearest year)
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9.19. Knee replacement surgery trends,  
2000 to 2015 (or nearest year)
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Caesarean sections
Rates of caesarean delivery have increased over time in 
nearly all OECD countries, although in a few countries this 
trend has reversed, at least slightly, in the past few years. 
Reasons for the increase include the rise in first births among 
older women and in multiple births resulting from assisted 
reproduction, malpractice liability concerns, scheduling 
convenience for both physicians and patients, and the 
increasing preference of some women to have a caesarean 
delivery. Nonetheless, caesarean delivery continues to 
result in increased maternal mortality, maternal and infant 
morbidity, and increased complications for subsequent 
deliveries, raising questions about the appropriateness of 
caesarean deliveries that may not be medically required.
In 2015, much as in previous years, caesarean section rates 
were lowest in Nordic countries (Iceland, Finland, Sweden 
and Norway), Israel and the Netherlands, with rates ranging 
from 15% to 17% of all live births (Figure 9.20). They were 
highest in Turkey, Mexico and Chile, with around one out 
of two live births delivered by caesarean section. 
Caesarean rates have increased since 2000 in most OECD 
countries, with the average rising from 20% in 2000 to 28% 
in 2015, although the rate of growth seems to have slowed 
over the past 5 years (Figure 9.21). Growth rates have been 
particularly rapid in Poland, the Slovak Republic and the 
Czech Republic which have historically had relatively low 
rates, as well as some of the countries with the highest 
rates today (Turkey, Korea). In other countries, the growth 
rate has shown a notable slowing since the mid-2000s, such 
as in Israel, Finland and Sweden. In Italy, caesarean rates 
have come down significantly in recent years, although 
they remain among the highest in Europe.
There can be substantial variations in caesarean rates across 
regions and hospitals within the same country. In Italy, there 
continue to be huge variations in caesarean rates, mainly 
driven by the southern regions of the country. Spain shows 
similar large variations across its regions (OECD, 2014).
In several countries, there is evidence that private hospitals 
tend to perform more caesarean sections than public 
hospitals. In France, private for-profit hospitals authorised 
to provide maternity care for pregnancies without 
complications have caesarean rates as high as public 
hospitals which have to deal with more complicated cases 
(FHF, 2008). In Switzerland, caesarean sections have been 
found to be substantially higher in private clinics (41%) 
than in public hospitals (30.5%) (OFSP, 2013).
A number of countries have taken different measures to 
reduce unnecessary caesarean sections. Public reporting, 
provider feedback, the development of clearer clinical 
guidelines, and adjustments to financial incentives have 
been used to try to reduce the inappropriate use of 
caesareans. In Australia, where caesarean section rates are 
high relative to most OECD countries, a number of States 
have developed clinical guidelines and required reporting 
of hospital caesarean section rates, including investigation 
of performance against the guidelines. These measures 
have discouraged variations in practice and contributed 
to slowing down the rise in caesarean sections. Other 
countries have reduced the gap in hospital payment rates 
between a caesarean section and a normal delivery, with 
the aim to discourage the inappropriate use of caesareans 
(OECD, 2014).
Definition and comparability
The caesarean section rate is the number of total 
caesarean deliveries performed per 100 live births. 
In Ireland, Mexico, New Zealand and the United 
Kingdom, the data only include activities in publicly-
funded hospitals (though for Ireland all of maternity 
units are located in publicly-funded hospitals). This 
may lead to an underestimate of caesarean section 
rates in these countries, since there is some evidence 
that private hospitals tend to perform more caesarean 
sections than public hospitals.
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9.20. Caesarean section rates, 2015 (or nearest year)
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9.21. Caesarian section trends in selected OECD countries, 2000 to 2015 (or nearest year)
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Ambulatory surgery
In the past few decades, the number of surgical procedures 
carried out on a same-day basis has markedly increased 
in OECD countries. Advances in medical technologies 
–  in particular the diffusion of less invasive surgical 
interventions  – and better anaesthetics have made this 
development possible. These innovations have improved 
patient safety and health outcomes, and have also, in 
many cases, reduced the unit cost per intervention by 
shortening the length of stay in hospitals. However, the 
impact of the rise in same-day surgeries on overall health 
spending may not be straightforward since the reduction in 
unit cost (compared to inpatient surgery), may be offset by 
the overall growth in the volume of procedures performed. 
There is also a need to take into account any additional cost 
related to post-acute care and community health services 
following the interventions.
Cataract surgery and tonsillectomy provide good examples 
of high-volume surgeries which are now carried out mainly 
on a same-day basis in many OECD countries. 
Day surgery now accounts for 90% or more of all cataract 
surgeries in a majority of OECD countries (Figure  9.22). 
In several countries, nearly all cataract surgeries are 
performed as day cases. However, the use of day surgery 
is still relatively low in Poland, Turkey, Hungary, the Slovak 
Republic and Mexico, where they still account for less than 
two thirds of all cataract surgeries. While this may be partly 
explained by limitations in the data coverage of outpatient 
activities in hospital or outside hospital, this may also 
reflect more advantageous reimbursement for inpatient 
stays or constraints on the development of day surgery. 
The number of cataract surgeries performed on a same-day 
basis has grown very rapidly since 2000 in many countries, 
such as Portugal and Austria (Figure 9.22). Whereas fewer 
than 10% of cataract surgeries in Portugal were performed 
on a same-day basis in 2000, this proportion has increased 
to 97% by 2015. In Austria, the share of cataract surgeries 
performed as day cases increased from 1% only in 2000 to 
75% in 2015. The number of cataract surgeries carried out 
as day cases has also risen rapidly in many other countries, 
with many of them carrying out 90% or more cases as 
ambulatory in 2015.
Tonsillectomy is one of the most frequent surgical 
procedures on children, usually performed on children 
suffering from repeated or chronic infections of the tonsils 
or suffering from breathing problems or obstructive sleep 
apnea due to large tonsils. Although the operation is 
performed under general anaesthesia, it is now carried 
out mainly as a same-day surgery in several countries, 
with children returning home the same day (Figure 9.23). 
However, the percentage of cases is not yet as high as for 
cataract, with a 34% OECD average and a maximum of 86% 
in Finland. Many countries still lag behind, but show signs 
of catching up. These large differences in the share of same-
day surgery may reflect variations in the perceived risks of 
postoperative complications, or simply clinical traditions 
of keeping children for at least one night in hospital after 
the operation.
Financial incentives can affect the extent to which minor 
surgeries are conducted on a same-day basis. In Hungary, 
budget caps for same-day surgery financially discouraged 
the practice. A recent policy change to abolish this budget 
cap is expected to increase the rates of same-day surgeries 
for cataracts and other minor surgeries. In Denmark and 
France, diagnostic-related group (DRG) systems have been 
adjusted to incentivise same-day surgery. In the United 
Kingdom, a financial incentive of approximately GBP 300 
per case was awarded for selected surgical procedures 
if the patient was managed on a day-case basis (OECD, 
2017).
Definition and comparability
Cataract surgery consists of removing the lens of the 
eye because of the presence of cataracts which are 
partially or completely clouding the lens, and replacing 
it with an artificial lens. It is mainly performed on 
elderly people. Tonsillectomy consists of removing the 
tonsils, glands at the back of the throat. It is mainly 
performed on children.
The data for several countries do not include outpatient 
cases in hospital or outside hospital (i.e., patients who 
are not formally admitted and discharged), leading 
to some under-estimation. In Ireland, Mexico, New 
Zealand and the United Kingdom, the data only include 
cataract surgeries carried out in public or publicly-
funded hospitals, excluding any procedures performed 
in private hospitals (in Ireland, it is estimated that 
approximately 15% of all hospital activity is undertaken 
in private hospitals). Data for Portugal relate only to 
public hospitals on the mainland. Data for Spain only 
partially include activities in private hospitals.
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9.22. Share of cataract surgeries carried out as ambulatory cases, 2000 and 2015 (or nearest year)
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9.23. Share of tonsillectomy carried out as ambulatory cases, 2000 and 2015 (or nearest year)
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Pharmaceutical expenditure
Pharmacists and pharmacies
Pharmaceutical consumption
Share of generic market
Research and development in the pharmaceutical sector
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10. PHARMACEUTICAL SECTOR
Pharmaceutical expenditure
Pharmaceuticals play a vital role in the health system. 
Policymakers need to balance access for new medicines 
while providing the right incentives to industry and 
acknowledging that health care budgets are limited. After 
inpatient and outpatient care, pharmaceuticals represent 
the third largest expenditure item of health care spending; 
accounting for more than a sixth (16%) of health expenditure 
on average across OECD countries in 2015 (not taking into 
account spending on pharmaceuticals in hospitals).
Similar to other health care functions, the cost of 
pharmaceuticals is predominantly covered by government 
financing or compulsory insurance schemes (Figure 10.1). 
Across OECD countries, these schemes cover on average 
around 57% of all retail pharmaceutical spending, with 
out-of-pocket payments (39%) and voluntary private 
insurance (4%) financing the remaining part. Coverage 
is most generous in Germany and luxembourg where 
government and compulsory insurance schemes pay for 
80% or more of all pharmaceutical costs. In eight OECD 
countries, public or mandatory schemes cover less than 
half the amount spent on medicines. This is the case in 
Poland (34%), latvia (35%), Canada and the United States 
(both 36%). In these countries, voluntary private insurance 
or out-of-pocket payments play a much bigger role in 
financing pharmaceuticals.
The total retail pharmaceutical bill across OECD countries 
was more than USD 800 billion in 2015. However, there are 
wide variations in pharmaceutical spending per capita 
across countries, reflecting differences in volume, patterns 
of consumption and pharmaceutical prices, as well as in 
the use of generics (Figure 10.2). The United States spent 
far more on pharmaceuticals than any other OECD country 
on a per capita basis (USD 1 162), and more than double the 
OECD average. Switzerland (USD 982) and Japan (USD 798) 
also spent significantly more on medicines per capita 
than other OECD countries. At the other end of the scale, 
Denmark (USD 282), Israel (USD 313) and Estonia (USD 326) 
had relatively low spending levels. 
Around 80% of total retail pharmaceutical spending 
is for prescribed medicines, with the rest spent on 
over-the-counter medicines  (OTC). OTC medicines are 
pharmaceuticals that can generally be bought without 
prescription and their costs are in most cases fully borne 
by patients. The share of OTC medicines is particularly high 
in Poland, accounting for half of pharmaceutical spending, 
but also in Spain (34%) and Australia (31%).
Average annual pharmaceutical spending growth in the 
2009-15 period has been much lower compared with pre-
crisis years (Figure 10.3). Between 2009 and 2015, expenditure 
on pharmaceuticals dropped by 0.5% per year on average 
across the OECD – mainly driven by cuts in spending by 
government or compulsory schemes and patent expiry of 
some “blockbuster” pharmaceuticals – while it increased 
by 2.3% each year in the 2003-09 period. The reduction 
was particularly steep in European countries that were 
affected by the economic and financial crisis, such as 
Greece (-6.5%), Portugal (-5.9%) and Ireland (-4.4%). As a 
response to mounting pressures on public budgets, many 
governments made reducing pharmaceutical expenditure 
a priority to rein in public spending. The policy measures 
included the de-listing of products (i.e.  excluding them 
from reimbursement) and the introduction or increase of 
user charges for retail prescription drugs (Belloni et al., 
2016). 
In more recent years a number of countries, including 
Germany, Switzerland, Belgium and the United States have 
seen the return of higher pharmaceutical spending growth 
again, partly due to steep increases in spending for certain 
high cost drugs such as Hepatitis C drugs or oncology drugs.
Definition and comparability
Pharmaceutical expenditure covers spending on 
prescription medicines and self-medication, often 
referred to as over-the-counter products. In some 
countries, other medical non-durable goods are also 
included. It also includes pharmacists’ remuneration 
when the latter is separate from the price of medicines. 
Final expenditure on pharmaceuticals includes 
wholesale and retail margins and value-added 
tax. Total pharmaceutical spending refers in most 
countries to “net” spending, i.e. adjusted for possible 
rebates payable by manufacturers, wholesalers or 
pharmacies. 
Pharmaceuticals consumed in hospitals and other 
health care settings as part of an inpatient or day 
case treatment are excluded (data available suggests 
that their inclusion would add another 10-20% to 
pharmaceutical spending). Comparability issues exist 
with regards to the administration and dispensing of 
pharmaceuticals for outpatients in hospitals. In some 
countries the costs are included under curative care 
whereas in others under pharmaceuticals.
Pharmaceutical expenditure per capita is adjusted to 
take account of differences in purchasing power.
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10.1. Expenditure on retail pharmaceuticals¹ by type of financing, 2015 (or nearest year)
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10.2. Expenditure on retail pharmaceuticals per capita, 2015 (or nearest year)
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10.3. Average annual growth in retail pharmaceutical expenditure¹ per capita, in real terms,  
2003-09 and 2009-15 (or nearest period)
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Pharmacists and pharmacies
Pharmacists are educated and trained health care 
professionals who manage the distribution of medicines 
to consumers/patients and help ensure their safe and 
efficacious use. The role of the pharmacist has changed 
over recent years. Although their main role is to 
dispense medications in retail pharmacies, pharmacists 
are increasingly providing direct care to patients (e.g. 
flu  vaccinations in Ireland and New Zealand, medicine 
adherence support in Australia, Japan, England and New 
Zealand), both in community pharmacies and as part of 
integrated health care provider teams.
Between 2000 and 2015, the number of pharmacists has 
increased by 30% in OECD countries. Japan has by far the 
highest density of pharmacists, at twice the OECD average, 
while the density of pharmacists is low in Turkey, Chile and 
the Netherlands (Figure 10.4). Between 2000 and 2015, the 
number of pharmacists per capita has increased in nearly 
all OECD countries, with the exception of Switzerland. It 
increased most rapidly in Portugal, Spain, Slovenia and 
the Slovak Republic. 
In Japan, the increase in the number of pharmacists 
can be largely attributed to the government’s efforts to 
separate more clearly drug prescribing by doctors from 
drug dispensing by pharmacists (the Bungyo system). 
Traditionally, the vast majority of prescription drugs in 
Japan were dispensed directly by doctors. However, in recent 
decades, the Japanese government has taken a number of 
steps to encourage the separation of drug prescribing from 
dispensing. 
Most pharmacists work in community retail pharmacies, 
but some also work in hospital, industry, research and 
academia (FIP, 2015). For instance, in Canada more than 
three-quarters of practising pharmacists worked in 
a community pharmacy, while about 20% worked in 
hospitals and other health care facilities in 2012 (CIHI, 
2015). In Japan, around 55% of pharmacists worked in 
community pharmacies in 2014, while around 20% worked 
in hospitals or clinics and the other 25% worked in other 
settings (Survey of Physicians, Dentists and Pharmacists 
2014).
Variation in the number of community pharmacies across 
OECD countries (Figure  10.5) can be explained by the 
different dispensing channels for medicines. In addition 
to community pharmacies, medicines can be dispensed 
through hospital pharmacies (both for inpatient and 
outpatient use) or can be provided directly by doctors in 
some countries. For example, the relatively low number of 
community pharmacies in the Netherlands may be partly 
explained by the fact that patients can also purchase 
their prescription drugs directly from some doctors 
(Vogler et al., 2012). Denmark has fewer community 
pharmacies, but these are often large, including branch 
pharmacies and supplementary pharmacy units attached 
to the main pharmacy (Vogler et al., 2012).
The range of products and services provided by the 
pharmacies varies across countries. In most European 
countries, for example, pharmacies can also sell cosmetics, 
food supplements, medical devices and homeopathic 
products. In a few countries pharmacies can also sell 
reading glasses and didactic toys (Martins et al., 2015).
Definition and comparability
Practising pharmacists are defined as the number of 
pharmacists who are licensed to practice and provide 
direct services to clients/patients. They can be either 
salaried or self-employed, and work in community 
pharmacies, hospitals and other settings. Assistant 
pharmacists and the other employees of pharmacies 
are normally excluded. 
In Ireland, the figures include all pharmacists 
registered with the Pharmaceutical Society of Ireland, 
possibly including some pharmacists who are not in 
activity. Assistant pharmacists are included in Iceland.
Community pharmacies are premises which in 
accordance to the local legal provisions and definitions 
may operate as a facility in the provision of pharmacy 
services in the community settings. The number of 
community pharmacies reported are the number of 
premises where dispensing of medicines happened 
under the supervision of a pharmacist. 
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10. PHARMACEUTICAL SECTOR
10.4. Practising pharmacists, 2000 and 2015 (or nearest year)
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10.5. Community pharmacies, 2015 (or nearest year)
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Pharmaceutical consumption
In general, pharmaceutical consumption continues to 
increase, partly driven by a growing need for drugs to 
treat ageing-related and chronic diseases, and by changes 
in clinical practice. This section examines consumption 
of four categories of pharmaceuticals: antihypertensive, 
cholesterol-lowering, antidiabetic and antidepressant 
drugs. 
Consumption of antihypertensive drugs has nearly doubled 
in OECD countries between 2000 and 2015. It has nearly 
quadrupled in luxembourg and Estonia (Figure 10.6). It is 
highest in Germany and Hungary, which report almost five 
times the consumption levels in Korea and Turkey. These 
variations reflect both differences in the prevalence of high 
blood pressure and in clinical practice. 
The use of cholesterol-lowering drugs has nearly quadrupled 
in OECD countries between 2000 and 2015 (Figure 10.7). The 
Slovak Republic, Denmark and the United Kingdom report 
the highest consumption per capita in 2015. Across OECD 
countries, there is an eight fold variation in consumption 
levels of cholesterol-lowering drugs. 
The use of antidiabetic drugs has almost doubled in OECD 
countries between 2000 and 2015 (Figure 10.8). This growth 
can be explained by the rising prevalence of diabetes, 
largely linked to increases in the prevalence of obesity 
(see indicators on overweight and obesity in Chapter 4), a 
major risk factor for the development of type 2 diabetes. In 
2015, the consumption of antidiabetic drugs was highest in 
Finland, the Czech Republic and Greece.
Consumption of antidepressant drugs has doubled in OECD 
countries between 2000 and 2015 (Figure 10.9). This might 
reflect improved recognition of depression, availability of 
therapies, guidelines and changes in patient and provider 
attitudes (Mars et al., 2017). However, there is significant 
variation in consumption of antidepressants between 
countries. Iceland reports the highest level of consumption 
of antidepressants in 2015, twice the OECD average, 
followed by Australia, Portugal and the United Kingdom. 
latvia, Korea and Estonia report the lowest consumption 
levels of antidepressants.
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Definition and comparability
Defined daily dose  (DDD) is the assumed average 
maintenance dose per day for a drug used for its 
main indication in adults. DDDs are assigned to each 
active ingredient(s) in a given therapeutic class by 
international expert consensus. For instance, the 
DDD for oral aspirin equals 3  grams, which is the 
assumed maintenance daily dose to treat pain in 
adults. DDDs do not necessarily reflect the average 
daily dose actually used in a given country. DDDs can 
be aggregated within and across therapeutic classes 
of the Anatomic-Therapeutic Classification (ATC). For 
more detail, see www.whocc.no/atcddd.
The volume of antihypertensive drugs consumption 
presented in Figure 10.6 refers to the sum of five ATC2 
categories, which can all be prescribed for hypertension 
(Antihypertensives, Diuretics, Beta-blocking agents, 
Calcium channel blockers and Agents acting on the 
Renin-Angiotensin system).
Data generally refer to outpatient consumption 
only, except for Chile, the Czech Republic, Estonia, 
Finland, France, Iceland, Italy, Korea, Norway, the 
Slovak Republic and Sweden, where data also include 
hospital consumption. The data for Canada relate to 
three provinces only (British Columbia, Manitoba 
and Saskatchewan). The data for luxembourg and 
Spain refer to outpatient consumption for prescribed 
drugs covered by the National Health System (public 
insurance). Data for luxembourg are underestimated 
due to incomplete consideration of products with 
multiple active ingredients.
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10.6. Antihypertensive drugs consumption, 2000 and 
2015 (or nearest year)
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10.8. Antidiabetic drugs consumption, 2000 and 2015 
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10.9. Antidepressant drugs consumption, 2000 and 
2015 (or nearest year)
12.3
20.3
24.8
28.3
37.3
38.0
40.0
44.4
45.1
46.5
48.1
49.8
53.7
55.0
56.4
56.5
56.8
60.3
60.3
68.2
72.8
73.1
77.0
78.3
90.1
92.5
94.2
95.1
0 20 40 60 80 100
129.6
104.2
2000 2015
Defined daily dose, per 1 000 people per day
Latvia
Korea
Estonia
Hungary
Chile
Turkey
Slovak Republic
Israel
Netherlands
Italy
Greece
France
Luxembourg
Czech Republic
Germany
Norway
Slovenia
OECD29
Austria
Finland
New Zealand
Spain
Denmark
Belgium
Canada
Sweden
United Kingdom
Portugal
Australia
Iceland
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933605540
192 HEAlTH AT A GlANCE 2017 © OECD 2017 
10. PHARMACEUTICAL SECTOR
Generics and biosimilars
All OECD countries view the development of generic 
markets as a good opportunity to increase efficiency in 
pharmaceutical spending, but many do not fully exploit 
the potential of generics (Figure 10.10). In 2015, generics 
accounted for more than three-quarters of the volume 
of pharmaceuticals sold in the United States, Chile, 
Germany, New Zealand and the United Kingdom, while 
they represented less than one-quarter of the market in 
luxembourg, Italy, Switzerland and Greece. 
Some of the differences in generic uptake can be explained 
by market structures, notably the number of off-patent 
medicines, and by prescribing practices, but generic uptake 
also depends on policies implemented by countries (EGA, 
2011; Vogler, 2012). Several countries have expanded their 
efforts to encourage generic uptake since the onset of the 
economic crisis in 2008. 
Financial incentives for physicians, pharmacists and 
patients have been implemented to boost the development 
of generic markets. For instance, France (in 2009 and 
2012) introduced incentives for GPs to prescribe generics 
through a pay-for-performance scheme while in Japan (in 
2012) payment bonuses also contributed to an increased 
share of generics in total prescribing. Pharmacies are often 
paid through mark-ups based on the price of medicines. 
This disincentive to substitute a generic for a more 
expensive drug has been addressed in some countries. 
France guarantees pharmacists an equivalent mark-up, 
while in Switzerland pharmacists receive a fee for generic 
substitution. Patients have a financial interest to choose 
cheaper drugs when their co-payment is lower for generic 
drugs than its equivalent. This is generally the case in all 
systems using reference prices (or fixed reimbursement 
amount) for clusters of products. In Greece, patients 
choosing originator over generic drugs are now required 
to pay for the difference. 
A biosimilar is a biological medicine highly similar 
to another already approved biological medicine (the 
“reference medicine”). Biological medicines contain 
active substances from a biological source, such as living 
cells or organisms. The rationale behind the introduction 
of biosimilars is to increase price competition, thereby 
reducing prices. There is large variation in the uptake 
for two biosimilars – Epoetin and Anti-Tumour Necrosis 
Factor (Anti-TNF) – across OECD countries (Figure 10.11). 
Biosimilars have 100% of the Epoetin market share in 
Finland, Hungary, Poland, the Slovak Republic and the 
Czech Republic, whereas it is 2% in Belgium and 6% in 
the United Kingdom. For Anti-TNF, biosimilars have 90% 
and 82% of the market share in Denmark and Norway 
respectively, while it is 2% in Switzerland and 5% in 
Belgium and Ireland.
Definition and comparability
A generic is defined as a pharmaceutical product 
which has the same qualitative and quantitative 
composition in active substances and the same 
pharmaceutical form as the reference product, and 
whose bioequivalence with the reference product 
has been demonstrated. Generics can be classified in 
branded generics (generics with a specific trade name) 
and unbranded generics (which use the international 
non-proprietary name and the name of the company).
Countries were requested to provide data for the 
whole market. However many countries provided data 
covering only the community pharmaceutical market 
or the reimbursed pharmaceutical market (see Figure 
notes). The share of generic market expressed in value 
can be the turnover of pharmaceutical companies, 
the amount paid for pharmaceuticals by third-party 
payers, or the amount paid by all payers (third-party 
and consumers). The share of generic market in 
volume can be expressed in DDDs or as a number of 
packages/boxes or standard units.
A Biosimilar Medicinal Product is the product granted 
regulatory approval, demonstrating similarity to the 
Reference Medicinal Product in terms of quality 
characteristics, biological activity, safety and efficacy. 
Referenced Medicinal Product is the original product, 
which was granted market exclusivity at the start of 
its life, but once exclusivity has expired the product 
has been categorised as referenced. The biosimilar 
market share is the number of biosimilar treatment 
days as a share of biosimilar and referenced product(s) 
volume. Volume is measured in Defined Daily Dose 
which is a measure of the average dose prescribed as 
defined by the WHO.
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10.10. Share of generics in the total pharmaceutical market, 2015 (or nearest year)
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10.11. Biosimilar market share (volume) for Epoetin and Anti-Tumour Necrosis Factor (Anti-TNF)  
vs reference product , 2015 (or nearest year)
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Research and development in the pharmaceutical sector
Funding for pharmaceutical research and development 
(R&D) is the result of a complex mix of private and public 
sources. Governments mainly support basic and early-
stage research. Such funding is made through direct budget 
allocations, research grants, publicly-owned research 
institutions and funding of higher education institutions. 
The pharmaceutical industry translates and applies 
knowledge generated by basic research to develop products, 
and invests in large clinical trials required to gain market 
approval. The industry also receives direct R&D subsidies 
or tax credits in many countries.
In 2014, governments of OECD countries budgeted about 
USD 51 billion on health-related R&D (a broader category 
than pharmaceuticals). This figure understates total 
government support, since it excludes most tax incentive 
schemes or funding for higher education or publicly-owned 
corporations. Meanwhile, the pharmaceutical industry 
spent approximately USD 100 billion on R&D across OECD 
countries. In high-income countries, the business sector 
has been estimated to contribute 60% of all health-related 
research, while 30% comes from governments and 10% from 
other sources, including private not-for-profit organisations 
and universities’ own funds (Røttingen et al., 2013). 
Most pharmaceutical R&D takes place in OECD countries. 
However, the share of non-OECD countries in global 
industry R&D expenditure is increasing (Chakma et al., 
2014), especially in China, where the industry spent 
approximately USD 11 billion on R&D in 2014 (0.05% of 
GDP). More than half of the spending in OECD countries 
(Figure  10.12) occurs in the United States, where the 
pharmaceutical industry spent about USD  56  billion 
(0.3% of GDP), and direct government budgets on health-
related R&D were USD 33 billion (0.2% of GDP). Industry 
spent USD 26 billion (0.1% of GDP) and governments 
budgeted USD 11 billion (0.05% of GDP) in Europe; and 
USD 15 billion (0.3% of GDP) and USD 1.6 billion (0.03% 
of GDP) respectively in Japan. As a share of GDP, industry 
spending is highest in Switzerland (0.6%), Belgium (0.6%) 
and Slovenia (0.4%), smaller countries with relatively 
large pharmaceutical sectors. 
The pharmaceutical industry is highly R&D intensive. On 
average across OECD countries, the industry spent some 
14% of its gross value added on R&D. This is almost as 
high as in the air and spacecraft (18%) and electronics and 
optical products industries (17%), and considerably higher 
than the average across manufacturing as a whole (6%) 
(Figure 10.13).
Expenditure on R&D in the pharmaceutical industry in OECD 
countries grew by more than 50% in real terms between 2004 
and 2014. However, this increase is not associated with higher 
output in terms of new drug approvals (NDAs). In the United 
States, the annual number of NDAs has remained relatively 
stable since the 1980s (Figure 10.14) while the number of 
approvals per inflation-adjusted R&D spending has declined 
steadily. Exceptions are the late 1990s, when a backlog of 
pending applications was cleared, and the years since 2010.
This pattern of constant output at increasing costs despite 
advances in technology (“Eroom’s law”) is driven by a 
complex combination of factors. These include growing 
requirements to obtain market approval that have increased 
clinical trial costs and an ever-increasing “back catalogue” 
of effective drugs that has shifted research efforts to more 
complex conditions (Scannell et al., 2012). Rising R&D costs 
can be both a cause and a result of higher drug prices, 
as the acceptance of higher prices by payers can make 
increasingly expensive R&D financially viable. Increasing 
R&D costs can then in turn drive up prices.
Definitions and comparability
Business enterprise expenditure on R&D (BERD) covers 
R&D carried out by corporations, regardless of the origin 
of funding, which can include government subsidies. 
BERD is recorded in the country where the R&D activity 
took place, not the country providing funding. National 
statistical agencies collect data primarily through 
surveys and according to the Frascati Manual (OECD, 
2015) but there is some variation in national practices. 
“Pharmaceutical R&D” refers to BERD by businesses 
classified in the pharmaceutical industry.
Government budgets for R&D (GBARD) capture both 
R&D performed directly by government and amounts 
paid to other institutions for R&D. “Health-related 
R&D” refers to GBARD aimed at protecting, promoting 
and restoring human health, including all aspects of 
medical and social care. It does not cover spending by 
public corporations or general university funding that 
is subsequently allocated to health.
The gross value added (GVA) of a sector equals gross 
output less intermediate consumption. It includes the 
cost of wages, consumption of fixed capital and taxes on 
production. Because GVA does not include intermediate 
consumption, it is less sensitive than gross output to 
sector-specific reliance on raw materials. OECD averages 
in Figure 10.13 are based on 15 countries for air and 
spacecraft, and 25-29 countries for all other industries.
References
Chakma, J. et al. (2014), “Asia’s Ascent – Global Trends in 
Biomedical R&D Expenditures”, New England Journal of 
Medicine, Vol. 370, No. 1, pp. 3-6.
OECD (2015), Frascati Manual 2015: Guidelines for Collecting 
and Reporting Data on Research and Experimental 
Development, OECD Publishing, Paris, http://dx.doi.
org/10.1787/9789264239012-en.
Røttingen, J.A. et al. (2013), “Mapping of Available Health 
Research and Development Data: What’s There, What’s 
Missing, What Role Is There for a Global Observatory?”, 
The Lancet, Vol. 382, No. 9900, pp. 1286-1307.
Scannell, J.W. et al. (2012), “Diagnosing the Decline in 
Pharmaceutigal R&D Efficiency”, Nature Reviews Drug 
Discovery, Vol. 11, No. 3, pp. 191-200.
195HEAlTH AT A GlANCE 2017 © OECD 2017
Research and development in the pharmaceutical sector
10. PHARMACEUTICAL SECTOR
10.12. Business enterprise expenditure for pharmaceutical R&D (BERD) and government budgets  
for health-related R&D (GBARD), 2014 or nearest year
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10.13. R&D intensity by industry: business enterprise R&D expenditure (BERD) as a proportion  
of gross value added (GVA), 2014 or nearest year
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10.14. Annual new drug approvals (NDAs) per billion USD pharmaceutical business expenditure  
on R&D in the United States, inflation-adjusted
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Demographic trends
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Demographic trends
longer life expectancies (see indicators on life expectancy 
in Chapter 3) and declining fertility rates mean that older 
people make up an ever-increasing proportion of the 
populations of OECD countries.
On average across OECD countries, the share of the 
population aged over 65 years increased from less than 
9% in 1960 to 17% in 2015, and is expected to continue 
to increase, reaching 28% in 2050 (Figure 11.1, left panel). 
In more than two-thirds of OECD countries, at least one-
quarter of the population will be over 65 years of age by 
2050. This proportion is expected to be especially large in 
Japan, Spain, Portugal, Greece and Korea, where nearly 
40% of the population will be aged over 65 years by 2050. 
Population ageing will also occur rapidly in China, where 
the share of the population over 65 is expected to nearly 
triple between 2015 and 2050, to reach a level just below 
the OECD average. Conversely, Israel, the United States and 
Mexico will see a more gradual increase in the share of the 
elderly population due to significant inflows of migrants or 
higher fertility rates.
The growth in the share of the population aged 80 years 
and over will be even more dramatic (Figure  11.1, right 
panel). On average across OECD countries, nearly 5% of the 
population was 80 years old and over in 2015. By 2050, the 
percentage will increase to more than 10%. In Italy, Spain, 
Portugal, and Germany, the proportion of the population 
aged over 80 is expected to more than double between 2015 
and 2050. The rise will be even faster in Korea, where the 
share of the population aged over 80 years will grow from 
3% to 14% over the next four decades. 
Population ageing is a phenomenon affecting most 
countries around the world, but the speed of the process 
varies (Figure 11.2). The speed of population ageing has 
been particularly fast in Japan, where the share of the 
population aged 80 years and over increased from 2% in 
1990 to nearly 8% in 2015, and is expected to rise to 15% by 
2050. The population in Korea remains relatively young, but 
is expected to age rapidly in the coming decades, so that by 
2050 the share of the population over 80 will be nearly the 
same as in Japan. The pace of population ageing has been 
slower in non-OECD countries, although it is expected to 
accelerate. In large partner countries including Brazil and 
China, less than 2% of the population was 80 years and over 
in 2015, though this share is expected to reach close to 7% 
in Brazil and more than 8% in China by 2050.
Although the pressure that this growing proportion of 
people aged  65 and 80 over will put on long-term care 
systems will depend on the health status of people as 
they reach these ages, population ageing will likely lead to 
greater demand for elderly care and contribute to increases 
in health spending. Nevertheless, most studies have found 
new technologies and rising incomes to be more significant 
drivers of health spending growth than population ageing 
(OECD, 2015).
As populations age, the potential supply of labour in the 
economy is expected to decline. On average across OECD 
countries, there were slightly more than four people of 
working age (15-64 years) for every person 65 years and 
older in 2012. This rate is projected to halve from 4.2 in 2012 
to 2.1 on average across OECD countries over the next 40 
years (OECD, 2013). Moreover, ageing may lead to shortfalls 
in certain revenue-raising mechanisms, particularly payroll 
taxes, making it more difficult for countries to maintain or 
increase government spending on health.
Definition and comparability
Data on the population structure have been extracted 
from the OECD historical population data and 
projections (1950-2050). The projections are based 
on the most recent “medium-variant” population 
projections from the United Nations, World Population 
Prospects – 2017 Revision.
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11.1. Share of the population aged over 65 and 80 years, 2015 and 2050
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11.2. Trends in the share of the population aged over 80 years, 1990-2050
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Life expectancy and healthy life expectancy at age 65 
life expectancy at age  65 has increased significantly 
for both men and women over the past few decades in 
OECD countries, rising by 5.4 years on average since 1970 
(Figure 11.3). Some of the factors explaining these gains 
in life expectancy at age 65 include advances in medical 
care combined with greater access to health care, healthier 
lifestyles and improved living conditions before and after 
people reach age 65.
Japan and Korea have achieved the highest gains in life 
expectancy at age 65 since 1970, with an increase of about 
eight years. The gains have been much more modest in 
Hungary, the Slovak Republic and Mexico, with an increase 
of only about three years. 
In 2015, people at age 65 in OECD countries could expect to 
live another 19.5 years: 21 years for women and 18 years 
for men (Figure 11.4). This gender gap of three years on 
average across OECD countries has been fairly stable over 
time. In 2015, life expectancy at age 65 was highest in Japan 
for women (24 years) and in Japan, Australia, and Iceland 
for men (nearly 20 years). Among OECD countries, it was 
lowest in Hungary for women (18 years) and in latvia for 
men (14 years).
Countries’ relative positions with respect to life expectancy 
at age 65 mirror closely their relative positions with regard 
to life expectancy at age 80. life expectancy at age 80 in 
2015 was highest in Japan for women (who can expect to 
live an additional 12 years) and highest in France for men 
(who can expect to live an additional 9 years).
Increased life expectancy at age 65 does not necessarily 
mean that the extra years lived are in good health. In 
Europe, an indicator of disability-free life expectancy 
known as “healthy life years” is calculated regularly, based 
on a general question about disability in the European 
Union Statistics on Income and living Conditions (EU-SIlC) 
survey. Among European countries participating in the 
survey, the average number of healthy life years at age 65 
was almost the same for women and men, at 9.3 years for 
women and 9.4 years for men in 2015 (Figure 11.5). The 
absence of any significant gender gap in healthy life years 
means that many of the additional years of life that women 
experience relative to men are lived with some type of 
activity limitation. Nordic countries (with the exception of 
Finland) had the highest number of healthy life years at 
age 65 in 2015. In Sweden, women could expect to live an 
average of an additional 17 years, and men 16 years, free 
of disability.
life expectancy and healthy life expectancy vary by 
educational status. For both men and women, highly 
educated people are likely to live longer and in better 
health. Differences in life expectancy by education level 
are particularly large in Central and Eastern European 
countries, especially for men. In the Slovak Republic, 
65-year-old men with a high level of education could expect 
to live five years longer than those with a low education 
level in 2015. By contrast, differences in life expectancy by 
education level are much smaller (less than two years) in 
Nordic countries (Denmark, Finland, Norway and Sweden) 
and Portugal (see Eurostat Database 2017). 
Definition and comparability
life expectancy measures how long on average a person 
of a given age can expect to live, if current death rates 
do not change. However, the actual age-specific death 
rate of any particular birth cohort cannot be known 
in advance. If rates are falling, as has been the case 
over the past decades in OECD countries, actual life 
spans will be higher than life expectancy calculated 
using current death rates. The methodology used to 
calculate life expectancy can vary slightly between 
countries. This can change a country’s estimates by 
a fraction of a year. life expectancy at age 65 is the 
unweighted average of the life expectancy at age 65 
of women and men.
Disability-free life expectancy (or “healthy life 
years”) is defined as the number of years spent free 
of activity limitation. In Europe, this indicator is 
calculated annually by Eurostat for EU countries and 
some EFTA countries. The disability measure is based 
on the Global Activity limitation Indicator  (GAlI) 
question, which comes from the European Union 
Statistics on Income and living Conditions (EU-SIlC) 
survey. The question asks: “For at least the past six 
months, have you been hampered because of a health 
problem in activities people usually do? Yes, strongly 
limited / Yes, limited / No, not limited”. While healthy 
life years is the most comparable indicator to date, 
there are still problems with translation of the GAlI 
question, although it does appear to satisfactorily 
reflect other health and disability measures (Jagger 
et al., 2010).
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11.3. Life expectancy at age 65, 1970 and 2015 (or nearest year)
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11.4. Life expectancy at age 65 by sex, 2015 (or nearest year)
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11.5. Healthy life years at age 65, European countries, 2015 (or nearest year)
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Self-reported health and disability at age 65
Most OECD countries conduct regular health surveys 
which allow respondents to report on different aspects 
of their health. These surveys often include a question 
on self-perceived health status, along the lines of: “How 
is your health in general?”. Although these questions are 
subjective, indicators of perceived general health have 
been found to be a good predictor of future health care use 
and mortality (Hirosaki et al., 2017; Schnittker and Bacak, 
2014). However, cross-country differences may be difficult 
to interpret, as survey questions may differ slightly and 
cultural factors can affect responses.
More than half of the population aged 65 years and over 
report being in good health in 14 of 34 OECD countries 
(Figure  11.6). In New  Zealand, Canada and the United 
States, more than three-quarters of older people report 
good health, though the response categories offered to 
survey respondents in these three countries are different 
from those used in most other OECD countries (see 
“Definition and comparability” box). Among European 
countries, older people in Norway, Sweden, Ireland, 
Switzerland, and the Netherlands report the best health 
status, with more than 60% assessing their health to be 
good. At the other end of the scale, less than 15% of the 
population aged 65 years and over in latvia and Portugal 
report being in good health. In nearly all countries, men 
over 65 were more likely than women to rate their health 
to be good. On average across OECD countries, 47% of men 
aged over 65 rated their health to be good or better, while 
41% of women did so.
Self-reported health status varies substantially by income. 
Across OECD countries on average, less than one-third 
of people aged 65 years and older in the lowest income 
quintile considered their health to be good, compared 
with close to 60% of those in the highest income quintile 
(Figure 11.7). In Sweden, more than four-fifths of people 
aged 65 and older in the highest income quintile consider 
their health to be good, while fewer than half of people in 
the lowest income quintile say the same.
Although measures of disability are not fully standardised 
across countries, the European Union Statistics on Income 
and living Conditions (EU-SIlC) survey collects data on 
the limitations that people face in their daily activities 
(Figure  11.8). Such limitations often correspond to a 
need for long-term care. On average across 26 European 
countries, 51% of all over-65s reported that they were 
limited either to some extent or severely in their usual 
daily activities because of a health problem in 2015 
(Figure 11.8). The lowest rates of disability were reported 
in Nordic countries, with around one in five over-65s 
reporting at least some limitation in daily activities in 
Sweden and Norway. The highest rates were found in 
Eastern European countries such as latvia and the Slovak 
Republic, where three-quarters of over-65s reported at 
least some limitations.
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Definition and comparability
Self-reported health reflects people’s overall 
perception of their own health, including both 
physical and psychological dimensions. Typically, 
survey respondents are asked a question such as: 
“How is your health in general? Very good, good, fair, 
poor, very poor”. OECD Health Statistics provides figures 
related to the proportion of people rating their health 
to be “good/very good” combined.
Caution is required in making cross-country comparisons 
of perceived health status, for at least two reasons. First, 
people’s assessment of their health is subjective and 
can be affected by cultural factors. Second, there are 
variations in the question and answer categories used to 
measure perceived health across surveys/countries. In 
particular, the response scale used in Australia, Canada, 
New Zealand and the United States is asymmetric 
(skewed on the positive side), including the following 
response categories: “excellent, very good, good, fair, 
poor”. The data reported in OECD Health Statistics refer 
to respondents answering one of the three positive 
responses (“excellent, very good or good”). By contrast, 
in most other OECD countries, the response scale is 
symmetric, with response categories being: “very good, 
good, fair, poor, very poor”. The data reported from these 
countries refer only to the first two categories (“very 
good, good”). Such differences in response categories 
may introduce an upward bias in the results from those 
countries that are using an asymmetric scale.
Perceived general disability is measured by the 
Global Activity limitation Indicator (GAlI) question, 
which comes from the European Union Statistics on 
Income and living Conditions (EU-SIlC) survey. The 
question is: “For at least the past six months, have 
you been hampered because of a health problem in 
activities people usually do? Yes, strongly limited / 
Yes, limited / No, not limited”. Persons in institutions 
are not surveyed, resulting in an under-estimation of 
disability prevalence. Again, the measure is subjective, 
and cultural factors may affect survey responses.
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11.6. Perceived health status in adults aged 65 years and over, 2015 (or nearest year) 
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11.7. Perceived health status in adults aged 65 years and over by income quintile, European countries, 2015  
(or nearest year) 
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11.8. Limitations in daily activities in adults aged 65 years and over, European countries, 2015 (or nearest year)
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Dementia prevalence
Dementia describes a variety of brain disorders which 
progressively lead to brain damage and cause a gradual 
deterioration of the individual’s functional capacity and 
social relations. Alzheimer’s disease is the most common 
form of dementia, representing about 60% to 80% of cases. 
There is currently no cure or disease modifying treatment, 
but better policies can improve the lives of people with 
dementia by helping them and their families adjust to 
living with the condition and ensuring that they have 
access to high quality health and social care.
In 2017, there were an estimated 18.7 million people living 
with dementia in OECD countries. This is equivalent 
to around one in every 69 people in the population as a 
whole, but dementia prevalence increases rapidly with 
age. Across all OECD countries, around 2% of people aged 
65-69 have dementia, compared with more than 40% of 
those aged over  90 (Figure  11.10). As a result, countries 
with older populations have more people with dementia: 
Japan, Italy, and Germany are estimated to have more than 
20 people with dementia per 1 000 population, while the 
Slovak Republic, Turkey and Mexico have fewer than nine 
(Figure 11.9).
Ageing populations mean that dementia will become 
more common in the future, and the most rapidly ageing 
countries will see prevalence more than double in the next 
20 years. This includes fast-ageing OECD countries (Korea 
and Chile) and partner countries such as Brazil, China, 
Colombia and Costa Rica. However, there is some evidence 
that the age-specific prevalence of dementia may be falling 
in some countries (Matthews et al., 2013) and it may be 
possible to reduce the risk of dementia through healthier 
lifestyles and preventive interventions. If such efforts are 
successful, the rise in prevalence may be less dramatic than 
these numbers suggest.
Behavioural and psychological symptoms affect many 
people with dementia and can make caring for them 
difficult. Antipsychotic drugs can reduce these symptoms, 
but the associated risks and ethical issues – and the 
availability of a range of effective non-pharmacological 
interventions –  mean they are only recommended as a 
last resort. However, the inappropriate use of these drugs 
remains widespread and reducing their overuse is a policy 
priority for many OECD countries.
New data collected by the OECD show that rates of 
prescribing of antipsychotics to older people vary by more 
than a factor of two across OECD countries (Figure 11.12). 
In 2015, Sweden, Norway the Netherlands, France, Australia 
and Denmark prescribed antipsychotics to fewer than 35 in 
every thousand people aged over 65, with rates either falling 
or constant. At the other extreme, more than 70 in every 
thousand people aged over 65 in Slovenia had a prescription 
of antipsychotics, an increase of 14% since 2011.
Rates of antipsychotic prescribing rise with age 
(Figure 11.11). On average across 13 OECD countries, 3% of 
people aged 65-69 had a prescription for antipsychotics in 
2015, compared to 12% of people aged over 90. This is likely 
to be driven in part by higher rates of dementia at older 
ages. However, the use of antipsychotics rises less steeply 
than dementia prevalence (Figure 11.10).
Definition and comparability
The prevalence estimates in Figure  11.9 are taken 
from the World Alzheimer Report 2015, which includes 
a systematic review of studies of dementia prevalence 
around the world. Prevalence by country has been 
estimated by applying these age-specific prevalence 
rates for the relevant region of the world to country-
specific population estimates from the United Nations 
(World Population Prospects: The 2017 Revision). 
Differences between countries are therefore driven by 
the age structure of populations – i.e. older countries 
have more people with dementia. The World Alzheimer 
Report 2015 analysis includes studies carried out since 
1980, with the assumption that age-specific prevalence 
is constant over time. This assumption is retained in 
the construction of this indicator, so that fixed age-
specific prevalence rates are applied for both 2017 and 
2037. Although gender-specific prevalence rates were 
available for some regions, overall rates were used in 
this analysis.
Antipsychotics are defined consistently across 
countries using Anatomical Therapeutic Classification 
(ATC) codes. The numerator includes all patients on 
the medications register with a prescription for a drug 
within the ATC subgroup N05A. The denominator 
is the total number of people on the register. Most 
countries are unable to identify which prescriptions 
relate to people with dementia, so the antipsychotics 
indicator covers all people aged over 65. Some caution 
is needed when making inferences about the dementia 
population, since it is not certain that a higher rate of 
prescribing among all over-65s translates into more 
prescriptions for people with dementia. Nonetheless, 
measuring this indicator, exploring the reasons for 
variation and reducing inappropriate use can help to 
improve the quality of dementia care.
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11.10 Prevalence of dementia across all OECD 
countries by age group, 2017
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11.11 Proportion of population with a prescription of 
antipsychotics, by age group, 2015 or nearest year
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Recipients of long-term care
As people age, they are more likely to develop disabilities 
and need support from family, friends and long-term care 
(lTC) services. As a result, while lTC services are delivered 
to younger disabled groups, the majority of lTC recipients 
are older people. On average across the OECD, 13% of 
people over 65 receive long-term care (Figure 11.13). The 
proportion of over-65s receiving long-term care varies from 
2% in Portugal and 6% in Estonia to more than 20% in Israel 
and Switzerland.
People aged over 80 make up on average more than half of 
all lTC recipients, and almost two-thirds of lTC recipients in 
Japan, Denmark and Australia (Figure 11.14). As populations 
age, demand for lTC services is likely to increase – although 
this effect may be partially offset by improving health in 
old age. Nonetheless, a significant number of younger 
disabled people require long-term care, making up as many 
as a third of all lTC recipients in Norway, Slovenia and the 
Netherlands.
While population ageing is a significant driver of the 
growth in lTC users over time, it explains relatively 
little of the cross-country variation. For example, Israel 
has one of the youngest populations in the OECD but a 
greater than average proportion receiving lTC. A more 
important driver is the availability of publicly funded lTC 
services. However, data for people receiving care outside 
of public systems are more difficult to collect and may 
be underreported, meaning that figures for countries 
that rely more heavily on privately-funded care may be 
artificially low. Cultural norms around the degree to which 
families look after older people may also be an important 
driver of the utilisation of formal services (see indicator 
on “Informal carers”). 
In response to most people’s preference to receive lTC 
services at home, many OECD countries have implemented 
programmes and benefits to support home-based care, in 
particular for older people. In most countries for which 
trend data are available, the proportion of lTC recipients 
aged 65 and over receiving long-term care at home has 
increased over the past ten years (Figure  11.15), with 
particularly large increases in Portugal and Sweden. In 
Portugal this reflects an expansion of home care services 
from a very low level in 2005. In Sweden it results from a 
deliberate policy to reduce institutional care capacity and 
encourage community care (Colombo et al., 2011).
While the proportion of lTC recipients living at home has 
increased over the past decade in most OECD countries, it 
has declined significantly in Finland and Estonia. In Finland, 
this has not been driven by an increase in traditional 
institutional care. Instead, there has been an increase in 
the use of “service housing” – where older people move 
into specially adapted houses where 24/7 care is available. 
Although this is classified as institutional care, it allows 
more independence and autonomy than a traditional care 
institution. In Estonia, there has been a significant increase 
in the use of institutional care, but there has been an even 
larger decrease in the number of “curators” appointed by 
local government to care for people at home.
Definition and comparability
lTC recipients are defined as persons receiving long-
term care by paid providers, including nonprofessionals 
receiving cash payments under a social programme. 
They also include recipients of cash benefits such 
as consumer-choice programmes, care allowances 
or other social benefits which are granted with the 
primary goal of supporting people with long-term care 
needs. lTC institutions refer to nursing and residential 
care facilities which provide accommodation and 
long-term care as a package. lTC at home is defined as 
people with functional restrictions who receive most 
of their care at home. Home care also applies to the 
use of institutions on a temporary basis, community 
care and day-care centres and specially designed 
living arrangements. Data for Poland, the United 
States, Ireland, Canada, the Slovak Republic, Iceland 
and Belgium are only available for people receiving 
long-term care in institutions, so the total number 
of recipients will be underestimated. In Estonia, data 
on recipients of home care refer only to those who 
have a “curator” appointed by local government. Other 
social services, without a personal care component, 
are not included in the data. It is possible that some 
of the decrease in recipients reflects the replacement 
of curators with these other services.
Data on lTC services is difficult to collect in many 
countries and there are some known limitations of the 
figures. Data for some countries refer only to people 
receiving publicly-funded care, while other countries 
include people who are paying for their own care. 
Data from France and the Czech Republic refer to 
the number of people claiming care benefits, which 
may not correspond directly to the number receiving 
services. Some countries use different age categories: 
instead of reporting people aged 65 and over, Belgium 
reports those aged 60 and over and Iceland those aged 
66 and over.
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11.13 Proportion of people aged 65 and over receiving long-term care, 2005 and 2015 (or nearest year)
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11.14 Share of long-term care recipients, by age, 2015 (or nearest year)
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11.15 Share of long-term care recipients aged 65 years and over receiving care at home, 2005 and 2015  
(or nearest year)
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Informal carers
Family and friends are the most important source of care for 
people with long-term care (lTC) needs in OECD countries. 
Because of the informal nature of care that they provide, it 
is not easy to get comparable data on the number of people 
caring for family and friends across countries, nor on the 
frequency of their caregiving. The data presented in this 
section come from national or international health surveys 
and refer to people aged 50 years and over who report 
providing care and assistance to family members and friends.
On average across OECD countries for which data is 
available, around 13% of people aged 50 and over report 
providing informal care at least weekly – but this figure 
is more than 20% in the Czech Republic and Belgium and 
less than 10% in Poland and Portugal (Figure 11.16). There 
is also variation in the intensity of the care provided. The 
lowest rates of daily care provision are found in Sweden, 
Switzerland, Denmark and the Netherlands – countries 
where the formal lTC sector is well-developed and public 
coverage is comprehensive.
Intensive caregiving is associated with a reduction in 
labour force attachment for caregivers of working age, 
higher poverty rates, and a higher prevalence of mental 
health problems. Many OECD countries have implemented 
policies to support family carers with a view to mitigating 
these negative impacts. These include paid care leave (e.g., 
Belgium), flexible work schedules (e.g., Australia and the 
United States), respite care (e.g., Austria, Denmark and 
Germany) and counselling/training services (e.g., Sweden). 
Moreover, a number of OECD countries provide cash 
benefits to family caregivers or cash-for-care allowances 
for recipients which can be used to pay informal caregivers 
(Colombo et al., 2011).
On average across OECD countries, 60% of those providing 
daily informal care are women (Figure 11.17). Poland and 
Portugal have the greatest gender imbalance, with 70% of 
informal carers being women. Sweden is the only country 
where more men than women report that they provide at 
least weekly informal care.
Around two thirds of carers are looking after a parent or a 
spouse, but patterns of caring vary for different age groups. 
Younger carers (aged between 50 and 65) are much more 
likely to be caring for a parent (Figure 11.18). They are more 
likely to be women – daughters provide much more care to 
their parents than sons – and may not be providing care 
every day. Carers aged over 65 are more likely to be caring 
for a spouse. Caring for a spouse tends to more intensive, 
requiring daily care, and men and women are equally likely 
to take on this role.
The fact that fewer people provide daily care in countries 
with stronger formal lTC systems suggests that there is 
a trade-off between informal and formal care. Declining 
family size, increased geographical mobility and rising 
participation rates of women in the labour market mean 
that there is a risk that fewer people will be willing and able 
to provide informal care in the future. Coupled with the 
effects of an ageing population, this could lead to higher 
demand for professional lTC services. Public lTC systems 
will need adequate resources to meet increased demand 
while maintaining access and quality.
Definition and comparability
Informal carers are defined as people providing any 
help to older family members, friends and people in 
their social network, living inside or outside of their 
household, who require help with everyday tasks. The 
data relate only to the population aged 50 and over, 
and are based on national surveys for Australia (Survey 
of Disability, Ageing and Carers, SDAC), the United 
Kingdom (English longitudinal Study of Ageing, ElSA), 
the United States (Health and Retirement Survey, 
HRS) and an international survey for other European 
countries (Survey of Health, Ageing and Retirement 
in Europe, SHARE). 
Questions about the intensity of care vary between 
surveys. In SHARE, carers are asked about how often 
they provided care in the last year and this indicator 
includes people who provided care at least weekly. 
In ElSA, people are asked if they have provided care 
in the last week, which may be broadly comparable 
with “at least weekly”. Questions in HRS and SDAC 
are less comparable with SHARE. Carers in HRS are 
included if they provided more than 200 hours of care 
in the last year. In SDAC, a carer is defined as someone 
who has provided ongoing informal assistance for at 
least six months. People caring for disabled children 
have been excluded for European countries but are 
included for the United States and Australia. However, 
the United States data only include those caring for 
someone outside of their household. As a result, 
data for Australia and the United States may not be 
comparable with other countries. 
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11.16. Share of informal carers among population aged 50 and over, 2015 (or nearest year)
%
11 9
19
17
5
8 7
5
7
9
7 6 4
7 7 6 6 4
8 1
0
8
6
10
11
12 8 8
10
7 5 6
6
7
4 4 5 5
7
3 1
2
0
5
10
15
20
25
Daily Weekly Total
Cz
ec
h R
ep
ub
lic
Be
lgi
um
Au
str
ali
a
Un
ite
d K
ing
do
m¹
Ne
the
rla
nd
s
Au
str
ia
Ge
rm
an
y
De
nm
ark
Fra
nc
e
Slo
ve
nia
OE
CD
18
Lu
xe
mb
ou
rg
Sw
itz
erl
an
d
Gr
ee
ce Ita
ly
Es
ton
ia
Isr
ae
l
Sw
ed
en
Sp
ain
Un
ite
d S
tat
es
Po
rtu
ga
l
Po
lan
d
Note: The definition of informal carers differs between surveys (see Definition and comparability).
1. United Kingdom refers to England.
Source: Wave 6 of the Survey of Health, Ageing and Retirement in Europe (2015), Survey of Disability, Ageing and Carers for Australia (2015), wave 7 of 
the English longitudinal Study of Ageing (2015), wave 12 of the Health and Retirement Survey for the United States (2014).
12 http://dx.doi.org/10.1787/888933605939
11.17. Share of women among informal daily carers aged 50 and over, 2015 (or nearest year)
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11.18. Share of informal carers in European1 population aged 50 and over, by recipients of care and age,  
daily and weekly, 2015
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Long-term care workers
long-term care (lTC) is a labour-intensive service. Formal 
lTC workers are defined as paid staff, typically nurses and 
personal carers, providing care and/or assistance to people 
limited in their daily activities at home or in institutions, 
excluding hospitals. Formal care is complemented by 
informal, usually unpaid, support from family and friends, 
which accounts for a large part of care for older people 
in all OECD countries (see indicator on “Informal carers”).
Relative to the population aged 65 and over, Norway, Sweden 
and the United States have the most lTC workers and the 
Slovak Republic and Portugal the fewest (Figure 11.19). In 
all countries except for Israel, Japan, Estonia and Korea, 
the majority of lTC staff work in institutions, even though 
the majority of recipients usually receive care at home 
(see indicator on care recipients). This reflects the fact that 
those in institutions often have more severe needs and 
require more intensive care. 
Most lTC workers are women and work part-time. At least 
90% of lTC workers are women in Korea, Denmark, the 
Slovak Republic, the Netherlands and Norway (Figure 11.20). 
Foreign-born workers also play an important role in lTC 
provision, though their presence is uneven across OECD 
countries. While Germany has very few foreign-born 
lTC workers, nearly one in four care workers in the United 
States is foreign-born (Colombo et al., 2011). 
The lTC sector represents a small but growing share of 
total employment in OECD countries, averaging just over 
2%. The number of lTC workers increased by more than 
50% in Japan, Korea, and Israel between 2005 and 2015 
(Figure  11.21). In Japan and Korea, this is related to the 
introduction of universal lTC insurance and the increasing 
professionalisation of lTC work. However, the Japanese and 
Korean populations are ageing rapidly and even with these 
changes, the growth in the lTC workforce has only just kept 
pace with the growth in the population aged over 80 – the 
people most likely to need lTC. In contrast, the number of 
long-term care workers decreased in Estonia, the Slovak 
Republic, and the Netherlands, despite large increases in 
the population aged 80+ over the same period (Figure 11.21).
On average, around one third lTC workers are nurses and 
the other two thirds are personal care workers (also referred 
to as  nursing aides, health assistants in institutions or 
home-based care assistants) with less formal training. 
Many OECD countries have set educational and training 
requirements for personal care workers, although these 
vary substantially, especially where home-based care is 
concerned (OECD/European Commission, 2013).
As populations continue to age, demand for lTC workers is 
likely to rise. Responding to increasing demand will require 
policies to improve recruitment (e.g. encouraging more 
unemployed people to consider training and working in 
the lTC sector); improve retention (e.g. enhancing pay and 
work conditions); and increase productivity (e.g. through 
reorganisation of work processes and more effective use 
of new technologies) (Colombo et al., 2011; European 
Commission, 2013).
Definition and comparability
long-term care workers are defined as paid workers 
who provide care at home or in institutions (outside 
hospitals). They include qualified nurses and personal 
care workers providing assistance with ADl and other 
personal support. Personal care workers include 
different categories of workers who may be called 
under different names in different countries. They may 
have some recognised qualification or not. Because 
personal care workers may not be part of recognised 
occupations, it is more difficult to collect comparable 
data for this category of lTC workers across countries. 
lTC workers also include family members or friends 
who are employed under a formal contract either by 
the care recipient, an agency, or public and private 
care service companies. They exclude nurses working 
in administration. The numbers are expressed as head 
counts, not full-time equivalent.
There are some differences in the methodologies that 
countries use to calculate the data, which could bias 
the results. Data for some countries refers only to 
workers employed in the public sector, while other 
countries include the private and non-profit sectors. 
Data from the Czech Republic and Japan are based 
on surveys of establishments, meaning that people 
who work in more than one establishment are double-
counted.
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11.19. Long-term care workers per 100 people aged 65 and over, 2015 (or nearest year)
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11.20. Proportion of long-term care workers who are women, 2015 (or nearest year)
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11.21. Long term care workers and population aged 80 and over, 2005 and 2015 (or nearest year)
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Long-term care beds in institutions and hospitals
The number of beds in long-term care (lTC) institutions 
and in lTC departments in hospitals provides a measure 
of the resources available for delivering lTC services to 
individuals outside of their home. 
On average across OECD countries, there were 50 lTC beds 
per 1  000  people aged  65 and over in 2015 –  46 in lTC 
institutions and four beds in lTC departments in hospitals 
(Figure 11.22). The Netherlands had the highest number 
of lTC beds in 2015, with around 87 beds per 1 000 people 
aged 65 and over, the vast majority of which were in lTC 
institutions. On the other hand, there were fewer than 
20 beds per 1 000 people aged 65 and over in Italy, latvia, 
Poland, and Turkey.
On average, there has been almost no change in the 
number of lTC beds per 1 000 population over 65 since 
2005, though this masks substantial variation between 
countries (Figure 11.23). At one extreme, some countries 
with well-established, comprehensive lTC systems have 
reduced residential lTC capacity. Between 2005 and 2015, 
Sweden reduced the number of lTC beds in institutions by 
23.5 beds per 1 000 population over 65. These reductions 
are attributable to a drive to move lTC out of residential 
facilities and into the community (Colombo et al., 2011). 
Iceland, Canada and Norway have also made significant 
reductions in the number of beds available. In contrast, 
Korea has seen a massive increase in capacity, increasing 
the number of beds from 13 to 58 per 1 000 population 
over  65 between 2005 and 2015, with the increase 
particularly marked since the introduction of a public lTC 
insurance scheme in 2008. 
While most countries allocate very few beds for lTC in 
hospitals, some still use hospital beds quite extensively for 
lTC purposes. Despite recent increases in the number of 
beds in lTC institutions in Korea, the majority of lTC beds 
are still in hospitals – although this may be driven in part 
by the reimbursement rules of the Korean lTC insurance, 
which require some facilities to be classified as hospitals. 
In Japan, many hospital beds are used for long-term care, 
though the number has decreased in recent years. Some 
European countries, such as Finland, Hungary and the 
Czech Republic, still have a significant number of lTC beds 
in hospitals, but in general there has been a move towards 
replacing hospital beds with institutional facilities, which 
are often cheaper and provide a better living environment 
for people with lTC needs. 
Providing lTC in institutions can be more efficient than 
community care for people with intensive needs, due to 
economies of scale and the fact that care workers do not 
need to travel to each person separately. However, it often 
costs more to public budgets, since informal carers make 
less of a contribution and lTC systems often pick up board, 
lodging and care costs. Moreover, lTC users generally prefer 
to remain at home. Most countries have taken steps in recent 
years to support this preference and promote community 
care. However, depending on individual circumstances, 
a move to lTC institutions may be the most appropriate 
option, for example for people living alone and requiring 
round-the-clock care and supervision (Wiener et al., 2009) 
or people living in remote areas with limited home-care 
support. It is therefore important that countries retain an 
appropriate level of residential lTC capacity, and that care 
institutions develop and apply models of care that promote 
dignity and autonomy. 
Definition and comparability
long-term care institutions refer to nursing and 
residential care facilities which provide accommodation 
and long-term care as a package. They include specially 
designed institutions or hospital-like settings where 
the predominant service component is long-term 
care for people with moderate to severe functional 
restrictions. Beds in adapted living arrangements for 
persons who require help while guaranteeing a high 
degree of autonomy and self-control are not included. 
For international comparisons, beds in rehabilitation 
centers should not be included. 
However, there are variations in data coverage across 
countries. Several countries only include beds in 
publicly-funded lTC institutions, while others also 
include private institutions (both profit and non-for-
profit). Some countries also include beds in treatment 
centers for addicted people, psychiatric units of 
general or specialised hospitals, and rehabilitation 
centers. 
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11.22. Long-term care beds in institutions and hospitals, 2015 (or nearest year)
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11.23. Trends in long-term care beds in institutions and hospitals, 2005-15 (or nearest year)
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Long-term care expenditure
long-term care (lTC) spending has seen the highest growth 
across the various functions (see Indicator on “Health 
expenditure by type of service”) and is expected to rise 
further in the coming years. Population ageing leads to 
more people needing ongoing health and social care; rising 
incomes increase expectations on the quality of life in old 
age; the supply of informal care is potentially shrinking; 
and productivity gains are difficult to achieve in such a 
labour-intensive sector. All these factors create upward 
pressures on spending.
A significant share of lTC services is paid for out of 
government or compulsory insurance schemes. Total 
government/compulsory spending on lTC (including both 
the health and social care components) accounted for 
1.7% of GDP on average across OECD countries in  2015 
(Figure 11.24). At 3.7% of GDP, the highest spender was the 
Netherlands, where public expenditure on long-term care 
was around double the OECD average. At the other end of the 
scale, Hungary, Estonia, Poland, Israel and latvia allocated 
less than 0.5% of their GDP, to the public provision of long-
term care. This variation can partly reflect differences in 
the population structure, but mostly the development 
of formal lTC systems, as opposed to more informal 
arrangements based mainly on care provided by unpaid 
family members. Despite problems of underreporting 
which limit comparability, available data on privately-
funded lTC expenditure suggests in some cases it can be 
substantial, playing a relatively large role in Switzerland 
(0.7% of GDP), Germany and the United Kingdom (both 0.6%). 
Consequently, the share of private spending – mainly out-
of-pocket expenditure – in total spending on lTC accounts 
for more than 30% in those countries. 
The boundaries between health and social lTC spending 
are still not fully consistent across countries, with some 
reporting particular components of lTC as health care, 
while others view it as social spending. Sweden and Norway 
spend 2.5% or more of their GDP on the health part of lTC 
financed from government/compulsory schemes, which is 
around double the OECD average (1.3%). With 1.3% of GDP, 
the Netherlands report the highest level of public spending 
on social lTC, much higher than the OECD average of 0.4%. 
The way lTC is organised in countries affects the 
composition of lTC spending and may also have an impact 
on overall lTC spending. Across the OECD, two-thirds of 
government and compulsory spending on lTC (health) 
was for inpatient lTC in 2015. This is mainly provided 
in residential lTC facilities (Figure 11.25). Yet in Poland, 
Finland, Denmark, Austria and Germany, spending on 
home-based lTC accounts for more than 50% of all lTC 
(health) spending. Spending for home-based lTC can be 
either due to services provided by professional lTC workers 
or informal workers, when a care allowance exists which 
remunerates the caregiver for the lTC services provided. 
Spending by government and compulsory insurance 
schemes on lTC has increased more rapidly than health 
care expenditure over the last decade. The annual growth 
rate was 4.6% between 2005 and 2015 across OECD countries 
(Figure 11.26). Spending growth stands out for Korea, which 
has implemented a number of measures to expand the 
coverage of their lTC systems in recent years, although 
total lTC spending still remains below the OECD average 
as a share of GDP. 
Projection scenarios suggest that public resources allocated 
to lTC as a share of GDP could double or more by 2060 (De 
la Maisonneuve and Oliveira Martins, 2013). One of the 
main challenges in the future will be to strike the right 
balance between providing appropriate social protection to 
people with lTC needs and ensuring that this protection is 
fiscally sustainable. 
Definition and comparability
lTC spending comprises both health and social services 
to lTC dependent people who need care on an on-
going basis. Based on the System of Health Accounts 
(SHA), the health component of lTC spending relates 
to nursing and personal care services (i.e. help with 
activities of daily living (ADl)). It covers palliative care 
and care provided in lTC institutions or at home. lTC 
social expenditure primarily covers assistance with 
instrumental activities of daily living (IADl). Despite 
progress made in improving the general comparability 
of lTC spending in recent years there is still some 
variation in reporting practices between the health 
and social components for some lTC activities across 
countries. In addition, lTC expenditure funded by 
governments and compulsory insurance schemes 
is more suitable for international comparisons as 
there is more variation in the comprehensiveness in 
reporting of privately-funded lTC expenditure across 
OECD countries.
Finally, some countries (e.g. Estonia, Israel, and the 
United States) can only report spending data for 
institutional care, and hence underestimate the total 
amount of spending on long-term care services by 
government and compulsory insurance schemes.
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11.24. Long-term care expenditure (health and social components) by government and compulsory  
insurance schemes, as a share of GDP, 2015 (or nearest year)
3.7
3.2
2.5 2.5
2.3 2.2
2.0
1.8 1.7 1.7 1.7
1.5 1.4 1.3 1.3 1.3 1.2 1.2
0.9 0.8 0.8 0.7
0.5 0.5 0.4 0.4 0.4 0.2 0.2
0
1
2
3
4
Long-term care (health) Long-term care (social)
Ne
the
rla
nd
s
Sw
ed
en
De
nm
ark
No
rw
ay
Be
lgi
um
Fin
lan
d
Ja
pa
n
Ice
lan
d
Fra
nc
e
Sw
itz
erl
an
d
OE
CD
15
Un
ite
d K
ing
do
m
Ire
lan
d
Cz
ec
h R
ep
ub
lic
Ge
rm
an
y
Lu
xe
mb
ou
rg
Au
str
ia
Ca
na
da
Slo
ve
nia
Ko
rea
Sp
ain Ita
ly
Po
rtu
ga
l
Un
ite
d S
tat
es
La
tvi
a
Isr
ae
l
Po
lan
d
Es
ton
ia
Hu
ng
ary
% GDP
Note: The OECD average only includes the 15 countries that report health and social lTC.
Source: OECD Health Statistics 2017.
12 http://dx.doi.org/10.1787/888933606091
11.25. Government and compulsory insurance spending on LTC (health) by mode of provision, 2015  
(or nearest year)
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11.26. Annual growth rate in expenditure on LTC (health and social) by government and compulsory  
insurance schemes, in real terms, 2005-15 (or nearest year)
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